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ABSTRACT  
   
Technology advancements in diagnostic imaging, smart sensing, and health information 
systems have resulted in a data-rich environment in health care, which offers a great 
opportunity for Precision Medicine. The objective of my research is to develop data fusion 
and system informatics approaches for quality and performance improvement of health 
care. In my dissertation, I focus on three emerging problems in health care and develop 
novel statistical models and machine learning algorithms to tackle these problems from 
diagnosis to care to system-level decision-making.  
The first topic is diagnosis/subtyping of migraine to customize effective treatment to 
different subtypes of patients. Existing clinical definitions of subtypes use somewhat arbitrary 
boundaries primarily based on patient self-reported symptoms, which are subjective and error-
prone. My research develops a novel Multimodality Factor Mixture Model that discovers 
subtypes of migraine from multimodality imaging MRI data, which provides complementary 
accurate measurements of the disease. Patients in the different subtypes show significantly 
different clinical characteristics of the disease. Treatment tailored and optimized for patients 
of the same subtype paves the road toward Precision Medicine.  
The second topic focuses on coordinated patient care. Care coordination between nurses 
and with other health care team members is important for providing high-quality and efficient care 
to patients. The recently developed Nurse Care Coordination Instrument (NCCI) is the first of 
its kind that enables large-scale quantitative data to be collected. My research develops a novel 
Multi-response Multi-level Model (M3) that enables transfer learning in NCCI data fusion. 
M3 identifies key factors that contribute to improving care coordination, and facilitates the 
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design and optimization of nurses’ training, workload assignment, and practice environment, 
which leads to improved patient outcomes.  
The last topic is about system-level decision-making for Alzheimer’s disease early 
detection at the early stage of Mild Cognitive Impairment (MCI), by predicting each MCI 
patient’s risk of converting to AD using imaging and proteomic biomarkers.  My research 
proposes a systems engineering approach that integrates the multi-perspectives, including 
prediction accuracy, biomarker cost/availability, patient heterogeneity and diagnostic 
efficiency, and allows for system-wide optimized decision regarding the biomarker testing 
process for prediction of MCI conversion.   
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CHAPTER 1 
INTRODUCTION 
1.1 Background 
Technology advancements in diagnostic imaging, smart sensing, and health 
information systems have resulted in a data-rich environment in health care. It is now 
possible to track every piece of information related to a patient’s diagnosis, treatment, and 
care. This offers a great opportunity for Personalized Medicine (PM), i.e., to offer the right 
medical decision-making to the right person at the right time. On the other hand, the size 
and complexity of the data overwhelms the modeling capability of existing statistical 
methods.  
The objective of my research is to develop data fusion and system informatics 
approaches for quality and performance improvement of healthcare system from diagnosis 
to care to system-level decision-making. In my dissertation, I focus on three emerging 
problems in health care and develop novel statistical models driven by the unique data 
structure and objectives of the specific problem domains. The three topics are (I) 
multimodality imaging data fusion and novel latent variable models for subtype discovery 
of migraine, (II) multi-source multi-level system-wide data fusion and novel transfer 
learning models for improving nurse care coordination and patient outcomes, and (III) 
Systems engineering approach for biomarker testing process optimization and Alzheimer’s 
disease early intervention.  
The three topics cover a full spectrum of decision makings in health care ranging 
from diagnosis (I), to care (II), and to process optimization (III). The objective of my 
dissertation research is not only to provide solutions to each of the three individual 
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problems, but also to demonstrate that advanced statistical and machine learning 
development integrated with domain knowledge through collaboration with medical 
professionals shows great promise for tackling challenging issues at different levels of the 
complex health care system.  
1.2 Summary of Research Topics and State of the Art 
Topic (I): Multimodality imaging data fusion and novel latent variable models for 
subtype discovery of migraine. Migraine is a neurological disease that ranks in the top 20 of 
the world’s most disabling medical illnesses. Over 10% of the population suffers from 
migraine and nearly 1 in 4 U.S. households includes someone with migraine. Treatment of 
migraine has not achieved much success because of not being tailored to different subtypes 
of the disease. Current clinical definitions of subtypes use somewhat arbitrary boundaries 
primarily based on patient self-reported symptoms, which are subjective and error-prone. 
Diagnostic structural MRI provides complementary, accurate multimodality measurements 
of the disease (Nan et al., 2013; Ung et al., 2012; Sundermann et al., 2014; Schwedt et al., 
2015; Chong et al., 2016). However, the existing imaging-based migraine research is 
supervised, i.e., it aims to find structural imaging biomarkers to differentiate migraine from 
healthy controls. However, it is known that there is substantial heterogeneity among 
patients with migraine. Also, even for patients that are diagnosed as having migraine, the 
clinical diagnostic criteria are symptom-based and use somewhat arbitrary boundaries 
developed by expert consensus. As a result, it is possible that patients with different 
outcomes or prognostications are lumped together. This inability to delineate patient 
heterogeneity leaves clinicians with inadequate information for early determination of the 
3 
 
most appropriate, personalized treatment strategy (i.e. more aggressive therapy vs. 
conservative therapy), and prevents them from accurately predicting functional outcomes 
for individual patients. To address this limitation of the existing research, I propose a 
multimodality factor mixture model (MFMM) for migraine subtype discovery.   
Topic (II): Multi-source multi-level data fusion and novel statistical models for 
improving nurse care coordination. Care coordination has been found to be instrumental 
for decreasing adverse events, improving quality and efficiency of care, and enhancing 
patient satisfaction (McDonald et al., 2007; Sticker et al., 2009). In coordinating patient 
care within the hospital, staff nurses, as the patient’s “ever-present” health care team 
members, play a vital role. In “Keeping Patients Safe”, a recent report by the Institute of 
Medicine, the role of staff nurses in care coordination that promotes patient safety and 
quality outcomes was highlighted. Recent qualitative studies illuminated the considerable 
amount of time staff nurses spend coordinating patient care via a broad range of activities 
from admission to discharge (Hendrich et al., 2008; Lamb et al., 2008; Aiken et al., 2008; 
Friese, 2008; Kazanjian et al. 2005; Laschinger et al. 2006). However, little research is 
available to reveal the relationship between the care coordination activities conducted by 
nurses and their demographics and workload as well as the characteristics of their practice 
environment. Such research is important for nursing process improvement and designing 
of the best practices. The recently developed Nurse Care Coordination Instrument (NCCI) 
is the first of its kind that enables quantitative data to be collected to measure various 
aspects of nurse care coordination (Lamb et al., 2008). Driven by this new development, 
we propose a multi-response multilevel model with joint fixed effect selection and joint 
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random effect selection across multiple responses. The proposed model is a combination 
of conventional multilevel models and modern variable selection techniques. Various 
variable selection techniques have been proposed in recent years, including lasso 
(Tibshirani, 1996), group lasso (Yuan et al., 2006), CAP (Zhao et al., 2009), just to name 
a few.  However, these methods are for single-level predictors; there is much less research 
in the multilevel setting. There are a few existing efforts in introducing variable selection 
in the multilevel setting (Schelldorfer et al., 2011; Ibrahim et al., 2011; Bondell et al., 2010; 
Ahn et al., 2012). However, these methods are for a single response only. In all, there is a 
lack of research in multi-response multilevel models with variable selection in the existing 
literature, which motives my research development. 
Topic (III): Imaging biomarker testing process optimization for prognostics of 
Mild Cognitive Impairment (MCI) conversion to AD.  Important to early detection and 
prevention of AD is the use of biomarkers to precisely predict the conversion of MCI to 
AD within a clinical time of interest. According to the new diagnostic guidelines 
recommended by the National Institute on Aging and the Alzheimer’s Association (1), the 
important biomarkers include those measuring A𝛽 deposition in plagues and those linked 
to downstream neuronal degeneration or injury processes, such as the phosphorylated tau 
(p-tau) level in cerebrospinal fluid (CSF), mean cerebral metabolism on 18F 
fludeoxyglucose positron emission tomography (FDG-PET), and hippocampal volume on 
structural magnetic resonance imaging (MRI). There has been a vast amount of studies 
aiming at using biomarker data to predict the conversion of MCI patients to AD (Borroni 
et al., 2006; Davatzikos et al., 2011; Hinrichs et al., 2011; Jack et al., 2005; Llano et al., 
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2011; Misra et al., 2009; Stoub et al., 2004; Tondelli et al., 2012; Westman et al., 2011). A 
particular area of study with clear clinical relevance is to achieve this prediction 
using baseline biomarker measurements (Davatzikos et al., 2011; Hinrichs et al., 2011; 
Llano et al., 2011; Misra et al., 2009). Although using longitudinal repeated measurements 
of the same biomarkers has a potential to improve the prediction accuracy, this prolongs 
the diagnostic time span and makes clinical trials more time consuming and costly. In using 
baseline biomarkers to predict MCI conversion, most of the existing studies built statistical 
classification models that assign each MCI patient to be a converter or non-converter using 
a pre-trained model. The accuracy on large public datasets like the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) has been reported to be between 60-72%. The existing 
studies have several limitations, including unsatisfactory accuracy due to MCI 
heterogeneity, use of conventional classification models that require biomarkers to be 
measured all at once instead of sequentially and as-needed, and use of raw numerical 
measurement of the biomarkers instead of discretized levels that are more robust to 
measurement errors and provide convenience for clinical utilization. To tackle these 
limitations, we propose a novel sequence tree-based classifier (STC) for predicting the 
conversion of MCI to AD. 
1.3 Expected Original Contribution 
The expected original contributions include: 
 We propose a multimodality factor mixture model (MFMM) for migraine 
subtype discovery. MFMM adopts a latent variable formulation that assumes 
there are latent variables of a much lower dimension underlying the observed 
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features of each modality and joins the modality-wise latent variables in a 
unified framework for identifying the cluster structure of a patient cohort. 
MFMM employs a novel double- 𝐿21 -penalized likelihood formulation to 
achieve hierarchical selection of informative imaging modes and features. This 
formulation is proven to satisfy a Quadratic Majorization (QM) condition that 
allows for an efficient Group-wise Majorization Descent (GMD) algorithm to 
be developed for model estimation. Simulation studies are performed and show 
significantly better performance of MFMM than competing methods. MFMM 
is applied to migraine subtype discovery based on brain cortical area, cortical 
thickness, and volume measurements from structural magnetic resonance 
imaging (MRI). Two migraine subtypes are found, whose subjects significantly 
differ in clinical characteristics. This finding shows promise of using imaging 
data to help with patient stratification and with development of biomarkers for 
personalized management of migraine.  
 We propose a novel multi-response multilevel model with joint fixed effect 
selection and joint random effect selection across multiple responses to reveal 
the relationship between the care coordination activities conducted by nurses 
and their demographics and workload as well as the characteristics of their 
practice environment. This model is particularly suitable for modeling the 
unique data structure of the NCCI due to its ability of jointly modeling of 
multilevel predictors, including demographic and workload variables at the 
individual/nurse level and characteristics of the practice environment at the unit 
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level, and multiple response variables that measure the key components of nurse 
care coordination. We develop a Block Coordinate Descent (BCD) algorithm 
integrated with an Expectation-Maximization (EM) framework for model 
estimation, and perform theoretical analysis to reveal the reason why the 
proposed model is able to outperform the existing multilevel method that 
models each response variable in separation. Asymptotic properties of the 
proposed model are derived. Simulation studies are performed, showing that 
the proposed model outperforms competing methods. We apply the proposed 
model to a dataset collected across four U.S. hospitals using the NCCI. Our 
model achieves a significantly higher prediction accuracy compared with 
competing methods and also facilitates knowledge discovery. 
 We propose a novel sequence tree-based classifier (STC) for predicting the 
conversion of MCI to AD. Different from conventional classification models, 
STC achieves a sequential, as-needed use of biomarkers and a three-category 
classification (high-risk converter, low-risk converter, and inconclusive 
diagnosis) by finding an optimal sequence of biomarkers and two-sided cutoffs 
of each biomarker that satisfy pre-specified accuracy requirements while 
minimizing the proportion of inconclusive diagnosis. STC is also a personalized 
approach as it allows patient characteristic variables to be included to help 
identify patient-specific cutoffs for each biomarker. We apply STC to two 
important clinical applications using the data from the worldwide Alzheimer’s 
Disease Neuroimaging Initiative (ADNI) project: prediction of MCI conversion 
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and patient selection for AD-related clinical trials. In the first application, STC 
achieves high prediction accuracy. It also allows multiple criteria, e.g., accuracy 
and efficiency, to be optimized using a Pareto optimal frontier. Compared with 
the conventional decision tree classifier, STC achieved higher PPV and NPV, 
saved biomarker testing costs and patient waiting time, facilitated timely 
medical decision making, and produced a model that is consistent with medical 
knowledge and biological principles and thus being clinically more trust-
worthy. In the other application, STC is able to identify a sub-cohort of MCI 
subjects with a high risk to convert to AD. The sub-cohort has a reasonable size 
appropriate for clinical trials.  
1.4 Dissertation Organization 
The proposed dissertation research will be presented in three chapters, followed by 
the conclusion in Chapter 5, as shown in Figure 1. Chapter 2 presents the development 
of topic (I): multimodality imaging data fusion and novel latent variable models for 
migraine subtype discovery. Chapter 3 presents the development of topic (II): multi-source 
multi-level data fusion and novel statistical models for improving nurse care coordination. 
Chapter 4 presents the development of topic (III): imaging biomarker testing process 
optimization for prognostics of MCI conversion to AD. Chapter 5 summarizes the 
dissertation with conclusion remarks and discussions on future work.  
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Figure 1 Dissertation framework 
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CHAPTER 2 
A MULTI-MODE FACTOR MIXTURE MODEL WITH HIERARCHICALLY-
STRUCTURED SPARSITY FOR IMAGING-BASED MIGRAINE SUBTYPE 
DISCOVERY 
2.1 Introduction 
Medical imaging technology has revolutionized health care over the past 30 years by 
greatly facilitating screening, early diagnosis, treatment planning, evaluation of response 
to therapy, and prognosis. That is why the New England Journal of Medicine ranked 
imaging as one of the top medical developments over the past 1,000 years. With the rapid 
advances in imaging technology, it is now possible to acquire imaging of different modes 
for the same patient. These modes consist of complementary information about the organ 
of interest, thus enabling better medical decision making.  
Medicine is experiencing a paradigm shift toward precision medicine (PM), a shift that 
facilitates individualized patient evaluation and administration of precise treatment to the 
right patient at the right time. Imaging data from multiple modes plays a pivotal role in PM. 
For PM to succeed, it is critically important that subtle differences amongst patients with a 
disease be identified, especially if those differences are associated with prognoses and 
treatment responses. Multi-mode imaging data are likely to contribute to this subgroup/ 
subtype discovery (Giardino et al. 2017).   
Subtypes exist for almost every complicated disease. Clinical definitions of subtypes 
are typically determined using somewhat arbitrary boundaries developed by expert 
consensus. These definitions, however, are generally inadequate for explaining the 
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considerable heterogeneity among patients in terms of prognosis and response to treatment. 
For example, migraine is a neurological disease that ranks in the top 20 of the world’s most 
disabling medical illnesses. Approximately 12% of the population suffers from migraine 
and nearly 1 in 4 U.S. households includes someone with migraine. The current clinical 
subtype classification of migraine is based on the International Classification of Headache 
Disorders 3 beta (ICHD-3 beta) criterion, according to which migraine is sub-classified 
into episodic vs. chronic migraine based on headache frequency and into migraine with 
aura vs. migraine without aura. Although this subtype classification can explain the patient 
heterogeneity to some extent, a large amount of the heterogeneity is left unexplainable, i.e., 
the patients within the same subtype can still have significantly different disease course, 
prognosis, and response to treatment. This is a strong indication that there may be 
undiscovered subtypes. Similar frustration exists for other diseases especially those that 
are either extremely fatal or currently lack effective disease management strategies for 
individual patients, such as Alzheimer’s disease (Komarova et al. 2011), Parkinson’s 
disease, (van Rooden et al. 2010), and Type-II diabetes (Li et al. 2015). If subtypes of these 
diseases could be more accurately identified, a focus on homogeneous groups would 
enhance the likelihood of success for understanding the underlying disease mechanisms 
and lead to tailored treatment strategies. This would pave the road toward PM in which 
medical care is designed to optimize diagnosis, prognosis and therapeutic benefit for each 
particular group of patients or even individual patients.  
The focus of this research is to develop a data-driven method for subtype identification 
using imaging data of multiple modes. A method like this belongs to the general category 
12 
 
of clustering or unsupervised learning methods in statistics. However, there are multifold 
challenges in developing a clustering method appropriate for our specific focus on multi-
mode data: 1) There can be quite a few modes of data used in a study and some of them 
may be uninformative to the differentiation of subtypes. These modes should be 
automatically selected out such that they will not mask the underlying clustering structure. 
We would like to point out that the proposed method can be easily extendable to including 
non-imaging data of different modes such as patient demographics, disease history, clinical 
symptoms, and genetic signatures. This would lead to a more comprehensive discovery of 
subtypes, but with a greater likelihood for including uninformative/noise modes. This 
makes the ability of mode selection critically important. 2) Within each mode, it is 
commonplace that there are many features and some of them may be uninformative to the 
differentiation of subtypes. These features should be selected out.  
To address these challenges, we propose a novel clustering method called Multi-mode 
Factor Mixture Model (MFMM) that enables an automatic, hierarchical selection of 
informative imaging modes and features. Here, “hierarchical selection” means that if a 
mode is uninformative, all the features it includes should be excluded; feature selection 
happens in the imaging modes that remain. This research contributes to both statistics and 
medicine: 
 Contribution to statistics: MFMM intersects with several existing research areas 
in statistics, such as sparse learning, model-based clustering, and factor models, but none 
of these areas has a method that is capable of clustering data from multiple modes with 
hierarchical mode and feature selection. In this sense, MFMM is the first of its kind. 
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Specifically, we propose a novel double-𝐿21-penalized likelihood formulation for MFMM 
to achieve mode and feature selection. We prove that this formulation satisfies a Quadratic 
Majorization (QM) condition such that an efficient Group-wise Majorization Descent 
(GMD) algorithm can be developed to estimate the MFMM, which greatly speeds up the 
Expectation-Maximization (EM) iterations.   
 Contribution to medicine: We applied MFMM to identification of potential 
subtypes of migraine by clustering subjects using their brain cortical area, cortical thickness, 
and volume measurements (treated as three modes) from structural Magnetic Resonance 
Imaging (MRI). Data were obtained from two medical institutions, Mayo Clinic at Arizona 
(MCA) and Washington University School of Medicine in St. Louis (WashU). MFMM 
found two clusters that are very well separated, indicating that subjects in the clusters have 
distinct imaging phenotypes. The imaging features selected by MFMM to produce the 
clustering result are well-documented in the literature to relate to migraine. Interestingly, 
we found that the two clusters also significantly differ in terms of clinical characteristics, 
with one cluster having more allodynia symptoms during migraine attacks, more migraine-
related disability, and a greater number of years with migraine. In essence, this study 
contributes to understanding of migraine heterogeneity from an imaging perspective. The 
finding that the identified imaging subtypes were associated with distinct clinical 
characteristics shows promise of using imaging subtypes to help stratify patients and to 
serve as biomarkers for personalized management of migraine.  
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The rest of this paper is organized as follows: Section 2.2 provides a literature review. 
Section 2.3 presents the development of MFMM. Section 2.4 shows simulation 
experiments. Section 2.5 presents the migraine application. Section 2.6 is conclusion.  
2.2 Literature Review 
The proposed method intersects with a number of existing research areas. Next, we 
will review them one by one and point out their limitations, which highlights the need for 
new methodological development.  
Sparse learning (SL): SL models (a.k.a. variable selection techniques) started to 
emerge a few decades ago, driven by the technological improvement on human genomic 
sequencing that produced high-dimensional genomic data, with the classic Least Absolute 
Shrinkage and Selection Operator (LASSO) model developed by Tibshirani in 1996 
(Tibshirani 1996). The basic idea of LASSO is a 𝐿1-penalized least squares method that 
results in the estimates of many irrelevant regression coefficients to be exactly zero. The 
following years have witnessed a booming development of SL models with different 
structural considerations or/and statistical properties, such as adaptive LASSO (Zou 2006), 
SCAD (Fan et al. 2001), elastic net (Zou et al 2005), group LASSO (Yuan et al. 2006), 
fused LASSO (Tibshirani et al. 2005), tree-guided LASSO (Kim et al. 2012), just to name 
a few. However, all these existing models are supervised learning methods, i.e., they aim 
to predict a response variable while our focus here on subtype discovery requires an 
unsupervised/clustering method.  
Model-based clustering (MBC): Clustering analysis is a classic research area in 
statistical modeling and machine learning. Clustering methods generally fall into two 
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categories: algorithm-based and model-based methods. The first category includes many 
methods such as hierarchical clustering, k-means, and more recently developed DBSCAN 
(Ram et al. 2010) and OPTICS (Ankerst et al. 1999) algorithms for big data. These 
algorithms are largely heuristic and not based on formal models. This is not necessarily a 
disadvantage since clustering, by nature, is exploratory. On the other hand, MBC methods 
are based on formal models, making it possible to study statistical properties and perform 
inferences (Melnykov et al. 2010). MBC methods assume that sample observations arise 
from a distribution that is a mixture of several components (i.e., the clusters) and each 
component can be described by a probability density function and has an associated 
probability or weight in the mixture. In principle, any probability model for the components 
can be adopted, while a multivariate Gaussian distribution is the most common.  
In recent years, sparse learning has been introduced into MBC. The basic idea of 
sparse MBC is to maximize the log-likelihood function of the mixture model subject to a 
penalty that is chosen to yield sparsity in the features. For example, Pan and Shen (Pan et 
al. 2007) assumed that the cluster-wise covariance matrix was diagonal and the same, and 
imposed a 𝐿1-penalty on the cluster-wise mean vectors. Xie et al. (Xie et al. 2008) proposed 
a more general approach that allowed for cluster-specific diagonal covariance matrices and 
penalized the variances together with the means.  Wang and Zhu (Wang et al. 2008) 
proposed two models that allowed for the cluster-specific mean parameters associated with 
the same feature to be penalized as a group. Raftery and Dean (Raftery et al. 2006) recast 
the feature selection problem as a model selection problem by comparing models 
containing nested subsets of features and making sure the nested models are sparse in 
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features. Witten and Tibshirani (Witten et al. 2010) developed a general framework for 
feature selection in MBC, and showed that k-means and hierarchical clustering can be 
represented as special cases of this framework with sparsity constraints. This work bridged 
algorithm-based and model-based clustering methods.  
For clustering of high-dimensional datasets, one approach is the above-reviewed 
sparse MBC. An alternative approach assumes that the observed high-dimensional features 
lie on a low-dimensional latent space, which is the idea of factor models. For clustering of 
imaging data, factor models are more appropriate than sparse MBC, because imaging 
features typically embrace a complex correlation structure, suggesting the existence of 
latent factors. For example, the imaging features used in our migraine application 
correspond to anatomically defined brain regions that are structurally and functionally 
related.  
Factor models: Earlier research adopts a two-step strategy in which a dimension 
reduction method such as Principal Component Analysis (PCA) and Correspondence 
Analysis (CA) is first used and clustering is then performed on the reduced space. However, 
treating dimension reduction and clustering as two separate steps may destroy the cluster 
structure in the data, as pointed out by Raftery (Raftery et al. 2006). More recent research 
developed the so-called factor mixture models (FMM). FMM is an extension of the classic 
factor analysis (FA). FA assumes that the sample observations are from a single 
distribution and aims at discovering the latent factors underlying the observed features. In 
contrast, FMM assumes that the factors are distributed as a mixture model and therefore 
represents a clustering approach. Different FMM models were developed based on 
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different assumptions on the mixture distribution (Lubke et al. 2005, Muthen et al. 2006, 
Montanari et al. 2010, Baek et al. 2010): Some assume only varying component means; 
some additionally assume the component covariance matrices to be different. Muthen and 
Lubke (Lubke et al. 2005) presented different strategies for integrating covariates in FMM 
with a notation that the heterogeneity in the observed features is caused by not only the 
factor mixture structure but also by covariates.  
FMM has been extensively used for subtype discovery of various diseases. For 
example, Lubke et al. (Lubke et al. 2007) used FMM to discover subtypes for Attention-
Deficit/Hyperactivity Disorder using behavioral data collected by a parent questionnaire. 
Rainbow et al. (Ho et al. 2014) applied FMM to find subtypes of breast cancer-related 
fatigue using fatigue symptom data. Pattyn et al. (Pattyn et al. 2015) used FMM to identify 
panic disorder subtypes on a broad range of anxiety symptoms. Litpon et al. (Lipton et al. 
2014) used FMM to identify migraine subtypes based on a broad collection of symptom 
measurements. However, the existing FMM models are essentially a single-mode approach, 
i.e., they forces all features to share the same latent factors even when the features are 
indeed from distinct modes (e.g., cortical area, thickness, and volume in the migraine 
application). This is not biologically valid and may lead to poor clustering performance 
because it destroys the inherent data structure. Also, the existing FMM does not have the 
ability for mode and feature selection. 
2.3 Development of MFMM 
2.3.1 MFMM Formulation  
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Consider 𝑀  modes of imaging data and let 𝒙𝑚  contain mean-centered features 
belonging to the 𝑚-th mode, 𝑚 = 1,… ,𝑀. Consider 𝒙𝑚 generated from low-dimensional 
factors 𝒇𝑚, i.e.,  
𝒙𝑚 = 𝐇𝑚𝒇𝑚 + 𝐁𝑚𝒛 + 𝜺𝑚                                           (2.1) 
𝒛 contains patient-specific covariates such as sex and age. 𝜺𝑚 contains random errors that 
follow a zero-mean Gaussian distribution with covariance matrix 𝚿𝑚 . 𝐇𝑚  and 𝐁𝑚  are 
coefficient matrices. In factor models, 𝐇𝑚 is also known as the loading matrix.  
Furthermore, let 𝒔 = (𝑠1, … , 𝑠𝐾)
𝑇 contain indicator variables for 𝐾 subtypes of a 
disease. 𝑠𝑘 = 1 if the patient has the 𝑘-th subtype and 0 otherwise. 𝒔 follows a multinomial 
distribution, i.e.,  
𝑓(𝒔) = 𝑓(𝑠1, … , 𝑠𝐾) =  ∏ (𝑤𝑘)
𝑠𝑘𝐾
𝑘=1 ,                             (2.2) 
where 𝑤𝑘 is the probability of the 𝑘-th subtype. 𝒔 is linked with the latent factors 𝒇𝑚 by 
𝒇𝑚  = 𝐀𝑚𝒔 + 𝝃𝑚.                                                  (2.3) 
𝐀𝑚is a coefficient matrix and 𝝃𝑚 contains random errors that follow a zero-mean Gaussian 
distribution with covariance matrix 𝚺𝑚. 𝐚𝑚,𝑘 is the 𝑘-th column of 𝐀𝑚, representing the 
mean value of 𝒇𝑚|𝑠𝑘 = 1. It is clear from (2.3) that the multiple imaging modes are 
coupled together through the shared latent subtype variables 𝒔.  
Put all the parameters into a set 𝚯 , i.e., 𝚯 = {{𝚯𝑚}𝑚=1
𝑀 , 𝒘} , where 𝚯𝑚 =
{𝐇𝑚, 𝐁𝑚, 𝐀𝑚, 𝚿𝑚, 𝚺𝑚} and 𝒘 = (𝑤1, … , 𝑤𝐾)
𝑇. We can write the complete log-likelihood 
function as: 
𝑙(𝚯) = ∑ {∑ 𝑙𝑜𝑔 (𝑓(𝒙𝑚,𝑖|𝒇𝑚,𝑖 , 𝒛𝑖; 𝚯))
𝑀
𝑚=1 +∑ 𝑙𝑜𝑔 (𝑓(𝒇𝑚,𝑖|𝒔𝑖; 𝚯))
𝑀
𝑚=1 + 𝑙𝑜𝑔(𝑓(𝒔𝑖; 𝚯))}
𝑁
𝑖=1 , (2.4) 
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where 𝑁  is the sample size; 𝒔  follows a multinomial distribution as shown in (2.2); 
𝒇𝑚,𝑖|𝒔𝑘,𝑖 = 1~𝑁(𝐚𝑚,𝑘 , 𝚺𝑚)  based on (2.3);  𝒙𝑚,𝑖|𝒇𝑚,𝑖, 𝒛𝑖~𝑁(𝐇𝑚𝒇𝑚,𝑖 + 𝐁𝑚𝒛𝑖, 𝚿𝑚) 
according to (2.1).  
Because (2.4) involves latent variables, we could use an EM algorithm to estimate 
the parameters. However, this approach does not consider that some modes or some 
features within a mode may be uninformative to the differentiation of subtypes. To help 
eliminate uninformative modes and features, we propose to add two 𝐿21-penalties to (2.4), 
which results in the following optimization problem: 
min 
𝚯
− 𝑙(𝚯) + 𝜆1∑ ∑ ‖𝐡𝑚
𝑗 ‖
2
𝑃𝑚
𝑗=1
𝑀
𝑚=1 + 𝜆2∑ ‖𝐀𝑚‖2
𝑀
𝑚=1 .             (2.5) 
𝐡𝑚
𝑗
 is the 𝑗-the row of 𝐇𝑚. ‖∙‖2 is the 𝐿2-norm of a vector or matrix. 𝜆1 and 𝜆2 are penalty 
parameters. It is well-known that an 𝐿21-penalty is able to zero out all the coefficients 
within the ‖∙‖2 as a group (Yuan, M. et al. 2006). Because of this property, the proposed 
MFMM in (2.5) can eliminate uninformative features hierarchically. That is, MFMM uses 
∑ ‖𝐀𝑚‖2
𝑀
𝑚=1  to eliminate uninformative modes (i.e., features of an uninformative mode 
will be eliminated altogether), and uses ∑ ∑ ‖𝐡𝑚
𝑗 ‖
2
𝑃𝑚
𝑗=1
𝑀
𝑚=1  to eliminate uninformative 
features within a mode. In this way, MFMM achieves both efficiency and flexibility. To 
see this more clearly, we can insert (2.3) into (2.1) and obtain the distribution of features 
𝒙𝑚 for the 𝑘-th subtype, i.e.,  
𝒙𝑚|𝑠𝑘 = 1~𝑁(𝐇𝑚𝐚𝑚,𝑘 + 𝐁𝑚𝒛,   𝐇𝑚𝚺𝑚𝐇𝑚
𝑇 +𝚿𝑚).                  (2.6) 
𝐚𝑚,𝑘 is the 𝑘-th column of 𝐀𝑚. (2.6) indicates that the distributions of 𝒙𝑚 for different 
subtypes differ in their means, because 𝐚𝑚,𝑘 is subtype-specific. If 𝐀𝑚 = 𝟎, i.e., 𝐚𝑚,𝑘 = 𝟎 
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for all subtypes, then the distribution of 𝒙𝑚 is the same regardless of the subtypes, i.e., all 
the features in 𝒙𝑚 are uninformative. Furthermore, given that 𝐀𝑚 ≠ 𝟎, if 𝐡𝑚
𝑗 = 𝟎, then the 
distribution of the 𝑗-th feature in 𝒙𝑚 is the same regardless of the subtypes, i.e., this feature 
is uninformative.  
Finally, to ensure model identifiability, we impose the following constraints to the 
MFMM: 
𝐸(𝒇𝑚) = 𝟎  and (𝒇𝑚) = 𝐈 . 
𝐈 is an identify matrix of an appropriate size.  
2.3.2 MFMM Estimation by EM Integrated with an Efficient GMD Alogorithm 
2.3.2.1 The EM Framework  
Because MFMM involves latent variables, we can adopt the EM framework for 
model estimation. Let {𝐗𝑚}𝑚=1
𝑀  be a dataset for the features of 𝑀 modes. Let {𝐅𝑚}𝑚=1
𝑀  and 
𝐒 be the missing data for the latent factors and subtype indicators. Also let 𝑔(𝚯) denote the 
objective function in (2.5). In the E-step, we will need to derive the expectation of 𝑔(𝚯) 
with respect to the conditional distribution of {𝐅𝑚}𝑚=1
𝑀 , 𝐒 given {𝐗𝑚}𝑚=1
𝑀  and the current 
estimate ?̃?, i.e.,  
{𝐅𝑚}𝑚=1
𝑀 ,𝐒 |{𝐗𝑚}𝑚=1
𝑀 ;?̃?(𝑔(𝚯))  
 = {∑ ∑ 𝐸𝒇𝑚,𝑖|𝒙𝑚,𝑖;?̃?(− log 𝑓(𝒙𝑚,𝑖|𝒇𝑚,𝑖, 𝒛𝑖; 𝚯))
𝑀
𝑚=1
𝑁
𝑖=1 + 𝜆1∑ ∑ ‖𝐡𝑚
𝑗 ‖
2
𝑃𝑚
𝑗=1
𝑀
𝑚=1 } +
      {∑ ∑ 𝐸𝒇𝑚,𝑖,𝒔𝑖|𝒙1,𝑖,…,𝒙𝑀,𝑖 ;?̃?(− log 𝑓(𝒇𝑚,𝑖|𝒔𝑖; 𝚯))
𝑀
𝑚=1
𝑁
𝑖=1 + 𝜆2∑ ‖𝐀𝑚‖2
𝑀
𝑚=1 } +
       ∑ 𝐸𝒔𝑖|𝒙1,𝑖,…,𝒙𝑀,𝑖 ;?̃?(− log 𝑓(𝒔𝑖; 𝚯))
𝑁
𝑖=1 .                                                                            (2.7) 
21 
 
Please see Appendix I for explicit forms of the expectations in (2.7) and detailed 
derivations to get them. In the M-step, we minimize (2.7) and obtain an updated estimate 
for 𝚯, i.e.,  
𝚯∗ = 𝑎𝑟𝑔min 
𝚯
𝐸{𝐅𝑚}𝑚=1𝑀 ,𝐒 |{𝐗𝑚}𝑚=1𝑀 ;?̃?(𝑔(𝚯)).                         (2.8) 
The two steps will iterate until convergence. A nice property of MFMM is that it allows 
the optimization in (2.8) to be decomposed into separate sub-optimization problems each 
with a smaller set of parameters to estimate, i.e.,   
𝐇𝑚
∗ , 𝐁𝑚
∗ = argmin
𝐇𝑚,𝐁𝑚
∑ 𝐸𝒇𝑚,𝑖|𝒙𝑚,𝑖;?̃?(− log 𝑓(𝒙𝑚,𝑖|𝒇𝑚,𝑖, 𝒛𝑖; 𝚯))
𝑁
𝑖=1 + 𝜆1∑ ‖𝐡𝑚
𝑗 ‖
2
𝑃𝑚
𝑗=1 ,          (2.9) 
{𝐀𝑚
∗ }𝑚=1
𝑀 = argmin 
{𝐀𝑚}𝑚=1
𝑀
   ∑ ∑ 𝐸𝒇𝑚,𝑖,𝒔𝒊|𝒙1,𝑖,…,𝒙𝑀,𝑖 ;?̃?(− log𝑓(𝒇𝑚,𝑖|𝒔𝑖;𝚯))
𝑀
𝑚=1
𝑁
𝑖=1 + 𝜆2∑ ‖𝐀𝑚‖2
𝑀
𝑚=1 ,      (2.10) 
𝑤𝑘
∗ =
∑ 𝑓(𝑠𝑘,𝑖=1|𝒙1,𝑖,…,𝒙𝑀,𝑖;?̃?)
𝑁
𝑖=1
∑ ∑ 𝑓(𝑠𝑘,𝑖=1|𝒙1,𝑖,…,𝒙𝑀,𝑖;?̃?)
𝐾
𝑘=1
𝑁
𝑖=1
, 𝑘 = 1,… , 𝐾, 
𝚿𝑚
∗ = 𝑑𝑖𝑎𝑔 (
1
𝑁
(∑ (𝒙𝑚,𝑖 − 𝐁𝑚
∗ 𝒛𝑖)(𝒙𝑚,𝑖 − 𝐁𝑚
∗ 𝒛𝑖)
𝑇𝑁
𝑖=1 − (∑ (𝒙𝑚,𝑖 − 𝐁𝑚
∗ 𝒛𝑖)𝐸 ((𝒇𝑚,𝑖)
𝑇
|𝒙𝑚,𝑖; ?̃?)
𝑁
𝑖=1 ) (𝐇𝑚
∗ )𝑇)),  
𝚺𝑚
∗ =
∑ ∑ 𝑓(𝑠𝑘,𝑖=1|𝒙1,𝑖,…,𝒙𝑀,𝑖;?̃?)(𝐸(𝒇𝑚,𝑖 (𝒇𝑚,𝑖)
𝑇
|𝒙1,𝑖,… , 𝒙𝑀,𝑖, 𝑠𝑘,𝑖 = 1; ?̃?)−𝐚𝑚,𝑘∗ (𝐚𝑚,𝑘∗ )
𝑇
)𝑁𝑖=1
𝐾
𝑘=1
∑ 𝑓(𝑠𝑘,𝑖=1|𝒙1,𝑖,…,𝒙𝑀,𝑖;?̃?)
𝑁
𝑖=1
, 
 = 1,… ,𝑀. Except (2.9) and (2.10), all other parameters can be estimated analytically. 
Therefore, the key to speeding up the EM iterations is to develop an efficient algorithm to 
solve the optimization problems in (2.9) and (2.10).  
2.3.2.2 The GMD Algorithm 
The optimization problem in (2.9) or (2.10) involves an 𝐿21-penalty (a.k.a. group-
lasso penalty). Classic approaches for solving 𝐿21 -penalized optimization include the 
block-wise descent (BD) algorithm (Yuan et al. 2006), block coordinate gradient descent 
algorithm (BCGD) (Meier et al. 2008), and Nesterov’s method (Liu et al. 2009). However, 
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these approaches are computationally slow. Recently, Yang and Zou (Yang et al. 2015) 
developed an efficient GMD algorithm that is 5~10 times faster than the classic algorithms. 
To apply GMD, the optimization problem must satisfy a QM condition. In what follows, 
we will first present the definition of the QM condition, then prove that the optimization 
problems in (2.9) and (2.10) satisfy the QM condition, and finally derive the GMD 
algorithm used to solve (2.9) and (2.10).  
Definition 1 (QM condition): Let 𝐃  denote a dataset and 𝜷  denote 𝑝 -dimensional 
parameters to be estimated in a minimization problem. 𝜷  is partitioned into 𝐽  groups, 
𝜷
(1)
, … ,𝜷
(𝐽)
. The minimization takes the form of  
argmin
𝜷
𝐿(𝜷|𝐃) + 𝜆∑ ‖𝜷
(𝑗)‖
2
𝐽
𝑗=1 .                                    (2.11)  
(2.11) satisfies the QM condition if and only if the following two assumptions hold: 
(i) 𝐿(𝜷|𝐃) is differentiable as a function of 𝜷, i.e., ∇𝐿(𝜷|𝐃) exists everywhere.  
(ii) There exists a 𝑝 × 𝑝 matrix 𝚲, which may only depend on the data 𝐃, such that 
for all 𝜷, 𝜷∗,   
𝐿(𝜷|𝐃) ≤ 𝐿(𝜷∗|𝐃) + (𝜷 − 𝜷∗)𝑇∇𝐿(𝜷∗|𝐃) +
1
2
(𝜷 − 𝜷∗)𝑇𝚲(𝜷 − 𝜷).  (2.12) 
Proposition 1: The minimization problem in (2.9) satisfies the QM condition.  
Proposition 2: The minimization problem in (2.10) satisfies the QM condition.  
Please see the proof of Proposition 1 in Appendix II. The proof of Proposition 2 
follows a similar idea so it is skipped due to space limit. Because the QM condition is 
satisfied, GMD can be used to solve (2.9) and (2.10). Next, we briefly describe the GMD 
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algorithm:  In step (𝜔 + 1) of the algorithm, we want to update the 𝑗-th group in 𝜷(𝜔) 
while keeping the other groups unchanged, i.e.  
𝜷(𝜔+1) − 𝜷(𝜔) = (0,…0, (𝜷(𝑗)
(𝜔+1)
− 𝜷(𝑗)
(𝜔)
)
𝑇
⏟              
𝑗−th group
, 0, … 0)
𝑇
. 
According to the QM condition in (ii), we can get following inequality:  
𝐿(𝜷(𝜔+1)|𝐃) ≤ 𝐿(𝜷(𝜔)|𝐃) + (𝜷(𝑗)
(𝜔+1)
− 𝜷(𝑗)
(𝜔)
)
𝑇
∇𝐿(𝑗) +
1
2
(𝜷(𝑗)
(𝜔+1)
− 𝜷(𝑗)
(𝜔)
)
𝑇
𝚲(𝒋) (𝜷(𝑗)
(𝜔+1)
− 𝜷(𝑗)
(𝜔)
), (2.13) 
where ∇𝐿(𝑗) and 𝚲(𝑗)  are sub-matrices of ∇𝐿(𝜷(𝜔)|𝐃) and 𝚲 only including the rows and 
columns corresponding to the 𝑗-th group. Furthermore, let 𝜏𝑗 be the largest eigenvalue of 
𝚲(𝑗) and set 𝜌𝑗 = (1 + 10
−6)𝜏𝑗. Then, (2.13) can be further relaxed as  
𝐿(𝜷(𝜔+1)|𝐃) ≤ 𝐿(𝜷(𝜔)|𝐃) + (𝜷(𝒋)
(𝜔+1)
− 𝜷(𝒋)
(𝜔)
)
𝑇
∇𝐿(𝑗) +
1
2
𝜌𝑗 (𝜷
(𝑗)(𝜔+1) − 𝜷(𝑗)
(𝜔)
)
𝑇
(𝜷(𝑗)
(𝜔+1)
− 𝜷(𝑗)
(𝜔)
), (2.14) 
where the inequality strictly holds unless 𝜷(𝑗)
(𝜔+1)
= 𝜷(𝑗)
(𝜔)
. Using (2.14), we can solve 
the optimization in (2.11) by solving 
argmin  
𝜷(𝑗)
(𝜔+1)
 𝐿(𝜷(𝜔)|𝐃) − (𝜷(𝑗)
(𝜔+1)
− 𝜷(𝑗)
(𝜔)
)
𝑇
∇𝐿(𝑗) −
1
2
𝜌𝑗 (𝜷
(𝑗)(𝜔+1) − 𝜷(𝑗)
(𝜔)
)
𝑇
(𝜷(𝑗)
(𝜔+1)
− 𝜷(𝑗)
(𝜔)
) +  𝜆 ‖𝜷(𝑗)
(𝜔)
‖
2
,  
(2.15) 
which has an analytical solution, i.e.,  
𝜷(𝑗)∗
(𝜔+1)
=
1
𝜌𝑗
(−∇𝐿(𝑗) + 𝜌𝑗𝜷
(𝑗)(𝜔)) (1 −
 𝜆
‖−∇𝐿(𝑗)+𝜌𝑗𝜷
(𝑗)
(𝜔)
‖
2
)
+
. (2.16) 
This greatly reduces the computational time for solving the optimization problem. Also, 
this algorithm is guaranteed to converge (proof is skipped).  
2.3.2.3 Model Selection 
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The numbers of subtypes and factors as well as the penalty parameters can be 
selected according to a model selection criterion that balances the model fit and complexity. 
The former is measured by the log-likelihood of the observed data, 𝑙, while the latter is 
given by the degree of freedom, 𝑑𝑓, that counts the number of non-zeros in the estimated 
parameters. There are various criteria to combine the fit and complexity in the literature, 
among which we found BIC works well in our simulation and real data experiments. BIC 
takes the form of −2𝑙 + 𝑙𝑜𝑔(𝑁) × 𝑑𝑓. Finally, once a model that minimizes the BIC has 
been identified, each subject/sample 𝑖 will be classified to a cluster for which the posterior 
probability of belonging to that cluster, i.e., 𝑃(𝑠𝑘,𝑖 = 1|𝒙1,𝑖, … , 𝒙𝑀,𝑖;𝚯
∗), is maximized.  
2.4 Simulation Studies 
We generate simulation data to assess the performance of MFMM and compare it 
with competing methods. Consider 120 subjects who have one of two subtypes for a disease. 
The probability of each subtype is 𝑤1 = 0.4 and 𝑤2 = 0.6. This means that among the 120 
patients, 48 have subtype 1 and 72 have subtype 2. Furthermore, suppose there are four 
imaging modes with two factors in each mode. In order to demonstrate the capability of 
MFMM in identifying informative or eliminating uninformative modes, we assume that 
the first two modes have a two-cluster structure corresponding to the two subtypes while 
the other two modes do not so they are uninformative modes. To accomplish this, we set 
the cluster-wise factor means of each mode according to Table 1. The factor means differ 
between two clusters in mode 1 and 2, but not in mode 3 and 4. We set the covariance 
matrices of the four modes according to (2.17), which do not differ between two clusters: 
𝚺1 = (
1 0.1
0.1 1
),  𝚺2 = (
1 0.1
0.1 1
), 𝚺3 = 𝐈, and 𝚺4 = 𝐈.                    (2.17) 
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Also, we consider three patient-specific covariates that are sampled from 𝑁(0,1). Once the 
data for the factors and covariates are generated from the aforementioned distributions, we 
proceed to generate the features using (2.1). The number of features is set to be 40 in each 
mode. In order to demonstrate the capability of MFMM in identifying informative or 
eliminating uninformative features within each mode, we assume that 10 features have a 
two-cluster structure corresponding to the two subtypes while the other 30 do not so they 
are uninformative features. To accomplish this, we set the coefficient matrices 𝐇𝑚 in (2.1) 
to be 
𝐇𝑚 = (
?̃?10×2
𝟎30×2
), 
with each element of ?̃? generated as follows: Generate a number from 𝑈𝑛𝑖𝑓𝑜𝑟𝑚 [1, 1.5], 
which is used as the magnitude of the element. To decide the sign of the element, generate 
another number from 𝑁(0,1). If this number is greater than -0.5, create a positive sign; 
otherwise, create a negative sign. Finally, we sample the random errors 𝛆𝑚 in (2.1) from 
𝑁(𝟎, 0.1 × 𝐈).  
Table 1: Factor means of each cluster/subtype within each mode 
Modes Clusters/subtypes 
𝑘 = 1 𝑘 = 2 
𝑚 = 1 𝐚1,1 = (1,1)
𝑇 𝐚1,2 = (−1,−1)
𝑇 
𝑚 = 2 𝐚2,1 = (0.75,0.75)
𝑇 𝐚2,2 = (−0.75,−0.75)
𝑇 
𝑚 = 3 𝐚3,1 = (0,0)
𝑇 𝐚3,2 = (0,0)
𝑇 
𝑚 = 4 𝐚4,1 = (0,0)
𝑇 𝐚4,2 = (0,0)
𝑇 
 
MFMM is applied to the simulation data. The experiment is repeated for 20 times. 
The two informative modes are correctly selected in 18 out of the 20 experiments, resulting 
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in 90% accuracy for mode selection by MFMM. Furthermore, to evaluate the feature 
selection accuracy of MFMM within each mode, we compute the sensitivity (i.e., the 
percentage of features with truly non-zero coefficients that are selected) and specificity 
(i.e., the percentage of features with truly zero coefficients that are not selected) of each 
experiment. Table 2 shows the average and standard deviation of sensitivity and specificity 
over all the experiments for each mode. These results show that MFMM achieves high 
accuracies in mode and feature selection.  
Table 2: Sensitivity and specificity of feature selection by MFMM (average ± standard 
deviation over all experiments) 
 Mode 1 Mode 2 Mode 3 Mode 4 
Feature selection 
sensitivity (%) 
100 ± 0 100 ± 0 100 ± 0 100 ± 0 
Feature selection 
specificity (%) 
92.8 ± 5.1 95.2 ± 4.1 93.3 ± 5.4 93.8 ± 4.5 
 
Furthermore, we compare MFMM with several completing methods, which are 
methods people would typically adopt if MFMM were not available. One competing 
approach is to apply conventional FMM on one mode at a time; the other is to apply FMM 
on pooled features from all the modes. For a fair comparison with MFMM, we add feature 
selection to FMM using an 𝐿21-penality, calle gFMM hereafter, and use BIC to select the 
penalty parameter. Because the ultimate performance measure for a clustering algorithm is 
its accuracy in discovering the true clustering structure, we compare the clustering accuracy 
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of the competing methods with MFMM. Figure 2 shows the overall clustering accuracy of 
each method, defined as the percentage of subjects correctly classified to their ground-truth 
subtypes. For the first completing approach of applying gFMM on each mode alone, we 
only show the results of mode 1 and 2, because the accuracies of mode 3 and 4 (i.e., the 
uninformative modes) are poor. It can be seen that MFMM achieves an overall accuracy 
of 90.8% ± 10.7%, which is significantly higher than the competing methods in Figure 2 
whose accuracies are 66.4% ± 13.2%, 60% ± 0%, and 61.6% ± 7.3%, respectively (p 
values < 0.001).  
 
Figure 2: Clustering accuracy of MFMM in comparison with three competing methods 
2.5 Application in Migraine Subtype Discovery from Multi-mode Imaging Data 
2.5.1 Data Collection and Image Processing 
The data used for this application were obtained from MCA and WashU through our 
clinical collaborators. A total of 120 subjects were included in this analysis. Migraine was 
diagnosed in accordance with the diagnostic criteria defined by the International 
Classification of Headache Disorders (Tibshirani 1996). Data collected from all subjects 
included demographics such as age and sex, and clinical characteristics and symptoms 
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measured through a number of instruments such as Beck Depression Inventory (BDI), 
State-Trait Anxiety Inventory (STAI), Allodynia Symptom Checklist 12 (ASC-12), 
Migraine Disability Assessment (MIDAS), Hyperacusis Questionnaire, Photosensitivity 
Assessment Questionnaire, together with a few individually measured key symptom 
variables such as headache frequency, number of years with migraine, and aura status.  
Structural MRI data were obtained from two Siemens 3T MRI machines. Details of 
the MRI acquisition were described in prior publications (Schwedt et al. 2017, Schwedt et 
al. 2015). Using a cortical reconstruction and segmentation program in the FreeSurfer 
image analysis suite (version 5.3, http://www.surfer.nmr.mgh.harvard.edu/), cortical area, 
thickness, and volume measurements of 68 Region of Interests (ROIs) were extracted. In 
our study, cortical area, cortical thickness, and volume are treated as three modes. Within 
each mode, 34 features correspond to ROIs at the right brain hemisphere, while the other 
34 correspond to same-name ROIs at the left hemisphere. Our analysis found no difference 
in the clustering structure between using 68 features in each mode and using 34 by 
averaging the features at the left and right hemispheres corresponding to the same-name 
ROI. Therefore, we will only present the result for the latter situation in this paper.  
2.5.2 Data Augmentation with Nuisance Modes and Features 
A challenge in applying any clustering method to real data is that the ground-truth 
clustering structure is unknown. This prohibits rigorous performance assessment for the 
clustering result using accuracy metrics like what can be done in a simulation study. On 
the other hand, this is what makes a clustering method appealing because it can lead to new 
discovery to extend the boundary of the existing knowledge in a domain. In this paper, we 
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design our study in a way that allows for performance assessment. Specifically, we add 
artificially generated nuisance modes and features to the real modes and features, apply 
MFMM to the combined data, and examine if MFMM is able to identify the real modes 
and features. In a prior study (Schwedt et al. 2017), we applied a non-penalized version of 
MFMM to the same dataset and found all three modes and 34 features within each mode 
to be relevant to a two-cluster (subtype) structure. This result was validated with the 
medical knowledge of our clinical collaborators and the existing literature of migraine 
studies. Therefore, the three modes are treated as real modes and 34 features as real features 
in the present study.  
To add nuisance modes and features, we employ the following steps: First, we add 68 
nuisance features ?̃?𝑚 to each real mode, which are generated by 
?̃?𝑚 = 𝟎68×1𝒇𝑚 + ?̃?𝑚𝒛 + ?̃?𝑚, 𝑚 = 1,2,3.                               (2.18) 
(2.18) takes the same form as (2.1) with 𝐇𝑚 = 𝟎68×1 because nuisance features are not 
supposed to have any clustering structure. To make the distribution of nuisance data as 
close as possible to the real data, we do not give the coefficient matrix ?̃?𝑚 arbitrarily but 
sample each row of ?̃?𝑚 with replacement from the rows of 𝐁𝑚. Although the true 𝐁𝑚 is 
unknown, we have a reliable estimate ?̂?𝑚  from a previous study that applied a non-
penalized version of MFMM to the real dataset (Schwedt et al. 2017). Similarly, we sample 
?̃?𝑚  from 𝑁(𝟎, ?̂?𝑚), where ?̂?𝑚  is from the previous study. Furthermore, we add three 
nuisance modes each having 34+68=102 features that match the size of augmented real 
modes. The features in a nuisance mode are generated by 
?̃̃?𝑚 = ?̃̃?𝑚?̃̃?𝑚 + ?̃̃?𝑚𝒛 + ?̃̃?𝑚, 𝑚 = 1,2,3,                                (2.19) 
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where each row of ?̃̃?𝑚 is sampled with replacement from the rows of ?̂?𝑚. Each of the first 
34 rows of ?̃̃?𝑚 are sampled from the rows of ?̂?𝑚 while the remaining 68 rows are all zeros. 
?̃̃?𝑚 is sampled from 𝑁(𝟎, ?̂?𝑚). We sample ?̃̃?𝑚 from 𝑁(0, 1) because nuisance modes are 
not supposed to have any clustering structure. Through this procedure, we create an 
augmented dataset of six modes (three real and three nuisance modes) and 102 features 
within each mode (34 real features in each real mode).  
2.5.3 Results from Application of MFMM  
We apply MFMM to the augmented data together with two patient-specific covariates, 
sex and age. All three real modes are correctly selected, resulting in 100% accuracy. Within 
the two real modes, the sensitivity and specificity of selecting out the real features is 100% 
and 96.6%, respectively. MFMM found two clusters/subtypes among the 120 subjects, 
each consisting of 53 and 67 subjects, respectively. Call these subtypes A and B hereafter. 
A total of seven factors (2, 3, 2 from cortical area, cortical thickness, and volume modes, 
respectively) are found to differentiate subtypes A and B. The correspondence between 
these factors and the imaging features is encoded in the estimated loading matrix ?̂?𝑚 and 
is shown in Figure 3. A clear pattern is that the within each mode, loadings that reflect the 
contributions to the imaging features from one factor (i.e., bars of one color) are different 
from another factor (i.e., bars of another color). This indicates that there may be more than 
one biological underpinning underlying the observed imaging features, and thus supporting 
the validity of multiple factors found in each mode. Furthermore, we highlight the ROIs in 
each mode whose measurements most contribute to differentiation of the two subtypes in 
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Figure 4. These ROIs are those whose loading magnitudes are greater than the 80-th 
percentile of all the loadings estimated by the MFMM.  
 
Figure 3: Estimated loadings (y axis) that show the contribution of factors to original 
features (x axis) for (a) area, (b) thickness, and (c) volume. Loadings whose magnitudes 
are less than the 80-th percentile of all loadings are suppressed and represented by short 
bars for better visualization. 
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Figure 4: The ROIs whose (a) area, (b) thickness, or (c) volume measurements most 
contribute to differentiation of the two subtypes are color-highlighted on a 3-D reading of 
the brain. 
Next, we would like to see how well subjects with subtype A and B are separated in 
terms of the seven factors. Since it is impossible to visualize the separation on a seven-
dimensional space, we choose to visualize it mode by mode. Figure 5(a)-(c) plot the 
subjects in terms of the two, three, and two factors within area, thickness, and volume 
modes, respectively. Figure 5(d) plots the posterior probability of each subject being 
subtype B, which reflects the joint effect of the seven factors in separating subjects with 
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the two subtypes. These results demonstrate that all the factors in each mode and all three 
modes contribute to the subtype separation. Also, the two clusters are separated very well, 
as the vast majority of the subjects in each cluster have a high posterior probability of being 
in the cluster they are assigned to, as shown in Figure 5(d).  
 
Figure 5: Separation of subjects with subtype A (red) and B (blue) in terms of the 
factors in each mode and the posterior probability of cluster membership. 
Finally, we would like to see how the two imaging-defined subtypes differ in clinical 
characteristics and symptoms. We focus on a panel of variables including the number of 
headache days per month, number of years with migraine, aura status, MIDAS score, STAI 
score, BDI score, allodynia during and between migraine attacks, hyperacusis, and 
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photophobia. We perform hypothesis testing to compare subtypes A and B in terms of each 
variable. Three variables are found to have statistically significant subtype difference: 
migraine subjects with subtype A have a greater number of years with migraine (p value = 
0.01), more migraine-related disability as measured by the MIDAS score (p value = 0.04), 
and greater symptoms of allodynia during migraine attacks (p value = 0.03).  
2.5.4 Discussion on Medical Implications 
The main finding of this application was identification of two clusters (i.e., subtype A 
and B) of the study cohort based on structural MRI measurements of brain cortical area, 
cortical thickness, and volume. The two clusters significantly differ in a number of clinical 
characteristics including the number of years with migraine, allodynia during migraine 
attacks, and migraine-related disability. These clinical variables have been previously 
reported to relate to brain imaging findings in migraine. For example, a number of studies 
have shown that the number of years with migraine is associated with brain structure and 
function (Chong et al. 2016, Chong et al. 2015, Jin et al. 2013). In general, the longer a 
person has had migraine and the more attacks they have had, the greater the brain 
differences. Allodynia symptom severity was measured using the ASC-12, a questionnaire 
that collects information about cutaneous allodynia – the sensation of pain to normally non-
noxious stimulation of the skin (Lipton et al. 2008). Several imaging studies have 
demonstrated associations between brain structure and function with symptoms of 
allodynia (Moulton et al. 2008, Schwedt et al. 2014, Chong et al. 2016, Russo et al. 2016). 
Disability could be a marker for the severity of migraine symptoms as well as the person’s 
ability to cope with their migraine symptoms [Ford et al. 2008]. Migraine severity and 
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coping mechanisms could both associate with measures of brain structure and function. 
The structural measurements that differentiated the two clusters in this study were of brain 
regions that have previously been shown to be aberrant in migraine and/or in individuals 
who have allodynia. (Schwedt et al. 2014, Russo et al. 2016, Schwedt et al. 2015, 
Hadjikhani et al. 2013, Russo et al. 2012, Schwedt et al. 2014, Schwedt et al. 2015, Liu et 
al. 2012, Zhao et al. 2013, Mickleborough et al. 2016, Schmitz et al. 2008). Of note, the 
clusters did not differ for headache frequency or aura status – characteristics that are 
currently used to subtype migraine in the ICHD 3 beta. Further investigations are needed 
to determine if brain imaging based subtyping of migraine is superior to current 
classification in regards to prognosticating outcomes, predicting development of co-
morbidities, and predicting treatment responses, which important components of precision 
medicine. 
2.6 Conclusion 
In this paper, we proposed a new method, MFMM, for clustering multi-mode image 
data to enable subtype identification. MFMM employed a double-𝐿21-penalized likelihood 
formulation to enable imaging mode and feature selection. We developed an efficient GMD 
algorithm embedded in the EM framework to estimate the model parameters. We 
performed simulation experiments to compare MFMM with competing methods and found 
significantly better performance of MFMM in terms of mode selection accuracy, feature 
selection accuracy, and clustering accuracy. We applied MFMM to migraine subtype 
discovery based on brain cortical area, cortical thickness, and volume measurements from 
MRI. Two clusters/subtypes were found and well separated using a total of seven factors. 
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Subjects in the two clusters had significant different clinical characteristics. Findings from 
this study showed promise for imaging-based subtyping of migraine and patient 
stratification toward PM. 
There are a number of extensions for the current study. In terms of statistical 
modeling, MFMM could be extended to include mixed-type features. In terms of migraine, 
functional imaging data such as fMRI could be combined with the currently used structural 
MRI for subtype identification on a broader range of structural and functional 
measurements. Also, MFMM and its extensions can be applied to subtype discovery of 
other diseases.   
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CHAPTER 3 
A MULTI-RESPONSE MULTILEVEL MODEL WITH APPLICATION IN NURSE 
CARE COORDINATION 
3.1 Introduction 
Due to the increasing prevalence of chronic illnesses and aging of our society, 
patients hospitalized for acute care episodes nowadays are likely to have at least one 
chronic illness (Anderson, 2007; Boltz et al., 2008). This has created a tremendous new 
challenge for the already-heavily-burdened health care system: treating and caring for the 
acute episode of a patient who has chronic comorbidities is complex, requiring well-
planned interventions and involving numerous providers. To tackle this challenge, care 
coordination has been recommended as one fundamental approach (Institute for Healthcare 
Improvement, 2004; MedPac, 2007) and effective care coordination has been found to 
decrease adverse events, improve quality and efficiency of care, and enhance patient 
satisfaction (McDonald et al., 2007; Sticker et al., 2009). In coordinating patient care 
within the hospital, staff nurses, as the patient’s “ever-present” health care team members, 
play a vital role. In “Keeping Patients Safe”, a recent report by the Institute of Medicine, 
the role of staff nurses in care coordination that promotes patient safety and quality 
outcomes was highlighted. Recent qualitative studies illuminated the considerable amount 
of time staff nurses spend coordinating patient care via a broad range of activities from 
admission to discharge (Hendrich et al., 2008; Lamb et al., 2008; Aiken et al., 2008; Friese, 
2008; Kazanjian et al. 2005; Laschinger et al. 2006). 
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Until recently, study of staff nurse care coordination was hampered by the lack of 
an operational definition of staff nurse care coordination and the absence of tools to 
measure the process. In a recent project sponsored by the Robert Wood Johnson 
Foundation, Lamb (one of the co-authors of this paper) and her team developed, for the 
first time, an operational definition for staff nurse care coordination through systematic 
analysis of extensive observations and interviews of staff nurses and members of their 
nursing and interdisciplinary teams. The definition of nurse care coordination, according 
to Lamb et al. (2008), is “the actions initiated by nurses with patients, families, and/or 
members of their health care team to manage and correct the sequence, timing, and/or 
effectiveness of patient care from hospital admission to discharge”. Based on this definition, 
Lamb further identified six categories of staff nurse care coordination activities: 
“organizing”, “checking”, “mobilizing”, “exchanging”, “assisting”, and “backfilling”, 
referred to as “o”, “c”, “m”, “e”, “a”, and “b” in this paper. Detailed definitions of the six 
categories can be found in Appendix A.1. Furthermore, Lamb led the design and validation 
of an instrument called the Nurse Care Coordination Instrument (NCCI) that allows for 
quantitative data to be collected to measure the coordination activities. This effort provided 
groundwork for advancing the understanding and improvement of nurse care coordination 
in the hospital.  
Capitalizing on the newly developed NCCI, we present a study in this paper that 
aims to examine and reveal how nurses’ care coordination is related to their practice 
environment, demographics, and workload. To achieve this goal, a multilevel model 
(Demidenko 2013) is a natural choice for analyzing the NCCI data, because the predictors 
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in the data come from two levels: demographic and workload variables at the 
individual/nurse level and characteristics of the practice environment at the 
organizational/unit level. However, simply adopting the existing multilevel model would 
not suffice. There are a number of challenges inspiring new model development in this 
paper. First, nurse care coordinate is not a univariate concept but includes multiple 
categories describing the multi-faceted coordination activities, such as “m”, “e”, and “a”. 
This results in multiple response variables to be modeled simultaneously. Simply applying 
the existing multilevel model to each response separately overlooks the correlation between 
the multiple responses. This correlation inherently exists and could be strong in our 
problem domain because prior research has found that nurses who engage more in one type 
of care coordination activities tend to engage more in another type of activities (Duva, 
2010). From the point of view of statistical modeling, joint modeling of multiple responses 
allows for the multiple models to borrow strength from each other and mitigates sample 
size limitation. Second, considering that the statistical model should be ultimately helpful 
for guiding the improvement and best practices of nurse care coordination, the model 
should be able to identify a small number of significant predictors out of the originally 
included predictors, many of which could be noise or have only a small effect on the 
responses. This provides convenience for practical implementation of the modeling results. 
Furthermore, with similar prediction accuracy, a model that uses the same subset of 
predictors to predict the multiple responses is more desirable than a model that uses 
different subsets of predictors to predict different responses. The former model typically 
requires a smaller number of total predictors to be measured in order to predict the multiple 
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responses, thus saving cost and effort for data acquisition. Also, if the predictors can be 
confirmed to causally affect the response variables of care coordination, the former model 
means a potential saving in the cost of intervention by adjusting fewer predictors to 
improve multiple aspects of the care coordination.   
To address the aforementioned challenges in modeling the NCCI data, we propose 
a multi-response multilevel model that uses two adaptive 𝑙21-penalties to enable joint fixed 
effect selection and joint random effect selection across multiple responses. To our best 
knowledge, such a model is not available in the existing literature. The contribution of this 
research is two-fold: To the field of statistical modeling, we propose a new formulation for 
a multi-response multilevel model driven by a newly emerged problem in the health care 
system, develop an efficient Block Coordinate Descent (BCD) algorithm integrated with 
an Expectation-Maximization (EM) framework for model estimation, perform theoretical 
analysis to reveal the insight as to how the proposed method “joins” the estimation of the 
model for each response variable together and the benefit of such a joint estimation, and 
demonstrate asymptotic properties. To the field of nursing research, our study is the first-
of-its-kind that elucidates the quantitative relationship between nurses’ practice 
environment, demographics, and workload and their multi-faceted care coordination 
activities. We anticipate that the knowledge and insights generated from our study could 
facilitate the design and optimization of nurses’ workload and practice environment, which 
leads to better care coordination and eventually better patient outcomes.  
The rest of the paper is organized as follows: Section 3.2 reviews the existing 
research related to the proposed statistical model; Section 3.3 presents the model 
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formulation; Section 3.4 presents the estimation algorithm; Section 3.5 investigates 
asymptotic properties; Section 3.6 presents simulation studies; Section 3.7 presents the 
application; Section 3.8 concludes the chapter.  
3.2 Literature Review 
The proposed model is a combination of conventional multilevel models and 
modern variable selection techniques. Conventional multilevel models have been 
extensively discussed in numerous papers and books, which do not include “variable 
selection” in their formulations. Variable selection techniques are modern statistical 
modeling and machine learning developments that were driven by the emergence of high-
dimensional datasets in various domains. The basic idea of variable selection is to add 
penalties to the regression coefficients in order to shrink the estimates for the regression 
coefficients of insignificant predictors to be exactly zero. Various forms of penalties have 
been proposed, which can model different structures of the predictors and/or have different 
statistical properties. The classic lasso model was proposed as a penalized least squares 
method with an 𝑙1-penalty that resulted in the estimates of some regression coefficients to 
be exactly zero (Tibshirani, 1996). Fan et al. (2001) conjectured the asymptotic 
inconsistency of lasso and proposed an SCAD penalty that enjoyed the oracle properties. 
Zhao et al. (2006) further discussed the consistency of lasso and proved an almost sufficient 
and necessary condition for lasso to select the true model. Zou (2006) proposed an adaptive 
lasso model that applied adaptive weights to the 𝑙1-penalty and proved the oracle properties 
of this model. To handle data with grouped predictors, Yuan et al. (2006) proposed a group 
lasso model capable of selecting a sparse set of groups by imposing an 𝑙1-penalty on the 
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regression coefficients of predictors from each group. Zou et al. (2005) proposed an elastic 
net model that encouraged a grouping effect among strongly correlated predictors. As an 
integration of some existing methods and bootstrap, random lasso was proposed to alleviate 
some of the limitations of lasso, elastic net, and related methods (Wang et al., 2011). A 
hierarchical lasso was proposed to not only remove unimportant groups of predictors but 
also select important predictors within a group (Zhou and Zhu, 2010). To achieve grouped 
and hierarchical variable selection, a Composite Absolute Penalties (CAP) family was 
proposed to add side information to boost the estimation of a regression or classification 
model (Zhao et al. 2009). In addition to frequentist methods, Bayesian methods for variable 
selection were also developed. George et al. (1997) discussed and compared a variety of 
approaches for Bayesian variable selection. Fahrmeir et al. (2010) provided a unified view 
between Bayesian methods and penalized frequentist methods for variable selection. Note 
that the review in this section by no means provides a complete list of existing variable 
selection approaches. However, a vast majority of the existing approaches including all the 
aforementioned ones are for single-level predictors; there is much less research in the 
multilevel setting.  
Among the few existing efforts in introducing variable selection in the multilevel 
setting, Schelldorfer et al. (2011) proposed a method that adds an 𝑙1-penalty to the fixed 
effects. This achieves variable selection on fixed effects alone, but not on random effects. 
A significant difficulty in variable selection on random effects is that, not like fixed effects 
that are characterized by regression coefficients, random effects are characterized by a 
covariance matrix, 𝚿. Therefore, variable selection on random effects will have to be done 
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through penalizing the covariance matrix, which is not straightforward.  To achieve this, 
Ibrahim et al. (2011) proposed a Cholesky decomposition on 𝚿, i.e., 𝚿 = 𝚲𝚲𝑇, where 𝚲 
is a lower triangular matrix. Then, the elements in each row of 𝚲 are penalized as a group. 
If some rows of 𝚲 are estimated to be zero, this will result in some rows and columns of 𝚿 
to be zero, which has an effect of removing the random effects corresponding to these 
rows/columns. Bondell et al. (2010) proposed a modified Cholesky decomposition to 
decompose 𝚿 into a lower triangular matrix, 𝚪, whose diagonal elements are all ones and 
a diagonal matrix 𝐃 , i.e., 𝚿 = 𝐃𝚪(𝐃𝚪)𝑇 . Then, an adaptive 𝑙1 -penalty is put on the 
diagonal elements of 𝐃 to shrink some elements to be zero, which has an effect of removing 
the rows/columns of 𝚿 corresponding to these elements and thereby excluding the random 
effects corresponding to the removed rows/columns. Ahn et al. (2012) proposed a moment-
based loss function for estimating the covariance matrix of random effects. Then, two types 
of penalties including a hard threshsholding operator and a sandwich-type soft thresholding 
penalty are imposed to achieve variable selection of random effects. However, all these 
existing methods are for a single response only.  
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3.3 A Multi-response Multilevel Model with Joint Fixed Effect Selection and Joint 
Random Effect Selection 
Figure 6: Data structure targeted by the proposed model 
It is evident from the literature review that little work has been done on multi-
response multilevel models with variable selection in both fixed and random effects. 
However, such a model is needed for properly modeling the NCCI data. This motivates our 
new model development. Our proposed model is aimed for a nested multilevel multi-
response data structure as depicted in Figure 6. First, 𝑦𝑖𝑗𝑠 is related to 𝒛𝑖𝑗  by a linear model, 
i.e., 𝑦𝑖𝑗𝑠 = 𝜶𝑖𝑠
𝑇 𝒛𝑖𝑗 + 𝜀𝑖𝑗𝑠. This is called a level-one model, which characterizes how nurses’ 
demographics and workload impact their care coordination. Then, this impact, reflected by 
𝜶𝑖𝑠, is related to 𝒙𝑖 by a level-two model, i.e., 𝜶𝑖𝑠 = 𝐁𝑠𝒙𝑖 + 𝒆𝑖𝑠. This model characterizes 
how units’ organizational characteristics affect the relationship between nurses’ 
demographics/workload and their coordination. Combining level-one and level-two 
models, we can get 
𝑦𝑖𝑗𝑠 = 𝒙𝑖
𝑇𝐁𝑠
𝑇𝒛𝑖𝑗 + 𝒆𝑖𝑠
𝑇 𝒛𝑖𝑗 + 𝜀𝑖𝑗𝑠,     (3.1) 
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where 𝒆𝑖𝑠~𝑁(𝟎, 𝜎𝑠
2𝚿𝑠)  and 𝜀𝑖𝑗𝑠~𝑁(0, 𝜎𝑠
2)  are between-unit and within-unit random 
errors. 𝐁𝑠 and 𝒆𝑖𝑠  are known as fixed and random effects, respectively.  Apply a modified 
Cholesky decomposition (Chen and Dunson, 2003) to the covariance matrix of the random 
effects, i.e., 𝚿𝑠 = 𝐃𝑠𝚪𝑠(𝐃𝑠𝚪𝑠)
𝑇, where 𝐃𝑠 is a diagonal matrix and 𝚪𝑠 is a lower triangular 
matrix. Then, the random effects can be re-parameterized as 𝒆𝑖𝑠 = 𝐃𝑠𝚪𝑠?̃?𝑖𝑠 , where 
?̃?𝑖𝑠~ N(𝟎, 𝜎𝑠
2𝐈). For the ease of subsequent discussion, we also re-parameterize the fixed 
effects as 𝒙𝑖
𝑇𝐁𝑠
𝑇𝒛𝑖𝑗 = 𝜷𝑠
𝑇𝒘𝑖𝑗 , where 𝒘𝑖𝑗  is a vector that concatenates 𝒙𝑖 , 𝒛𝑖𝑗 , and the 
interactions between them, and 𝜷𝑠  is a vector consisting of the elements of 𝐁𝑠 . 
Considering these re-parameterizations, (3.1) becomes  
𝑦𝑖𝑗𝑠 = 𝜷𝑠
𝑇𝒘𝑖𝑗 + (𝐃𝑠𝚪𝑠?̃?𝑖𝑠)
T𝒛𝑖𝑗 + 𝜀𝑖𝑗𝑠,   (3.2) 
Stacking up the data of all the nurse within the 𝑖 -th unit, we can get 𝒚𝑖𝑠 = 𝐖𝑖𝜷𝑠 +
𝒁𝑖(𝐈 ⊗ 𝐃𝑠)(𝐈 ⊗ 𝚪𝑠)?̃?𝑠 + 𝜺𝑖𝑠, which corresponds to the grey blocks in Figure 7. Further 
stacking up the data of all the units as illustrated in Figure 7, we can get 
  𝒚𝑠 = 𝐖𝜷𝑠 + 𝐙(𝐈⊗ 𝐃𝑠)(𝐈⊗ 𝚪𝑠)?̃?𝑠 + 𝜺𝑠.        (3.3) 
The parameters to be estimated for the model in (3.3) can be put into a vector 𝝓𝑠 =
(𝜷𝑠
𝑇 , 𝒅𝑠
𝑇 , 𝜸𝑠
𝑇)𝑇, where 𝒅𝑠 is a vector consisting of the diagonal elements of 𝐃𝑠 and 𝜸𝑠 is a 
vector consisting of the elements in 𝚪𝑠. Considering all the responses, the total parameters 
to be estimated are 𝝓 = (𝝓1
𝑇 , … ,𝝓𝕊
𝑇)𝑇. 
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Figure 7: A graph illustration for the model in (3.3) 
According to (3.3), 𝒚𝑠  follows a normal distribution with a mean 𝐖𝜷𝑠  and a 
covariance matrix ?̃?𝑠 = 𝐷𝑖𝑎𝑔(𝐕1𝑠, … , 𝐕𝑖𝑠, … , 𝐕𝑁𝑠), where 𝐕𝑖𝑠 = 𝜎𝑠
2(𝐙𝑖𝐃𝑠𝚪𝑠𝚪𝑠
𝑇𝐃𝑠
𝑇𝐙𝑖
𝑇 +
𝐈). Then, dropping constants, the log-likelihood function of the parameter set 𝝓 can be 
written as: 
𝑙(𝝓|{𝒚𝑠}𝑠=1
𝕊 ) = −
𝟏
𝟐
∑ {𝑙𝑜𝑔⌊?̃?𝑠⌋ + (𝒚𝑠 −𝐖𝜷𝑠)
𝑇?̃?𝑠
−1
(𝒚𝑠 −𝐖𝜷𝑠)}
𝕊
𝑠=1 .    (3.4) 
Furthermore, by treating the random effects in ?̃?𝑠 as observed data and dropping constants, 
we can write the complete-data log-likelihood function as 
 𝑙(𝝓|{𝒚𝑠}𝑠=1
𝕊 , {?̃?𝑠}𝑠=1
𝕊 ) = −
∑ 𝑛𝑖
𝑁
𝑖=1 +𝑁ℚ
2
∑ 𝑙𝑜𝑔 𝜎𝑠
2𝕊
𝑠=1 −
1
2
∑
1
𝜎𝑠
2 (
‖𝒚𝑠 − 𝐙(𝐈 ⊗ 𝐃𝑠)(𝐈 ⊗ 𝚪𝑠)?̃?𝑠 −𝐖𝜷𝑠‖
2
+?̃?𝑠
𝑇 ?̃?𝑠
)𝕊𝑠=1 .   (3.5)                    
Let ℙ and ℚ denote the dimensions of the fixed and random effects, respectively. 
To enable joint variable selection in fixed effects across all the responses, we impose an 
𝑙21 -penalty on 𝜷𝑠 , i.e., ∑ √∑ 𝛽𝑝𝑠2
𝕊
𝑠=1  
ℙ
𝑝=1 . This 𝑙21 -penalty allows for the fixed effects 
corresponding to the same predictor across all the responses to be selected as a group, i.e., 
these fixed effects are either all kept in or dropped out of the model. To achieve the same 
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purpose for random effects, we impose another 𝑙21-penalty on 𝐝s, i.e., ∑ √∑ 𝑑𝑞𝑠2
𝕊
𝑠=1  
ℚ
𝑞=1 . 
The consequence of this 𝑙21-penalty is that if the 𝑑𝑞𝑠’s corresponding to a predictor across 
all the responses (e.g., the 𝑑𝑞′1, … , 𝑑𝑞′𝕊 corresponding to the 𝑞′-th predictor across all the 
responses) are zero, then the 𝑞′-th row and 𝑞′-th column of 𝚿1, … ,𝚿𝕊 are automatically 
zero by definition of the modified Cholesky decomposition. As a result, the random effects 
corresponding to the 𝑞′-th predictor across all the responses are dropped out of the model 
as a group. Furthermore, we want to have adaptive weights to penalize different 
coefficients and thus using an adaptive 𝑙21-penalty in the form of ∑ √∑ (
𝛽𝑝𝑠
?̃?𝑝𝑠
)
2
𝕊
𝑠=1  
ℙ
𝑝=1 and 
∑ √∑ (
𝑑𝑞𝑠
?̃?𝑞𝑠
)
2
𝕊
𝑠=1  
ℚ
𝑞=1 , where 𝛽𝑝𝑠 is an adaptive weight for 𝛽𝑝𝑠 and ?̃?𝑞𝑠 is an adaptive weight 
for 𝑑𝑞𝑠. The purpose is to have a large amount of shrinkage for zero coefficients and a 
smaller amount of shrinkage for nonzero coefficients, thus achieving improved estimator 
efficiency and variable selection properties. With all these considerations, we define an 
adaptive 𝑙21-penalized complete-data log-likelihood criterion as follows: 
      𝑓(𝝓|{𝒚𝑠}𝑠=1
𝕊 , {?̃?𝑠}𝑠=1
𝕊 ) =  −𝑙(𝝓|{𝒚𝑠}𝑠=1
𝕊 , {?̃?𝑠}𝑠=1
𝕊 ) + 𝜆1∑ √∑ (
𝛽𝑝𝑠
?̃?𝑝𝑠
)
2
𝕊
𝑠=1  
ℙ
𝑝=1 + 𝜆2∑ √∑ (
𝑑𝑞𝑠
?̃?𝑞𝑠
)
2
𝕊
𝑠=1  
ℚ
𝑞=1 .     (3.6) 
λ1 and λ2 are regularization parameters for the fixed and random effects, respectively. In 
the next section, we present model estimation based on (3.6).  
3.4 Model Estimation by EM Integrated with a BCD Optimization Algorithm 
The proposed adaptive 𝑙21-penalized complete-data log-likelihood function in (3.6) 
involves unobserved variables, ?̃?𝑠. This makes the EM algorithm a proper choice for model 
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estimation. EM is a general method for finding the maximum likelihood estimate of model 
parameters from data with missing values (Dempster et al., 1977). It has also been used 
when optimizing the likelihood function is intractable analytically but is possible if some 
quantities in the likelihood function can be assumed known. These quantities are treated as 
missing/unobserved data in EM. EM works by iteratively conducting two steps. The E-step 
is to find the expectation of the complete-data log-likelihood with respect to the unobserved 
data given the observed data and the current parameter estimates. The M-step is to find 
parameter estimates that maximize the expectation in the E-step. The two steps are repeated 
until convergence. The EM framework has a nice property that it is guaranteed to converge 
to a local maximum of the likelihood function (Wu, 1983).  
The challenges in using the general EM framework in specific model estimation 
are to derive the expectation specific to that model formulation in the E-step and to develop 
an efficient optimization algorithm in the M-step. In what follows, we will discuss the two 
steps specific to our problem setting in (3.6):   
In the E-step at the ω-th iteration, our goal is to compute the expectation of the 
criterion in (3.6) with respect to the conditional distribution of {?̃?𝑠}𝑠=1
𝕊  given {𝒚𝑠}𝑠=1
𝕊  and 
the current estimate for 𝝓, 𝝓(𝜔) . It can be derived that this conditional distribution is 
normal with a mean and a covariance matrix given by (please see the derivation in 
Appendix A.2): 
?̂?𝑠
(𝜔) = (?̃?𝑠
𝑇(𝜔) ?̃?𝑠
(𝜔)𝐙𝑇𝐙?̃?𝑠
(𝜔)?̃?𝑠
(𝜔) + 𝐈)−1(𝐙?̃?𝑠
(𝜔)?̃?𝑠
(𝜔))𝑇(𝒚𝑠 −𝐖 𝜷𝑠
(𝜔) ),  (3.7) 
𝐔𝑠
(ω)
= 𝜎𝑠
2(𝜔) (?̃?𝑠
𝑇(𝜔) ?̃?𝑠
(𝜔)𝐙𝑇𝐙?̃?𝑠
(𝜔)?̃?𝑠
(𝜔) + 𝐈)−1,    (3.8) 
respectively. Here, ?̃?𝑠
(ω) = 𝐈⊗ 𝐃𝑠
(ω)
, ?̃?s
(ω) = 𝐈⊗ 𝚪𝑠
(ω)
, and the 𝜎𝑠
2(𝜔) in (3.8) is given by  
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𝜎𝑠
2(𝜔) =
(𝒚𝑠−𝐖𝜷𝒔
(𝜔)
 )
𝑇
(𝐙?̃?𝑠
𝑇(𝜔) 
?̃?𝑠
(𝜔)
𝐙𝑇𝐙?̃?𝑠
(𝜔)
?̃?𝑠
(𝜔)
𝐙𝑇+𝑰)−1×(𝒚𝑠−𝐖 𝜷𝒔
(𝜔)
)
∑ n𝑖
𝑁
𝑖=1
.   (3.9) 
Then, the expectation of the criterion in (3.6) can be obtained as:  
𝑔(𝝓|𝝓(𝜔)) =
 ∑
1
2𝜎𝑠
2(𝜔)
 𝕊𝑠=1 ([
𝜷𝑠
𝒅𝑠
]
𝑇
[
𝐖𝑇𝐖 𝐖𝑇𝐙 𝐷𝑖𝑎𝑔(?̃?𝑠?̂?𝑠
(𝜔)
)(𝟏𝑁⊗  𝐈)
 (𝟏𝑁⊗  𝐈)
𝑇𝐷𝑖𝑎𝑔(?̃?𝑠?̂?𝑠
(𝜔)
)𝐙𝑇𝐖 (𝟏𝑁⊗  𝐈)
𝑇(𝐑 °  ?̃?𝑠𝐆𝑠
(𝜔)
?̃?𝑠
𝑇) (𝟏𝑁⊗  𝐈)
] [
𝜷𝑠
𝒅𝑠
] −
2 𝒚𝒔
𝑻 [𝐖 𝐙 𝐷𝑖𝑎𝑔(?̃?𝑠?̂?𝑠
(𝜔)
)(𝟏𝑁⊗  𝐈)] [
𝜷𝑠
𝒅𝑠
]) + 𝜆1∑ √∑ (
𝛽𝑝𝑠
?̃?𝑝𝑠
)
2
𝑆
𝑠=1  
𝑃
𝑝=1 + 𝜆2∑ √∑ (
𝑑𝑞𝑠
?̃?𝑞𝑠
)
2
𝑆
𝑠=1  
𝑄
𝑞=1 ,   (3.10) 
where ?̃?𝑠 = 𝐈⊗ 𝚪𝑠 , 𝟏N is a 𝑁 × 1 vector of ones, 𝐷𝑖𝑎𝑔(?̃?𝑠?̂?𝑠
(𝜔)
) is a diagonal matrix 
whose diagonal elements being ?̃?𝑠?̂?𝑠
(𝜔)
, 𝐑 = 𝐙𝑇𝐙 , ?̂?𝑠
(𝜔)
= E(?̃?𝑠?̃?𝑠
𝑇) = 𝐔𝑠
(ω)
+ ?̂?𝑠
(𝜔)
?̂?𝑠
𝑇(𝜔) 
. 
“ ° ” represents the Hadamard product operator. 
In the M-step, our goal is to minimize 𝑔(𝝓|𝝓(𝜔)) with respect to 𝝓. Recall that 𝝓 
includes 𝜷𝑠 , 𝒅𝑠 , and 𝚪𝑠 , 𝑠 = 1, . . , 𝕊 . Therefore, the optimization of 𝑔(𝝓|𝝓
(𝜔))  with 
respect to 𝝓  can be done by iterating between two sub-optimizations: One sub-
optimization is to minimize 𝑔(𝝓|𝝓(𝜔)) with respect to 𝚪𝑠 , treating (𝜷𝑠
𝑇 , 𝒅𝑠
𝑇)𝑇  as given. 
This sub-optimization has a closed-form solution. The other sub-optimization is to 
minimize 𝑔(𝝓|𝝓(𝜔))  with respect to (𝜷𝑠
𝑇 , 𝒅𝑠
𝑇)𝑇 , treating 𝚪𝑠  as given. This sub-
optimization takes the following form: 
                 𝑚𝑖𝑛{𝜷𝑠}𝑠=1𝕊 ,{𝒅𝑠}𝑠=1𝕊    
{
 
 
 
 ∑
1
2𝜎𝑠
2(𝜔)
 𝕊𝑠=1 ([
𝜷𝑠
𝒅𝑠
]
𝑇
𝐀𝑠 [
𝜷𝑠
𝒅𝑠
] − 2 𝒃𝒔
𝑻 [
𝜷𝑠
𝒅𝑠
] ) + 
𝜆1∑ √∑ (
𝛽𝑝𝑠
?̃?𝑝𝑠
)
2
𝕊
𝑠=1  
ℙ
𝑝=1 + 𝜆2∑ √∑ (
𝑑𝑞𝑠
?̃?𝑞𝑠
)
2
𝕊
𝑠=1
ℚ
𝑞=1
}
 
 
 
 
,   (3.11)      
where 𝐀𝑠  and 𝒃𝑠
𝑇  are known and their forms can be obtained by comparing (3.11) and 
(3.10). To solve the optimization problem in (3.11), we note that (3.11) is a convex 
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optimization whose non-smooth parts, i.e., the adaptive 𝑙21-norms, are separable. This 
property motivates us to develop a BCD algorithm that is guaranteed to converge to a 
global minimum. Next, we describe the proposed BCD algorithm: 
Each “coordinate” in the BCD algorithm corresponds to a fixed or random effect, 
so there are ℙ + ℚ coordinates. BCD cycles through the coordinates until convergence. In 
what follows, we will discuss one cycle of BCD that estimates the 𝑝-th fixed effect. Other 
cycles that estimates the other fixed effects and the random effects share a similar 
procedure. Specifically, in the cycle that estimates the 𝑝 -th fixed effect, 𝜷𝑝 =
(𝛽𝑝1, … , 𝛽𝑝𝕊) is the parameter to be estimated, whereas all other fixed effects and all 
random effects are treated as known. Considering this, the optimization in (3.11) can be 
written as: 
𝑚𝑖𝑛𝜷𝑝  ∑
1
2𝜎𝑠
2(𝜔)
 𝕊𝑠=1 (
[?̂?1𝑠  ⋯ ?̂?𝑝−1,𝑠 𝛽𝑝𝑠 ?̂?𝑝+1,𝑠  ⋯ ?̂?𝑃𝑠 ?̂?𝑠
𝑇]𝐀𝑠[?̂?1𝑠  ⋯ ?̂?𝑝−1,𝑠 𝛽𝑝𝑠 ?̂?𝑝+1,𝑠  ⋯ ?̂?𝑃𝑠 ?̂?𝑠
𝑇]
𝑇
−2 𝒃𝑠
𝑇[?̂?1𝑠  ⋯ ?̂?𝑝−1,𝑠 𝛽𝑝𝑠 ?̂?𝑝+1,𝑠  ⋯ ?̂?𝑃𝑠 ?̂?𝑠
𝑇]𝑇
) +
 𝜆1√∑ (
𝛽𝑝𝑠
?̃?𝑝𝑠
)
2
𝕊
𝑠=1 .           (3.12) 
Denote the objective function in (3.12) by 𝑔(𝜷𝑝) and optimal solution by 𝜷𝒑∗, i.e., 𝜷𝒑∗ =
𝑎𝑟𝑔𝑚𝑖𝑛𝜷𝑝  𝑔(𝜷
𝑝) . The subgradients of 𝑔(𝜷𝑝) are 𝜕𝑔(𝜷𝑝) = [𝑙𝑝1, … , 𝑙𝑝𝕊]
𝑇 + 𝜆1𝒌𝑝 , where 
𝑙𝑝𝑠 =
1
𝜎𝑠
2(𝜔)
(𝐀𝑠
𝑝[?̂?1𝑠  ⋯ ?̂?𝑝−1,𝑠 𝛽𝑝𝑠 ?̂?𝑝+1,𝑠  ⋯ ?̂?ℙ𝑠 ?̂?𝑠
𝑇]
𝑇
− 𝑏𝑝𝑠), 𝑠 = 1,… , 𝕊.  𝐀𝑠
𝑝
 is the 𝑝-th 
row of 𝐀𝑠  and 𝑏𝑝𝑠  is the 𝑝-th element of 𝒃𝑠
𝑇 . Furthermore, the necessary and sufficient 
condition for 𝜷𝒑∗ to be zero is that the equations [𝑙𝑝1, … , 𝑙𝑝𝕊]
𝑇 + 𝜆1𝒌𝑝 = 𝟎 have a solution 
with 𝒌𝑝 ∈ {(
𝑡𝑝1
?̃?𝑝1
, … ,
𝑡𝑝𝕊
?̃?𝑝𝕊
)
𝑇
|  (𝑡𝑝1, … , 𝑡𝑝𝕊) ≜ 𝒕𝑝, ||𝒕𝑝||2 ≤ 1} , where 𝑙𝑝𝑠 =
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1
𝜎𝑠
2(𝜔)
(𝐀𝑠
𝑝[?̂?1𝑠  ⋯ ?̂?𝑝−1,𝑠 0 ?̂?𝑝+1,𝑠  ⋯ ?̂?ℙ𝑠 ?̂?𝑠
𝑇]
𝑇
− 𝑏𝑝𝑠) . One equivalent criterion for 𝜷
𝒑∗ to 
be zero is ‖(𝑙𝑝1 × 𝛽𝑝1, … , 𝑙𝑝𝕊 × 𝛽𝑝𝕊)‖2
≤ 𝜆1. If this criterion is not satisfied, we minimize 
(3.12) by a one-dimensional search over 𝜷𝑝 = (𝛽𝑝1, … , 𝛽𝑝𝕊)  as follows: Focus on the 
step in the search that estimates 𝛽𝑝𝑠 while treating other elements in 𝜷
𝑝 as known. Then, 
(3.12) becomes an optimization problem with respect to 𝛽𝑝𝑠, i.e.,  
                                𝑚𝑖𝑛𝛽𝑝𝑠  {ℎ(𝛽𝑝𝑠) + 𝜆1√(
𝛽𝑝𝑠
?̃?𝑝𝑠
)
2
+ 𝑐−𝑝𝑠2 }.                       (3.13) 
ℎ(𝛽𝑝𝑠) is a quadratic convex function of 𝛽𝑝𝑠, i.e.,  
                                           ℎ(𝛽𝑝𝑠)  =
{𝐀𝑠}𝑝𝑝
2
𝜎𝑠
2(𝜔)
 𝛽𝑝𝑠
2 + 2𝑙𝑝𝑠 𝛽𝑝𝑠,                                     (3.14) 
where {𝐀𝑠}𝑝𝑝  is the 𝑝-th diagonal element of 𝐀𝑠 . 𝑐−𝑝𝑠
2  is the sum of squared adaptive 
estimates for the elements in 𝜷𝑝 except 𝛽𝑝𝑠, i.e.,  
                          𝑐−𝑝𝑠
2 = (
?̂?𝑝1
?̃?𝑝1
)
2
+⋯+ (
?̂?𝑝,𝑠−1
?̃?𝑝,𝑠−1
)
2
+ (
?̂?𝑝,𝑠+1
?̃?𝑝,𝑠+1
)
2
+⋯+ (
?̂?𝑝,𝕊
?̃?𝑝,𝕊
)
2
.              (3.15) 
So 𝑐−𝑝𝑠
2  is a non-negative known constant at this step. The solution to the optimization in 
(3.13) is motivated by the following proposition (proof of the proposition is not shown due 
to space limit): 
Proposition 2.2.1: Let 𝛽𝑝𝑠
0  be the minimizer of (3.14), i.e., 𝛽𝑝𝑠
0 = −
𝑙𝑝𝑠
{𝐀𝑠}𝑝𝑝
2
𝜎𝑠
2(𝜔)⁄
. A 
sufficient and necessary condition for 𝛽𝑝𝑠
∗  to be the solution to (3.13) is: 
                           𝛽𝑝𝑠
∗ = 𝑠𝑖𝑔𝑛(𝛽𝑝𝑠
0 ) (|𝛽𝑝𝑠
0 | −
𝜆1
2|?̃?𝑝𝑠|{𝐀𝑠}𝑝𝑝
2
𝜎𝑠
2(𝜔)⁄
)
+
, if 𝑐−𝑝𝑠
2 = 0           (3.16) 
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                                             𝛽𝑝𝑠
∗ + 𝜆1
𝛽𝑝𝑠
∗
√𝛽𝑝𝑠
∗ 2+𝑐−𝑝𝑠
2
= 𝛽𝑝𝑠
0 ,                if 𝑐−𝑝𝑠
2 ≠ 0            (3.17) 
Based on Proposition 2.2.1, to solve (3.13), we can apply a simple soft-thresholding 
rule to 𝛽𝑝𝑠
0  if 𝑐−𝑝𝑠
2 = 0; otherwise, the solution that satisfies the equation in (3.17) will have 
to be obtained numerically (no close-form exists). This completes our discussion on the 
parameter estimation. Interested readers can find the pseudo code of our EM and BCD 
algorithms in Supplementary Material.  
Furthermore, we would like to examine the parameter estimation process described 
previously and reveal the insight as to how the proposed method “joins” the estimation of 
the model for each response variable together and the benefit of such a joint estimation. As 
a matter of fact, Proposition 2.2.1 reveals how the estimation for one response is joined 
with other responses. Specifically, (3.17) shows that the estimate for an effect in the 𝑠-th 
response, i.e., 𝛽𝑝𝑠
∗ , is related to 𝑐−𝑝𝑠
2 , which is a sum of squares of the same effects in other 
responses. Corollary 2.2.1 further shows that the relationship is monotonic, i.e., the larger 
the 𝑐−𝑝𝑠
2 , the smaller the shrinkage on 𝛽𝑝𝑠
∗ . This is indeed an advantage of the proposed 
method: Consider the situation when a predictor has a non-trivial fixed or random effect 
on all the responses, but the effects on some responses are small. If each response was 
modelled separately, these small-effects would be easily missed. In contrast, the proposed 
method is able to borrow strength from other responses with larger effects to help identify 
the small effects.  
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Corollary 2.2.1: Let 𝑐−𝑝𝑠,1
2  and 𝑐−𝑝𝑠,2
2  be two values for 𝑐−𝑝𝑠
2 . Let 𝛽𝑝𝑠,1
∗  and 𝛽𝑝𝑠,2
∗  be the 
𝛽𝑝𝑠
∗  that satisfies (3.17) corresponding to 𝑐−𝑝𝑠,1
2  and 𝑐−𝑝𝑠,2
2 , respectively. If  𝑐−𝑝𝑠,1
2 < 𝑐−𝑝𝑠,2
2 , 
then  
|𝛽𝑝𝑠,1
∗ |
|𝛽𝑝𝑠
0 |
<
|𝛽𝑝𝑠,2
∗ |
|𝛽𝑝𝑠
0 |
. 
Finally in this section, we discuss the choice of tuning parameters. There are two 
tuning parameters in the proposed method, i.e., λ1 and λ2 corresponding to the fixed and 
random effects, respectively.  The previously presented EM and BCD algorithms apply to 
a given pair of (𝜆1, 𝜆2). To find the best pair, a common practice is to choose one that 
minimizes a certain model selection criterion such as BIC, AIC, and cross-validated 
prediction errors. We propose a BIC-type criterion and found it to work well in simulation 
studies and the application. For a given pair of (𝜆1, 𝜆2), the criterion takes the following 
format: 
                       𝐵𝐼𝐶(𝜆1, 𝜆2) = −𝟐(𝑙(?̂?|{𝒚𝑠}𝑠=1
𝕊 )) + 𝑙𝑜𝑔(∑ 𝑛𝑖
𝑁
𝑖=1 ) ×  𝑑𝑓(𝜆1, 𝜆2),     (3.18) 
where 𝑙(?̂?|{𝒚𝑠}𝑠=1
𝕊 ) is the log-likelihood function defined in (3.4) when the parameters in 
𝝓 take their estimated values and 𝑑𝑓(𝜆1, 𝜆2) is the number of non-zero fixed and random 
effects in ?̂?. The pair of (𝜆1, 𝜆2) that minimizes this criterion is used to produce the final 
parameter estimation. 
3.5 Asymptotic Properties 
Having presented the formulation and estimation for the proposed model in 
Sections 3 and 4, respectively, we further study the asymptotic properties of the model in 
this section. First, we define some new notations. Let 𝑄{(𝝓𝑠)𝑠=1
𝕊 } be the adaptive 𝑙21-
penalized log-likelihood function, i.e., 
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𝑄({𝝓𝑠}𝑠=1
𝕊 ) = 𝑙({𝝓𝑠}𝑠=1
𝕊 ) − 𝜆𝑁1∑ √∑ (
𝛽𝑝𝑠
?̃?𝑝𝑠
)
2
𝕊
𝑠=1  
ℙ
𝑝=1 − 𝜆𝑁2∑ √∑ (
𝑑𝑞𝑠
?̃?𝑞𝑠
)
2
𝕊
𝑠=1  
ℚ
𝑞=1 .   (3.19) 
𝑙{(𝝓𝑠)𝑠=1
𝕊 } is the log-likelihood function defined in (3.4).  
Let ?̃?𝑠  be the true value for 𝝓𝑠 . ?̃?𝑠 = (?̃?𝑠1
𝑇 , ?̃?𝑠2
𝑇 )𝑇 . ?̃?𝑠1
𝑇 = (?̃?𝑠1
𝑇 , ?̃?𝑠1
𝑇 , ?̃?𝑠1
𝑇 )𝑇  is a 
vector whose elements are non-zero. Without loss of generality, assume that the first ℙ′ 
elements of  𝜷𝑠
𝑇 are non-zero, which are stored in ?̃?𝑠1
𝑇 , and the first ℚ′ elements of 𝒅𝑠
𝑇 are 
non-zero, which are stored in ?̃?𝑠1
𝑇 . Let |?̃?𝑠1| denote the dimension of ?̃?𝑠1
𝑇 . So the dimension 
of ?̃?𝑠1
𝑇  is ℙ′ +ℚ′ + |?̃?𝑠1|. ?̃?𝑠2
𝑇 = (?̃?𝑠2
𝑇 , ?̃?𝑠2
𝑇 , ?̃?𝑠2
𝑇 )𝑇 consists the remaining elements of ?̃?𝑠, 
i.e.,  ?̃?𝑠2
𝑇 = 𝟎. Put the ?̃?𝑠1
𝑇 , 𝑠 = 1,… , 𝕊, into one vector, i.e., ?̃?1 = (?̃?11
𝑇 , … , ?̃?𝕊1
𝑇 )
𝑇
, and 
the ?̃?𝑠2
𝑇 , 𝑠 = 1,… , 𝕊, into another vector, i.e., ?̃?2 = (?̃?12
𝑇 , … , ?̃?𝕊2
𝑇 )
𝑇
. Let ?̃? = (
?̃?1
?̃?2
).  
Following the same decomposition as ?̃?𝑠, let 𝝓𝑠 = (𝝓𝑠1
𝑇 , 𝝓𝑠2
𝑇 )𝑇. Similarly, define 
𝝓1 = (𝝓11
𝑇 , … , 𝝓𝕊1
𝑇 )𝑇 , 𝝓2 = (𝝓12
𝑇 , … , 𝝓𝕊2
𝑇 )𝑇 , and 𝝓 = (
𝝓1
𝝓2
) . Let 𝑄 {(𝝓
1
𝟎
)}  denote the 
𝑄({𝝓𝑠}𝑠=1
𝕊 ) in (3.19) with 𝝓2 = 𝟎. According to the sequence of 𝝓 = (
𝝓1
𝝓2
), we rearrange 
𝐖𝑠 ,  𝐙𝑠  , and ?̃?𝑠  to be 𝐖𝑠(1) , 𝐙𝑠(1)  and ?̃?𝑠(1)  = 𝐙𝑠(1)(𝐈 ⊗ 𝐃𝑠(1))(𝐈 ⊗ 𝚪𝑠(1))(𝐈 ⊗
 𝚪𝑠(1))
𝑇
(𝐈 ⊗ 𝐃𝑠(1))
𝑇
𝐙𝑠(1)
𝑇 + 𝐈. (3.19) can be written as the following equation. 
𝑄({𝝓𝑠}𝑠=1
𝕊 ) = ∑ 𝑙(𝝓𝑠)
𝕊
𝑠=1 − 𝜆𝑁1∑ √∑ (
𝛽𝑝𝑠(1)
?̃?𝑝𝑠(1)
)
2
𝕊
𝑠=1  
ℙ
𝑝=1 − 𝜆𝑁2 ∑ √∑ (
𝑑𝑞𝑠(1)
?̃?𝑞𝑠(1)
)
2
𝕊
𝑠=1  
ℚ
𝑞=1 ,         (3.20) 
where 𝑙(𝝓𝑠) = −
𝟏
𝟐
{𝑙𝑜𝑔⌊?̃?𝑠(1)⌋ + (𝒚𝑠 −𝐖(1)𝜷𝑠(1))
𝑇
?̃?𝑠(1)
−1
(𝒚𝑠 −𝐖(1)𝜷𝑠(1))}. 
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The following Theorems hold under common regularity conditions. Theorems and 
1 and 2 together show that the proposed method can identify the true model with probably 
tending to one. Theorem 2.3 indicates that the estimator in the proposed method enjoys the 
oracle property. Proofs of the Theorems can be found in Supplementary Material.  
Theorem 2.2.1: If  
𝜆𝑁1
√𝑁
⟶ 0 and 
𝜆𝑁2
√𝑁
⟶ 0 , then there exists a local maximizer ?̂? = (?̂?
1
𝟎
) 
of 𝑄 {(𝝓
1
𝟎
)} such that ?̂?1 is √𝑁 consistent for ?̃?1. 
Theorem 2.2: If 𝜆𝑁1⟶∞ and 𝜆𝑁2⟶∞ , then with probability tending to one for any 
given 𝝓1satisfying ‖𝝓1 − ?̃?1‖ ≤
𝐶
√𝑁
 and some constant 𝐶 > 0 , 
𝑄 {(𝝓
1
𝟎
)} =   𝑄 {(
𝝓1
𝝓2
)}
‖𝝓2‖≤
𝐶
√𝑁
𝑚𝑎𝑥        . 
Theorem 2.3: If 𝜆𝑁1⟶∞ , 𝜆𝑁2⟶∞ , 
𝜆𝑁1
√𝑁
⟶ 0 and 
𝜆𝑁2
√𝑁
⟶ 0 , then 
√𝑁 𝐼(?̃?1) ((?̂?1 − ?̃?1) + 𝐼(?̃?1)−1(𝒗1
𝑇 ,⋯ , 𝒗𝕊
𝑇)𝑇) ⟶𝑑 𝑁(0, 𝐼(?̃?
1)), 
where  
𝒗𝑠 =
(
  
 
𝜆𝑁1
𝑁
×
𝛽1𝑠
|?̃?1𝑠|
2
√∑ (
𝛽1𝑠
?̃?1𝑠
)
2
𝕊
𝑠=1
, … ,
𝜆𝑁1
𝑁
×
𝛽
ℙ′𝑠
|?̃?
ℙ′𝑠
|
2
√∑ (
𝛽
ℙ′𝑠
?̃?
ℙ′𝑠
)
2
𝕊
𝑠=1
,
𝜆𝑁2
𝑁
×
𝑑1𝑠
|?̃?𝑠 |
2
√∑ (
𝑑1𝑠
?̃?1𝑠
)
2
𝕊
𝑠=1
, … ,
𝜆𝑁2
𝑁
×
𝑑
ℚ′𝑠
|?̃?
ℚ′𝑠
|
2
√∑ (
𝑑
ℚ′𝑠
?̃?
ℚ′𝑠
)
2
𝕊
𝑠=1
, 0, … ,0 
)
 
 
𝑇
,  
𝑠 = 1,…  , 𝕊. The number of zeros at the end of 𝒗𝑠 is |?̃?𝑠1|. 𝐼(?̃?
1) is the Fisher 
Information with 𝝓2 = 𝟎.  
3.6 Simulation Studies 
  In this section, we present the performance of our proposed method. For each 
simulation setting, we report the True Positive Rate (TPR), True Negative Rate (TNR), and 
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accuracy for the fixed effect identification, and those for the random effect identification, 
under the optimal λ1 and λ2 chosen by the BIC criterion in (3.18). The TPR measures the 
proportion of identified non-zero fixed (random) effects that are truly non-zero. The TNR 
measures the proportion of identified zero fixed (random) effects that are truly zero. The 
accuracy measures the proportion of fixed (random) effects that are correctly identified. 
For comparison, we also fit a multilevel model with an adaptive 𝑙1 -penalty for each 
response variable separately and use a BIC criterion to choose the tuning parameter for the 
adaptive 𝑙1-penalty. This is the method proposed by Bondell et al. (2010), and is referred 
to as the “competing method” in the rest of this paper.  
3.6.1 Study for the Impact of Effect Size, Sample Size, and Sample Distribution on 
Performance 
We conduct four experiments, in all of which there are three response variables. 
For each response, we consider the multilevel model to consist of ten and four fixed and 
random effects, respectively. Because both the proposed and competing methods enable 
variable selection, we set three out of the ten fixed effects and three out of the four random 
effects to be non-zero. Furthermore, to induce correlation between the models of the three 
responses, we set the same fixed and random effects to be non-zero across all the responses.  
In the first experiment, we set the fixed effects for the three responses to be 𝛃1 =
(0.1,1,1,0, … ,0)𝑇 , 𝛃2 = (1,0.1,1,0, … ,0)
𝑇 , and 𝛃3 = (1,1,0.1,0,… ,0)
𝑇 , and the random 
effects to be 𝐝1 = (1,1,0.3,0)
𝑇 , 𝐝2 = (1,0.3,1,0)
𝑇 , 𝐝3 = (1,1,1,0)
𝑇, 𝚪s = 𝐈, and σs
2 = 1 
for s = 1,2,3. The sample sizes are set to be 𝑁 = 30 units and 𝑛𝑖 = 5 individuals per unit. 
Furthermore, for each unit 𝑖, the data of predictors corresponding to the fixed effects, i.e., 
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𝐖𝑖, are generated as follows: To account for the possible correlation structure among the 
predictors, we first generate a random matrix of size 𝑛𝑖 × ℙ = 5 × 10, whose elements are 
independently sampled from a 𝑁(0,1) distribution. Denote this random matrix by 𝐕𝑖. Then, 
let 𝐖𝑖,𝑝 =
𝐕𝑖,𝑝+𝐕𝑖,ℙ+1
√2
, 𝑝 = 1, … , ℙ. 𝐖𝑖,𝑝 and 𝐕𝑖,𝑝 are the 𝑝–th column of matrix 𝐖𝑖 and 𝐕𝑖. , 
respectively. This idea of generating corrected predictors has also been adopted by a few 
other papers (Yuan et al, 2006). Furthermore, we generate the data of predictors 
corresponding to the random effects, i.e., 𝐙𝑖, by setting 𝐙𝑖 = (𝟏𝑛𝑖 ,𝐖𝑖,1,𝐖𝑖,2,𝐖𝑖,3). Finally, 
the data for each response variable are generated according to (3.3). We apply the proposed 
and competing methods to the data. Table 3 summarizes the result based on 200 simulation 
runs. Both methods have high TNRs. The proposed method also has high TPRs, while the 
TPRs for the competing method are significantly lower. This is because the competing 
method fails to identify the small fixed and random effects of 0.1 and 0.32, while the 
proposed method is able to do so due to its ability of performing a joint estimation across 
all the responses.   
Table 3: Comparison between the proposed and competing methods (𝑁 = 30, 𝑛𝑖 = 5, 
𝐝3 = (1,1,1,0)
𝑇): average (standard deviation) of TPR/TNR/accuracy  
 Fixed effect identification Random effect identification 
TPR  TNR Accuracy TPR TNR Accuracy 
Proposed method  
 
99.4% 
(2.4%) 
99.0%  
(4.1%) 
99.1%  
(3.0%) 
96.0%  
(8.5%) 
98.9%  
(7.4%) 
96.7%  
(6.5%) 
Competing method  
 
69.3%  
(5.8%) 
96.2%  
(3.8%) 
88.2%  
(2.9%) 
75.0%  
(8.8%) 
99.4%  
(4.3%) 
81.1%  
(6.7%) 
 
The second experiment aims to evaluate the performance with a greater number of 
small random effects. To this end, we modify the setting of the first experiment by changing 
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𝐝3 = (1,1,1,0)
𝑇 to 𝐝3 = (1,0.3,0.3,0)
𝑇. Table 4 reports the performance. Compared with 
Table 3, we can see that the TPR of random effect identification for the competing method 
is deteriorated significantly, while this performance of the proposed method remains high.  
Table 4: Comparison between the proposed and competing methods (𝑁 = 30, 𝑛𝑖 = 5, 
𝐝3 = (1,0.3,0.3,0)
𝑇): average (standard deviation) of TPR/TNR/accuracy  
 Fixed effect identification Random effect identification 
TPR  TNR Accuracy TPR TNR Accuracy 
Proposed 
method  
 
99.6% 
(2.0%) 
99.1%  
(4.3%) 
99.3%  
(3.1%) 
90.8%  
(14.2%) 
99.7%  
(3.0%) 
93.1%  
(10.8%) 
Competing 
method  
 
69.8%  
(5.9%) 
96.2%  
(4.1%) 
88.3%  
(3.5%) 
59.6%  
(7.2%) 
99.5%  
(4.2%) 
69.6%  
(5.5%) 
 
The third experiment aims to show the sample size impact. We keep the setting of 
the second experiment but increase the unit sample size from 𝑛𝑖 = 5 to 𝑛𝑖 = 10. Table 5 
reports the performance. Compared with Table 4, we observe that doubling the sample size 
increases the average and decreases the standard deviation of the TPR for random effect 
identification by the proposed method.  This performance improvement is less obvious by 
the competing method.      
Table 5: Comparison between the proposed and competing methods (𝑁 = 30, 𝑛𝑖 = 10, 
𝐝3 = (1,0.3,0.3,0)
𝑇): average (standard deviation) of TPR/TNR/accuracy  
 Fixed effect identification Random effect identification 
TPR  TNR Accuracy TPR TNR Accuracy 
Proposed 
method  
 
99.4% 
(2.4%) 
100%  
(0.0%) 
99.8%  
(0.7%) 
97.4%  
(5.0%) 
98.7%  
(8.1%) 
97.7%  
(4.7%) 
Competing 
method  
 
70.3%  
(5.7%) 
97.3%  
(3.3%) 
89.2%  
(2.9%) 
62.5%  
(7.8%) 
99.3%  
(4.7%) 
71.7%  
(5.9%) 
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In the fourth experiment, noting that the total sample size is a product of the number 
of units and the unit sample size, i.e., 𝑁 × 𝑛𝑖, we would like to study the impact of the 
sample distribution between 𝑁 and 𝑛𝑖 on the performance. To this end, we keep the setting 
of the second experiment, which has a total sample size of 𝑁 × 𝑛𝑖 = 30 × 5 = 150, but 
re-distribute the samples to have 𝑁 = 15 and 𝑛𝑖 = 10. Table 6 reports the performance. 
Compared with Table 4, we observe that the sample re-distribution does not change the 
performance of both methods. Therefore, it is more likely that the performance of the 
methods is affected by the total sample size.  
Table 6: Comparison between the proposed and competing methods (𝑁 = 15, 𝑛𝑖 = 10, 
𝐝3 = (1,0.3,0.3,0)
𝑇): average (standard deviation) of TPR/TNR/accuracy  
 Fixed effect identification Random effect identification 
TPR  TNR Accuracy TPR TNR Accuracy 
Proposed 
method  
 
99.6% 
(2.0%) 
99.8%  
(1.9%) 
99.7%  
(1.4%) 
90.9%  
(16.5%) 
99.4%  
(4.3%) 
93.0%  
(12.3%) 
Competing 
method  
 
70.1%  
(5.2%) 
97.2%  
(3.6%) 
89.1%  
(3.0%) 
60.3%  
(7.8%) 
98.3%  
(7.4%) 
69.8%  
(6.1%) 
 
3.6.2 Study for the Impact of the Number of Response Variables 2.1 Introduction 
All the experiments in the previous section have three response variables. The focus 
of this section is to study performance with respect to different numbers of response 
variables. We consider scenarios with two, five, and eight responses, in all of which there 
are six fixed effects (two being non-zero) and three random effects (two being non-zero). 
Specifically, the first scenario has the fixed effects for the two responses as 𝛃1 =
(0.1,1,0, … ,0)𝑇and 𝛃2 = (−1,0.1,0, … ,0)
𝑇 , and random effects as 𝐝1 = (1,0.3,0)
𝑇  and 
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𝐝2 = (1,0.3,0)
𝑇. The second scenario has the same fixed and random effects for the first 
two responses as the first scenario, and 𝛃3 = (0.5,1,0, … ,0)
𝑇, 𝛃4 = (−1,1,0,… ,0)
𝑇, 𝛃5 =
(1,0.5,0, … ,0)𝑇 , 𝐝3 = (1,1,0)
𝑇 , 𝐝4 = (1,0.8,0)
𝑇 , and 𝐝5 = (1,1,0)
𝑇 for the remaining 
three responses. The third scenario has the same fixed and random effects for the first five 
responses as the second scenario, and 𝛃6 = 𝛃3, 𝛃7 = 𝛃4, 𝛃8 = 𝛃5, 𝐝6 = 𝐝3, 𝐝7 = 𝐝4, and 
8 = 𝐝5 for the remaining three responses. The sample sizes are set to be 𝑁 = 20 units 
and 𝑛𝑖 = 5 individuals per unit. Note that we purposely choose a small sample size so that 
the performance in the two-response scenario is not good. This would allow us to see if 
adding more responses could remedy the sample size shortage. Under these settings, the 
data is generated in the same way as Section 6.1. Table 7 summarizes the results. With two 
responses, the TPR for random effect identification by the proposed method is low 
(53.8% ± 0.12% ). This is significantly improved by having five responses (90% ±
0.17%, 𝑝𝑣𝑎𝑙𝑢𝑒 < 0.0001), which is further improved by having eight responses ((94.7% ±
0.1%, 𝑝𝑣𝑎𝑙𝑢𝑒 = 0.015). There is no significant difference in the TPR for fixed effect 
identification across the three scenarios. However, this does not mean that having more 
responses would not improve the TPR for fixed effects. It is simply because the TPR with 
two responses is already very high, leaving little room to demonstrating improvement. In 
contrast, the competing method has low TPR for both random and fixed effects, and adding 
more responses does not help. Furthermore, in terms of TNR, both methods perform well 
across all three scenarios with the proposed method having slightly higher TNR for fixed 
effects.  
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Table 7: Comparison between the proposed and competing method with varying numbers 
of responses 
Number of 
responses 
Fixed effect identification Random effect identification 
TPR  TNR Accuracy TPR TNR Accuracy 
 
2 
Proposed 
method  
100% 
(0.0%) 
98.8%  
(0.06%) 
99.2%  
(0.04%) 
53.8%  
(0.12%) 
100%  
(0.0%) 
69.2%  
(0.08%) 
Competing 
method  
60%  
(0.15%) 
94.4%  
(0.09%) 
82.9%  
(0.08%) 
53.8%  
(0.09%) 
100%  
(0.0%) 
69.2%  
(0.06%) 
 
5 
Proposed 
method  
98.8% 
(0.06%) 
100%  
(0.0%) 
99.6%  
(0.02%) 
90%  
(0.17%) 
100%  
(0.0%) 
93.3%  
(0.11%) 
Competing 
method  
61.2%  
(0.13%) 
93.8%  
(0.09%) 
82.9%  
(0.07%) 
51.3%  
(0.06%) 
100%  
(0.0%) 
67.5%  
(0.04%) 
 
8 
Proposed 
method  
98.7% 
(0.06%) 
98.7%  
(0.06%) 
98.7%  
(0.04%) 
94.7%  
(0.1%) 
97.4%  
(0.1%) 
95.6%  
(0.09%) 
Competing 
method  
57.9%  
(0.15%) 
93.4%  
(0.08%) 
81.6%  
(0.08%) 
56.6%  
(0.1%) 
100%  
(0.0%) 
71.1%  
(0.08%) 
 
3.6.3 BIC vs. AIC  
While BIC has been used for choosing the tuning parameters in previous simulation 
studies, it is of interest to study if other criteria such as AIC may offer some advantage. To 
this end, we repeat the experiments in Section 6.2 but selecting the tuning parameters of 
the proposed and competing methods using AIC. The results are shown in Table 8. 
Compared with Table 7, we can see that AIC has significantly lower TNR than BIC in both 
the proposed and competing methods, while the TPR performances of the two criteria are 
similar. Also, the standard deviations of TPR and TNR under AIC are much higher than 
BIC, indicating a less stable performance of AIC. While several previous studies have 
suggested advantages of AIC over BIC (Burnham & Anderson, 2002; 2004; Yang, 2005), 
these studies did not specifically compare the two criteria for multilevel models. Our 
experiments, on the other hand, empirically demonstrate better performance of BIC for 
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multilevel models. Theoretical explanation behind this empirical observation is left for 
future research.   
Table 8: Results of the experiments in Section 6.2 using AIC for tuning parameter 
selection 
Number of 
responses 
Fixed effect identification Random effect identification 
TPR TNR Accuracy TPR TNR Accuracy 
 
2 
Proposed 
method 
100% 
(0.0%) 
71.3% 
(0.45%) 
80.8% 
(0.3%) 
58.8% 
(0.19%) 
97.5% 
(0.11%) 
71.7% 
(0.11%) 
Competing 
method 
66.3% 
(0.15%) 
80.6% 
(0.15%) 
75.8% 
(0.13%) 
62.5% 
(0.15%) 
100% 
(0.0%) 
75% 
(0.1%) 
 
5 
Proposed 
method 
98.8% 
(0.06%) 
76.3% 
(0.35%) 
83.8% 
(0.23%) 
95% 
(0.13%) 
77.5% 
(0.41%) 
89.2% 
(0.17%) 
Competing 
method 
66.3% 
(0.12%) 
83.8% 
(0.12%) 
77.9% 
(0.09%) 
57.5% 
(0.12%) 
97.5% 
(0.11%) 
70.8% 
(0.07%) 
 
8 
Proposed 
method 
98.7% 
(0.06%) 
90.8% 
(0.24%) 
93.4% 
(0.16%) 
94.7% 
(0.1%) 
79% 
(0.3%) 
89.5% 
(0.14%) 
Competing 
method 
61.8% 
(0.19%) 
82.9% 
(0.15%) 
75.9% 
(0.13%) 
67.1% 
(0.19%) 
97.4% 
(0.11%) 
77.2% 
(0.13%) 
 
3.7 Application in Nurse Care Coordination 
We apply the proposed method to a dataset created using the NCCI (Duva, 2010; 
Shuai et al, 2014). The dataset includes 614 nurses from 32 medical-surgical units of four 
hospitals in the metro Atlanta area. These data are used in this paper with permission. Three 
categories of variables are measured in the dataset, as shown in Table 9. The first category 
consists of nurse care coordination activities belonging to six constructs, “m”, “e”, “a”, “b”, 
“o”, and “c”. For example, “I initiate actions to get my nursing team members to do what 
is needed to keep my patients on their plan” is an activity belonging to “m”. “I 
communicate information to my interdisciplinary team members they need to know to 
carry out their patient care activities or to make changes in their plan of care” is an activity 
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belonging to “e”. “I ask my nursing team members to assist me with my patient activities 
when I am tied up with one or more of my patients” is an activity belonging to “a”. “I 
prompt my interdisciplinary team to do the work they are responsible for so I can get my 
own work done and keep patients on their plan of care” is an activity belonging to “b”. “I 
organize the supplies that I need to be able to keep the care of my patients on track” is an 
activity belonging to “o”. “I perform my patient assessments so that they will be useful to 
everyone on the team” is an activity belonging to “c”. A total of 45 activities were measured 
in the form of 45 questions asked to the nurses in a questionnaire. The answer to each 
question is a five-point likert-type scale with higher scores representing greater amounts of 
the corresponding activity. The correspondence between each question and the latent 
construct is known by the design of the NCCI. To get a measurement for each construct, 
we average the scores of the corresponding questions. The second category of variables in 
the dataset are nurse demographic and workload variables, and three of them are included 
in this study as shown in Table 9. The third category consists of organizational 
characteristic variables of nurses’ practice environment, i.e., their units. Seven variables 
are included, which measure the availability of certain infrastructure, technology, and 
policies that may potentially facilitate nurse care coordination.  
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Table 9: Description of the NCCI data 
 
 
Next, we discuss roles of the variables in the proposed model. Among the six 
constructs, “m”, “e”, “a”, and “b” measure the inter-dependent activities among nurses, i.e., 
their coordination, while “o” and “c” measure their independent activities that are 
instrumental to their coordination. We focus on three out of the four inter-dependent 
constructs, “m”, “e”, and “a”, because there has been some controversy over whether “b” 
plays a positive or negative role in care coordination (Duva, 2010). Among “m”, “e”, and 
“a”, “m” is treated as one response variable. Originally, we tried making “e” and “a” two 
other response variables, but the result was not as good as combining them into one 
response variable. This is an interesting finding: On the one hand, “a” and “e” are different 
in the sense that the former concerns coordination between nurses while the latter concerns 
coordination initiated by nurses but with other professionals in the patient care team. On 
the other hand, the fact that combining “e” and “a” gives better model performance is an 
indication that there might be a higher-level abstraction making “e” and “a” more similar 
Category Variable Value Level
Mobilizing (m) numerical nurse
Exchanging (e) numerical nurse
Assisting (a) numerical nurse
Backfilling (b) numerical nurse
Organizing (o) numerical nurse
Checking (c) numerical nurse
Years of being a registered nurse numerical nurse
Length of shift numerical nurse
Shift that worked on (day/night) binary nurse
Availability of policy that addresses physician response time to nurse calls binary unit
Availability of on-side representative from nursing homes binary unit
Availability of assistance with discharge planning binary unit
Availability of clinical nurse specialists binary unit
Availability of nurse case manager binary unit
Availability of nursing team walk-around to discuss ongoing patient care binary unit
Availability of team meetings to discuss binary unit
Nurse care 
coordination
Demographics 
and workload
Organizational 
characteristics
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to each other in terms of characterizing care coordination than to other constructs like “m”. 
Pending further investigation, we focus on presenting the results of modeling two response 
variables in this paper, i.e., “m” and combined “e/a”. Furthermore, we include demographic 
and workload variables as well as “o” and “c” as individual-level predictors, and 
organizational characteristics as unit-level predictors.  
We apply the proposed method to link the predictors with the two responses, “m” 
and “e/a”. Two tuning parameters λ1  and λ2  are chosen by BIC. The responses and 
predictors are standardized, so that the fixed effects do not include an intercept but the 
random effects still do. In Table 10 under “Proposed method”, we show the estimated fixed 
effects and the variances of the estimated covariance matrix of random effects. Several 
observations can be drawn: 1) Same effects are found to be zero (non-zero) in both 
responses, although the magnitudes of non-zero effects are somewhat different. This is 
expected because of the use of an adaptive 𝑙21-penalty in our method. 2) “O” and “c” are 
found to have non-zero fixed effects among the five individual-level predictors. This makes 
sense because independent nurse care activities like “c” and “o” form the basis for nurses 
to perform interdependent coordination activities. The positive signs of the effects of “c” 
and “o” suggest that such independent activities have a positive impact on interdependent 
coordination activities. 3) Among the seven unit-level predictors, “the availability of 
assistance with discharge planning in the unit” is found to have a non-zero fixed effect. 
The positive sign of this effect suggests that providing assistance with discharge planning 
in a unit helps create a positive practice environment for the nurses in the unit to conduct 
care coordination.  4) Among the random effects, “o” is found to be non-zero in addition 
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to the intercept. This reinforces the important role of independent nurse care activities on 
care coordination especially “o”.  
Table 10: Estimated fixed effect regression coefficients and random effect 
variances by the proposed and competing methods
 
For comparison, we also apply the competing method to model each response 
variable separately. The result is presented in Table 10 under “Competing method”. The 
competing method also finds “o” and “c” to have non-zero fixed effects for the two 
responses, but two additional non-zero fixed effects for the response “e/a”. Furthermore, 
the competing method finds three unit-level predictors to have non-zero fixed effects, 
including the predictor of “the availability of assistance with discharge planning in the unit” 
that is also found by the proposed method, for the response “m”. However, all unit-level 
predictors for the response “e/a” are found to have zero fixed effects. Lastly, although the 
competing method also finds “o” to have a non-zero random effect, it finds more non-zero 
Mobilizing (Y1) Exchanging/assisting (Y2) Mobilizing (Y1) Exchanging/assisting (Y2)
Years of being a registered nurse 0 0 0 0.020765
Length of shift 0 0 0 0
Shift that worked on (day/night) 0 0 0 -0.016058
Checking 0.22067 0.31566 0.21781 0.30974
Organizing 0.11321 0.23374 0.11869 0.25483
Availability of policy that addresses 
physician response time to nurse calls 0 0 0.029156 0
Availability of on-site representative 
from nursing homes 0 0 0.0099464 0
Availability of assistance with discharge 
planning 0.029396 0.0010848 0.07649 0
Availability of clinical nurse specialists 0 0 0 0
Availability of nurse case manager 0 0 0 0
Availability of nursing team walk-around 
rounds to discuss onging patient care 0 0 0 0
Availability of team meetings to discuss 0 0 0 0
Intercept 0.38389 0.15508 0.42642 0.16398
Years of being a registered nurse 0 0 0.012954 0
Length of shift 0 0 -1.83E-05 -0.028343
Shift that worked on (day/night) 0 0 0 2.54E-05
Checking 0 0 0 0
Organizing 3.34E-05 7.98E-05 6.22E-05 7.03E-05
Fixed 
Effects
Random 
Effects
Proposed method Competing method
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random effects for the two responses than the proposed method. In summary, the proposed 
method finds 10 non-zero fixed and random effects, whereas the competing method finds 
17.  
Finally, we would like to compare the prediction performances of the two methods. 
A common metric is the average Mean Squared Prediction Error (MSPE), MSPE̅̅ ̅̅ ̅̅ ̅̅ , through 
a 𝐾-fold Cross Validation (CV). Because both our proposed method and the competing 
method are multilevel models, the generic CV procedure needs some modification. 
Specifically, the 𝐾-fold division is done within each unit, i.e., the samples within each of 
the 32 units are divided into 𝐾 folds. Then, the samples of 𝐾 − 1 folds within each unit are 
pooled together and used for training. Furthermore, the trained model is applied to the 
pooled remaining one fold from each unit to compute a MSPE. This modified CV 
procedure is to make sure that the training model includes at least some samples from each 
unit. We apply this modified CV procedure to the proposed and competing methods. 
Noting that the results could vary depending on the number of folds in the CV, we vary 𝐾 
from 2 to 8. Also noting that the results could vary even with a fixed 𝐾 because of the 
randomness of the CV partition, we run the CV partition three times for each fixed 𝐾. This 
procedure results in 8 × 3 = 24 pairs of MSPE̅̅ ̅̅ ̅̅ ̅̅  to compare the proposed and competing 
methods. We count the proportion of times the proposed method has a lower MSPE̅̅ ̅̅ ̅̅ ̅̅  than 
the competing method and conduct hypothesis testing for this proportion. The hypothesis 
testing yields a p value of 0.037, indicating that the proposed method has a significantly 
smaller MSPE̅̅ ̅̅ ̅̅ ̅̅ . A smaller prediction error provides evidence to support the appropriateness 
of the joint modelling of two responses by the proposed method.  
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3.8 Conclusion 
In this paper, we developed a multi-response multilevel model to characterize the 
relationship between nurse care coordination and nurses’ practice environment, 
demographics, and workload. Our model development was driven by the recently available 
NCCI that was the first of its kind allowing quantitative data to be collected to measure 
nurse care coordination, and was further driven by the unique data structure that required 
a joint modeling of multiple response variables in relation to predictors at two levels (unit 
level and individual/nurse level). Our model development included a unique formulation 
that used two adaptive 𝑙21-penalties to enable joint fixed effect selection and joint random 
effect selection across the multiple responses, and an efficient BCD algorithm integrated 
with an EM framework for parameter estimation. We performed theoretical analysis to 
reveal that the reason for the proposed method to outperform a separate modeling of each 
response was the consideration of a sum of squares of the effects in all other responses 
when estimating the effect in one response. In this way, the estimate was less shrunk, 
leading to better identification of small non-zero effects. We conducted simulation studies, 
which demonstrated that the proposed method achieved high TFRs and TNRs for both 
fixed and random effect identification, and the TFRs of our method were consistently 
higher than the competing method that modelled each response variable separately, 
especially when the non-zero effects were small. Our simulation studies also revealed the 
sample size and sample distribution influences on the proposed method in comparison with 
the competing method. We applied our method to the dataset created using the NCCI to 
model the relationship between two response variables measuring nurse care coordination 
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and five level-one predictors characterizing nurses’ demographics and workload and seven 
level-two predictors characterizing the practice environment of the nurses’ residing units. 
Our method achieved a significantly higher prediction accuracy on the two response 
variables compared with the competing method. Our method also identified a significantly 
smaller number of predictors to have non-zero effects than the competing method and these 
predictors were shared by the two responses. A model that requires fewer predictors 
without sacrificing the prediction accuracy and that is able to use the same subset of 
predictors to predict multiple response variables is desirable in practice. This means a 
greater saving in the effort and cost for data acquisition, and a potential saving in the cost 
of intervention if the significant predictors can be confirmed to “causally” affect the 
response variables of care coordination. In particular, our result showed that two 
independent nurse care activities, “c” and “o”, and one unit characteristic, “the availability 
of assistance with discharge planning in the unit”, had a significant positive relation to care 
coordination.  
We would like to point out several limitations of the study in this paper, which also 
open opportunities for future research. First, although our study identified three significant 
predictors for nurse care coordination, the causality between them and care coordination is 
yet to be established. Finding not only predictors but also causal factors that influence care 
coordination is important for designing improvement strategies and the best practices. 
Second, we cannot rule out the possibility that the predictors not selected by our method 
may have a non-zero effect on the responses. They are just not as significant as the 
predictors that were selected under the limited and specific samples in our dataset. More 
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data, especially data across hospitals at different geographical locations beyond the Atlanta 
area, are needed to validate and generalize the current findings. Third, our model 
formulation allows a selection of the same subset of predictors across all responses, which 
is a strength and a restriction. An immediate future extension of our model is to adopt a 
different choice for the penalties to allow for both joint variable selection across the 
responses and unique variable section within each response, such as the sparse group lasso 
penalty (Simon et al. 2013).  
The long-term goal of this research is to inform interventions to improve staff nurse 
care coordination within hospital units that would in turn lead to improved patient 
outcomes, e.g., shorter length of stay, few medication errors, less likelihood for re-
admission, and greater satisfaction. Achieving this goal is important to the current health 
care system because many hospitalized patients nowadays have multiple co-existing 
chronic illnesses demanding a great amount of coordinated care within the health care team 
especially the nurses who are the patients’ “ever-present” care professionals. Without 
effective nurse care coordination, these patients would be at an elevated risk for poor 
outcomes, which not only decrease their quality of life but also result in unnecessary costs 
to the health care system.  
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CHAPTER 4 
A SEQUENTIAL TREE-BASED CLASSIFICATION FOR PERSONALIZED 
BIOMARKER TESTING OF ALZHEIMER’S DISEASE RISK 
4.1 Introduction 
Alzheimer’s disease (AD) is an irreversible neurodegenerative disease of the brain 
characterized by debilitating impairment in daily activities and cognitive decline. More 
than five million people in the U.S. currently have AD, and the number is expected to 
increase to 16 million by 2050. The direct health care cost is over $200 billion per year and 
projected to reach $1.2 trillion by 2050. Recent clinical trials designed to treat AD at the 
mild-to-moderate dementia phase have been largely unsuccessful. There is a growing 
consensus that treatment should target the disease in its early phases before irreversible 
brain damage occurs. Mild cognitive impairment (MCI) is a prodromal phase of AD at 
which patients experience cognitive decline but have not developed dementia. Treatment 
at the MCI phase could potentially delay the progression to AD or even prevent the patient 
from developing AD, and therefore has considerable interest. 
Important to early detection and prevention of AD is the use of biomarkers to 
precisely predict the conversion of MCI to AD within a clinical time of interest. According 
to the new diagnostic guidelines recommended by the National Institute on Aging and the 
Alzheimer’s Association [Albert et al. 2011], the important biomarkers include those 
measuring Aβ deposition in plagues and those linked to downstream neuronal degeneration 
or injury processes, such as the phosphorylated tau (p-tau) level in cerebrospinal fluid 
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(CSF), mean cerebral metabolism on 18F fludeoxyglucose positron emission tomography 
(FDG-PET), and hippocampal volume on structural magnetic resonance imaging (MRI).  
There has been a vast amount of studies aiming at using biomarker data to predict 
the conversion of MCI patients to AD (Barnes et al. 2014, Cui et al. 2011, Heister et al. 
2011, Hinrichs et al. 2011, Jack et al. 2010, Risacher et al. 2009, Wee et al. 2013, Ye et al. 
2012, Yu et al. 2012, Zhang et al. 2012, Zhang et al. 2012). A particular area of study with 
clear clinical relevance is to achieve this prediction using baseline biomarker 
measurements (Barnes et al. 2014, Cui et al. 2011, Heister et al. 2011, Hinrichs et al. 2011, 
Jack et al. 2010, Risacher et al. 2009, Wee et al. 2013, Ye et al. 2012, Yu et al. 2012, Zhang 
et al. 2012, Zhang et al. 2012)Although using longitudinal repeated measurements of the 
same biomarkers has a potential to improve the prediction accuracy, this prolongs the 
diagnostic time span and makes clinical trials more time consuming and costly. In using 
baseline biomarkers to predict MCI conversion, most of the existing studies built statistical 
classification models that assign each MCI patient to be a converter or non-converter using 
a pre-trained model. The accuracy on large public datasets like the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) has been reported to be between 60-72%. The existing 
research has a few limitations: 
First, the prediction accuracy is unsatisfactory. This can be attributed to the 
heterogeneity of MCI patients. That is, there may be subgroups across which different 
biomarkers or different combinations of biomarkers are useful for predicting conversion to 
AD. MCI heterogeneity is a known challenge in AD studies and has been reported in many 
papers (Cerami et al. 2015, Yu et al. 2012). A recent study using the comprehensive dataset 
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collected through the worldwide ADNI project revealed that there is little agreement in 
using different biomarkers for predicting the conversion of MCI to AD, such as the p-tau 
level in CSF, mean cerebral metabolism on FDG-PET, and hippocampal volume on MRI. 
Conflicting predictions by the different biomarkers happen in roughly every third MCI 
patient (Alexopoulos et al. 2014). This provides strong evidence that MCI is a 
heterogeneous group and that the existing research of “one-model-fits-all (OMFA)” is 
unlikely to work well. Here, OMFA means building one classification model, which 
assumes the same multivariate association of biomarkers with conversion/non-conversion, 
across all the MCI patients. 
Second, the existing research is bounded by an inherent limitation of conventional 
classification models that require the biomarkers to be measured all at once. This is because 
a conventional classification model takes the form of 𝑌 = 𝑓(𝑋1, … , 𝑋𝑝), where 𝑋1, … , 𝑋𝑝 
are biomarkers and 𝑌 is a binary variable of conversion or. non-conversion. When using 
this model to predict an MCI patient, data on all the biomarkers included in the model, i.e. 
𝑋1, … , 𝑋𝑝 , must be available. Otherwise, the model cannot be applied. Almost all the 
commonly used classification models have this limitation, such as logistic regression, 
discriminate analysis, support vector machine, and artificial neural network. However, 
requiring biomarkers to be available all at once at the time of making a prediction/diagnosis 
does not reflect the reality of clinical practices in which biomarkers are typically measured 
sequentially. That is, the most predictive biomarker is first tested for a patient. If the result 
is conclusive, e.g., the patient is predicted to be a converter or non-converter with a high 
confidence, no other biomarkers need to be tested. Otherwise, if the result from the first 
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biomarker is inconclusive, an additional biomarker may be tested. More biomarkers may 
be added until a conclusive diagnosis is reached. It is also possible that no conclusive 
diagnosis can be reached even with all the biomarkers having been tested, which is 
common for early stages of a disease. If this happens, the patient will be asked to come 
back to re-test during a follow up visit.  
Lastly, in most existing research that uses biomarkers to predict MCI conversion, 
biomarkers are treated as numerical variables. Although the raw biomarker measurement 
is on a numerical scale, clinical interpretation is typically based on a cutoff that 
dichotomizes the biomarker into “positive” and “negative”. For example, 1.21, 3260 𝑚𝑚3, 
and 23 pg/mL are the currently used clinical cutoffs for the mean cerebral metabolism on 
FDG-PET, hippocampal volume on MRI, and p-tau level in CSF, respectively (Jack et al. 
2008, Kim et al. 2011). Both approaches have limitations: Using the raw, numerical 
measurement of biomarkers is clinically inconvenient. Also, there may be measurement 
errors associated with the testing instrument and bias due to patient’s health condition and 
exposure to environmental factors that potentially confound with the target disease. This 
makes the use of raw biomarker measurement a less robust approach. On the other hand, 
using a single cutoff as in the current clinical practice is an over-simplification by ignoring 
the quantitative relationship between biomarker values and disease risks. Between using 
the numerical measurement and a single cutoff, a “middle” approach that uses more 
discretized levels of a biomarker may be more appropriate.  
To overcome the aforementioned limitations of the existing research, we propose a 
sequential tree-based classifier (STC) for predicting MCI patients’ risks of converting to 
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AD in this paper. Compared with conventional classification models, STC does not require 
all the biomarkers be available for every patient at the time of the prediction, but 
sequentially adds biomarkers only when necessary. Another difference is that not like 
conventional classification models that enforce a binary decision (conversion vs. non-
conversion) for each patient, STC classifies patients into three categories: a clinically-
defined high-risk (HR) category, a clinically-defined low-risk (LR) category, and an 
inconclusive category. The HR and LR categories includes MCI patients that will convert 
to AD within a clinical time of interest with a high and a low probability, e.g., 80% and 
20%, respectively. HR patients need immediate medical attention. LR patients can be 
cleared of the disease or put on long-term observation. Patients falling into the inconclusive 
category at the baseline may be asked for a re-test in a follow up visit. In essence, STC 
achieves the sequential, as-needed use of biomarkers and the three-category classification 
by finding an optimal sequence of biomarkers and two-sided cutoffs of each biomarker that 
satisfy the HR and LR requirement while minimizing the proportion of MCI patients 
classified as inconclusive. Also, STC is personalized because it allows patient-specific 
information such as age, gender, education level, and genotyping to be included to help 
identify patient-specific cutoffs for each biomarker. Additionally, STC is flexible in the 
sense that it can be developed depending on the available biomarkers in a clinic. Each clinic 
has a different level of resources, which may limit its biomarker testing capability. A model 
has limited use if it has to assume the same biomarkers to be tested across different clinics. 
Finally, we would like to stress that STC approaches the challenge of low accuracy in 
predicting MCI conversion, which is faced by the existing research, from a different angle. 
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That is, a target prediction accuracy is first defined, which is reflected by HR and LR, and 
it is then used by STC for identifying groups of patients for which this accuracy can be 
reached. This capability has tremendous value for disease management and patient 
selection in clinical trials.  
We apply STC to two important clinical applications using the ADNI data. One is 
to predict/classify MCI patients into HR, LR, or inconclusive categories so that appropriate 
medical decisions can be made for each patient. The other application is to help patient 
selection in clinical trials, i.e., identify a sub-cohort of MCI patients with a HR of 
converting to AD, as these patients are more likely to benefit from the intervention being 
tested. The remaining of this paper is organized as follows: Section 4.2 provides a literature 
review of the statistical methods used for prediction of MCI conversion to AD.  Section 
4.3 presents the formulation, estimation, and algorithm of the proposed STC model. 
Section 4.4 presents the application. Section 5 concludes the chapter.  
4.2 Literature Review 
One of the most prominent findings on AD is that AD patients have significant 
hippocampal atrophy that can be seen on an MRI scan. Because of this, abundant research 
has been devoted to using MRI imaging data for prediction of MCI conversion to AD. 
Risacher et al. (Risacher et al. 2009) analyzed MRI data using voxel-based morphometry 
and automated parcellation methods,  and identified the degree of neurodegeneration in 
medial temporal structures as the best antecedent MRI marker of imminent conversion, 
with decreased hippocampal volume being the most robust. Zhang et al. (Zhang et al., 2012) 
applied a logistic regression model on MRI imaging, and found that combining a medical 
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temporal lobe atrophy scale (MTAS) and a brain atrophy and lesion index (BALI) results 
in an improved predictive accuracy for MCI conversion. Wee et al. (Wee et al. 2013) 
proposed a novel approach to extract correlative morphological information from MRI, and 
demonstrated that combining this information with the conventional ROI-based 
information via multi-kernel support vector machines improves the prediction of MCI 
conversion.  
Due to the complicated nature of MCI, it has been acknowledged that using MRI 
data alone may not suffice. As a result, abundant research has been done to integrate MRI 
with other data sources such as CSF measurement, cognitive test scores, and functional 
imaging like FDG-PET. Barnes et al., (Barnes et al. 2014) proposed a point-based risk 
score for prediction of MCI conversion, which combines MRI hippocampal subcortical 
volume and middle temporal cortical thinning together with the scores from several 
cognitive test instruments.  Heister et al. (Heister et al. 2011) used a cox proportional hazard 
model to predict MCI conversion, which integrated medial temporal atrophy measured by 
MRI, CSF biomarker levels, and the degree of learning impairment measured by the Rey 
Auditory Verbal Learning Test. Jack et al. (Jack et al. 2010) proposed to integrate 
hippocampal volumes on MRI with CSF Aβ42 levels and Pittsburgh compound B PET 
measures in prediction of time-to-conversion from MCI to AD. Ye et al., (Ye et al.  2012) 
proposed a sparse learning model that integrated 15 features from MRI scans, cognitive 
measures, and APOE genotype.  
Because multi-source data have been used in prediction of MCI conversion, there 
is a growing interest to evaluate which source carries the most weight. Toward this end, a 
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number of comparative studies have been performed. Landau et al. (Landau et al, 2010) 
compared APOE ϵ4 allele frequency, CSF measurement, FDG-PET, hippocampal volume 
on MRI, and episodic memory performance at baseline. Their result showed that FDG-
PET and episodic memory best predicted MCI conversion to AD. Cui et al. (Cui et al. 2011) 
compared MRI morphometry features, CSF measurement, and neuropsychological and 
functional measures (NMs). Their result showed that NMs outperformed CSF and MRI 
features. Yu et al., (Yu et al. 2012) compared MRI, FDG-PET, and CSF measurement, and 
found that MRI measures had the best predictive power. Overall, the existing comparative 
studies reached inconsistent conclusions regarding the relative importance of different data 
sources. The inconsistency might be caused by the difference in the subject pools included 
in each study and in the statistical methods used for the data analysis. Another possible 
reason may be the inherent heterogeneity of the MCI population. However, almost all the 
studies reached the same conclusion that integrating multi-source information yields a 
significantly better accuracy than using a single data source alone.  
In additional to the aforementioned studies using baseline data, longitudinal data 
has also been used for MCI prediction. Zhang et al. (Zhang et al. 2012) developed a 
longitudinal feature selection method to jointly select brain regions across multiple time 
points and proposed a multi-kernel support vector machine for MCI prediction based on 
MRI, FDG-PET and cognitive scores. Misra et al. (Misra et al. 2009) investigated baseline 
and longitudinal patterns of brain atrophy in MCI patients, and found MCI converters 
displayed significantly lower volume in a number of white matter and grey matter regions. 
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Hinrichs et al. (Hinrichs et al. 2011) developed predictive markers for MCI conversion 
using a multi-kernel learning (MKL) framework.      
4.3 Proposed method – a sequential tree-based classifier (STC) 
4.3.1 Formulation of STC 
Suppose there are 𝑝  biomarkers 𝐗  = {𝑋1, … , 𝑋𝑝} , 𝑞  patient characteristic 
variables/risk factors 𝐙 ={𝑍1, … , 𝑍𝑞}, and a binary diagnostic outcome 𝑌. For example, in 
diagnosing/predicting the conversion of MCI to AD, commonly used biomarkers include 
the p-tau level in CSF, mean cerebral metabolism on FDG-PET, and hippocampal volume 
on MRI, referred to as P-tau, FDG-PET, and MRI hereafter. Risk factors may include age, 
education level, and status of APOE e4 gene (Landau et al. 2012). 𝑌 = 1 if an MCI patient 
converts to AD within a clinical time of interest and 𝑌 = 0 otherwise. Our objective is to 
find a testing sequence for the biomarkers as well as a lower and an upper cutoff value for 
each biomarker adjusted for patient difference in terms of the risk factors, in order to 
classify patients into a HR, a LR, or an inconclusive category.  
First, we focus on a less complicated problem in which the sequence of biomarkers 
is given. Without loss of generality, assume the sequence to be 𝑋1 → 𝑋2 → ⋯ → 𝑋𝑝. Also 
assume a positive correlation between each biomarker and the disease risk, i.e., a higher 
value of a biomarker means a higher risk of the disease. Although negative correlations 
exist for some biomarkers, we can always turn the correlations into positive by 
transforming the biomarkers. This assumption was made for simplicity of the subsequent 
discussion. We would like to sequentially find two cutoffs for each biomarker. That is, we 
would like to first find a lower and an upper cutoff for 𝑋1 , 𝑙1(𝐙) and 𝑢1(𝐙), that are 
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functions of the risk factors 𝐙, such that a patient will have a HR of having the disease if 
𝑋1 ≥ 𝑢1(𝐙), a LR if 𝑋1 ≤ 𝑙1(𝐙), and be inconclusive otherwise. HR and LR patients will 
need no more biomarker testing. Inconclusive patients will be further tested for the second 
biomarker 𝑋2. Therefore, we will need to find a lower and an upper cutoffs for 𝑋2, 𝑙2(𝐙) 
and 𝑢2(𝐙), such that an inconclusive patient from the previous biomarker testing will have 
a HR of having the disease if 𝑋2 ≥ 𝑢2(𝐙), a LR if 𝑋2 ≤ 𝑙2(𝐙), and continuously be 
inconclusive otherwise. The inconclusive patients at the current step will be further tested 
for 𝑋3. This process will continue until all the biomarkers have been tested.  
In a mathematically rigorous way, we can formulate the 𝑖-th step of the above 
process as follows: Let 𝐷𝑖−1 be the cohort of inconclusive patients from the previous step. 
The goal of the 𝑖-th step is to find 𝑙𝑖(𝐙) and 𝑢𝑖(𝐙) for 𝑋𝑖 that:  
min
𝑙𝑖(𝐙),𝑢𝑖(𝐙)
𝑝( 𝑙𝑖(𝐙) ≤ 𝑋𝑖  ≤ 𝑢𝑖(𝐙)|𝐷𝑖−1)                                    (4.1) 
s.t.    𝑝(𝑌 = 1|𝑋𝑖  ≥ 𝑢𝑖(𝐙), 𝐙, 𝐷𝑖−1) ≥ 𝑟ℎ, 
                                𝑝(𝑌 = 1|𝑋𝑖  ≤ 𝑙𝑖(𝐙), 𝐙, 𝐷𝑖−1) ≤ 𝑟𝑙 .                                  (4.2) 
The objective function is to minimize the proportion of inconclusive patients. This is 
important to patients by reducing the need and the associated cost and waiting time for 
another biomarker testing before a conclusive diagnosis can be made. It is also important 
to the clinic by reducing the overall cost including the labor and resource spent on the 
diagnosis. 𝑟ℎ  and 𝑟𝑙  are clinically-defined HR and LR thresholds, respectively, and are 
typically known to specific applications. For example, in diagnosis, 𝑟ℎ is typically 80-85% 
and 𝑟𝑙  10-20%. 𝑟ℎ  is not necessarily equal to 1 − 𝑟𝑙 . Proposition 1 shows that the 
optimization problem in (4.1) is equivalent to two simpler sub-optimization problems.  
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Proposition 1: Let 𝑙𝑖(𝐙) and ?̃?𝑖(𝐙) denote the optimal solutions to (4.1). Let 𝑙𝑖
∗(𝐙) and 
𝑢𝑖
∗(𝐙) be the optimal solutions to the optimization problems in (4.2) and (4.3), respectively.  
                     𝑙𝑖
∗(𝐙) = {
max
𝑙𝑖(𝐙)
𝑙𝑖(𝐙)
𝑠. 𝑡.   𝑝(𝑌 = 1|𝑋𝑖  ≤ 𝑙𝑖(𝐙), 𝐙, 𝐷𝑖−1) ≤ 𝑟𝑙  
.                                 (4.3) 
                   𝑢𝑖
∗(𝐙) = {
min
𝑢𝑖(𝐙)
𝑢𝑖(𝐙)
𝑠. 𝑡.   𝑝(𝑌 = 1|𝑋𝑖  ≥ 𝑢𝑖(𝐙), 𝐙, 𝐷𝑖−1) ≥ 𝑟ℎ 
.                                (4.4) 
Then, 𝑙𝑖
∗(𝐙) = 𝑙𝑖(𝐙) and 𝑢𝑖
∗(𝐙) = ?̃?𝑖(𝐙). (Proof skipped.) 
Proposition 1 implies that 𝑙𝑖
∗(𝐙) can be obtained by first finding the feasible region of 𝑙𝑖(𝐙), 
following which the 𝑙𝑖
∗(𝐙) can be naturally obtained by using the maximum value in that 
region. The same implication applies to 𝑢𝑖
∗(𝐙).  
Furthermore, to facilitate identification of the feasible region for 𝑢𝑖(𝐙), we apply 
Bayes’ rule to the constraints in (4.4) and (4.3) and get   
            
1−𝜑𝑋𝑖|𝑌=1,𝐙=𝐳(𝑢𝑖
(𝐙))  
1−𝜑𝑋𝑖|𝑌=0,𝐙=𝐳(𝑢𝑖
(𝐙))  
≥
𝑟ℎ
1−𝑟ℎ
×
1−𝜋(𝐙)
𝜋(𝐙)
, and                                   (4.5) 
                         
𝜑𝑋𝑖|𝑌=1,𝐙=𝐳(𝑙𝑖
(𝐙)) 
𝜑𝑋𝑖|𝑌=0,𝐙=𝐳(𝑙𝑖
(𝐙))
≤
𝑟𝑙
1−𝑟𝑙
×
1−𝜋(𝐙)
𝜋(𝐙)
,                                                (4.6) 
respectively. 𝐷𝑖−1 was dropped for notation simplicity. 𝜑𝑋𝑖|𝑌,𝐙(𝑥) denotes the cumulative 
distribution function (CDF) of 𝑋𝑖  given 𝑌  and 𝐙. 𝜋(𝐙) = 𝑝(𝑌 = 1|𝐙) is the prior of 𝑌 
before the biomarker 𝑋𝑖 is tested. In (4.5) and (4.6), 𝑟ℎ and 𝑟𝑙 are given constants. 𝜋(𝐙) can 
be known from population statistics, i.e., the probability for people with a certain 
demographic profile (e.g., female, older than 65, and APOE e4 carrier) to have the disease. 
Therefore, the key to identifying the feasible regions of 𝑙𝑖(𝐙) and 𝑢𝑖(𝐙) is to know the 
distribution of 𝑋𝑖|𝑌, 𝐙. Because biomarkers are typically measured on a continuous scale, 
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we assume a Gaussian distribution for 𝑋𝑖|𝑌, 𝐙. Note that even though the distribution of a 
biomarker may not be strictly Gaussian, we can apply Box-Cox transformation (Box et al. 
1964) to make it approximately Gaussian. Under the Gaussian distribution, we can further 
link 𝑋𝑖 and 𝑌, 𝐙 by a linear model, i.e.,  
                                   𝑋𝑖 = 𝛽0,𝑖 + 𝛽𝑦,𝑖𝑌 + 𝛃𝑧,𝑖
𝑇 𝐙 + 𝜀𝑖,                                       (4.7) 
where 𝜀𝑖~𝑁(0, 𝜎𝑖
2). Then, 𝜑𝑋𝑖|𝑌,𝐙(𝑥) becomes Φ(
𝑥−(𝛽0,𝑖+𝛽𝑦,𝑖𝑌+𝛃𝑧,𝑖
𝑇 𝐙)
𝜎𝑖
), where Φ(∙) is the 
CDF of 𝑁(0, 1) . Inserting this into (4.5) and (4.6) and further into the optimization 
problems in (4.2) and (4.3), we get: 
          𝑙𝑖
∗(𝐙) =
{
 
 
 
 
max
𝑙𝑖(𝐙)
𝑙𝑖(𝐙)
𝑠. 𝑡.   
Φ(
𝑙𝑖(𝐙)−(𝛽0,𝑖+𝛽𝑦,𝑖+𝛃𝑧,𝑖
𝑇 𝐙)
𝜎𝑖
) 
Φ(
𝑙𝑖(𝐙)−(𝛽0,𝑖+𝛃𝑧,𝑖
𝑇 𝐙)
𝜎𝑖
)
≤
𝑟𝑙
1−𝑟𝑙
×
1−𝜋(𝐙)
𝜋(𝐙)
 
.                                       (4.8) 
          𝑢𝑖
∗(𝐙) =
{
 
 
 
 
min
𝑢𝑖(𝐙)
𝑢𝑖(𝐙)
𝑠. 𝑡.   
1−Φ(
𝑢𝑖(𝐙)−(𝛽0,𝑖+𝛽𝑦,𝑖+𝛃𝑧,𝑖
𝑇 𝐙)
𝜎𝑖
)
1−Φ(
𝑢𝑖(𝐙)−(𝛽0,𝑖+𝛃𝑧,𝑖
𝑇 𝐙)
𝜎𝑖
)
≥
𝑟ℎ
1−𝑟ℎ
×
1−𝜋(𝐙)
𝜋(𝐙)
 
.                                 (4.9) 
Next, we present an important property of the solutions to the optimization 
problems in (4.8) and (4.9) in Propositions 2 and 3, respectively. The proof for Proposition 
2 is given in the Appendix. The proof for Proposition 3 is similar and therefore not provided.  
Proposition 2: The solution to (4.8) exists and is unique. When 
𝑟𝑙
1−𝑟𝑙
×
1−𝜋(𝐙)
𝜋(𝐙)
∈ (0,1), 
𝑙𝑖
∗(𝐙) is the feasible solution at which the equality of the constraint is achieved. When 
𝑟𝑙
1−𝑟𝑙
×
1−𝜋(𝐙)
𝜋(𝐙)
≥ 1, 𝑙𝑖
∗(𝐙) = ∞.  
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Proposition 3: The solution to (4.9) exists and is unique. When 
𝑟ℎ
1−𝑟ℎ
×
1−𝜋(𝐙)
𝜋(𝐙)
> 1, 𝑢𝑖
∗(𝐙) 
is the feasible solution at which the equality of the constraint is achieved. When 
𝑟ℎ
1−𝑟ℎ
×
1−𝜋(𝐙)
𝜋(𝐙)
∈ (0,1], 𝑢𝑖
∗(𝐙) = −∞.    
4.3.2 Model Estimation for STC 
Proposition 2 sheds some light on how to find the lower cutoff of the biomarker, 
𝑙𝑖
∗(𝐙) . Before the patient takes the biomarker testing, his/her 
𝑟𝑙
1−𝑟𝑙
×
1−𝜋(𝐙)
𝜋(𝐙)
 will be 
computed. If it is greater than or equal to one, the lower cutoff of the biomarker for this 
patient is infinity. This means that the patient can be considered LR regardless of the 
biomarker value. In other words, this patient does not need to be tested for the biomarker. 
Such situations rarely happen in practice, except for people with extremely high resistance 
to a certain disease, e.g., people carrying some genes that are disease-protective. In most 
cases, people coming to a clinic for diagnosis of a disease usually bear a fairly extensive 
amount of suspicion or risk for the disease. Therefore, we focus on the condition when 
𝑟𝑙
1−𝑟𝑙
×
1−𝜋(𝐙)
𝜋(𝐙)
∈ (0,1). Then, the problem becomes finding the 𝑙𝑖(𝐙) satisfying the equality 
of  
           
Φ(
𝑙𝑖(𝐙)−(𝛽0,𝑖+𝛽𝑦,𝑖+𝛃𝑧,𝑖
𝑇 𝐙)
𝜎𝑖
) 
Φ(
𝑙𝑖(𝐙)−(𝛽0,𝑖+𝛃𝑧,𝑖
𝑇 𝐙)
𝜎𝑖
)
=
𝑟𝑙
1−𝑟𝑙
×
1−𝜋(𝐙)
𝜋(𝐙)
.                                                  (4.10) 
Unfortunately, this problem does not have an analytical solution. To solve it, we may adopt 
one of two approaches: a numerical approach that finds the 𝑙𝑖(𝐙) satisfying (4.10) for any 
given 𝐙 . This approach can achieve any required precision for the solution, but is 
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computationally intensive. An alternative approach is to use an approximation for Φ(𝑥) 
proposed by (Bowling et al., 2009), i.e.,  
                   Φ(𝑥) ≈
1
1+𝑒𝑥𝑝(−1.702𝑥)
.                                                                  (4.11) 
By substituting (4.11) into (4.10), 𝑙𝑖
∗(𝐙) can be solved analytically as 
        𝑙𝑖
∗(𝐙) = −
𝜎𝑖
1.702
𝑙𝑛 (
1−
𝑟ℎ
1−𝑟ℎ
×
1−𝜋(𝐙)
𝜋(𝐙)
𝑟ℎ
1−𝑟ℎ
×
1−𝜋(𝐙)
𝜋(𝐙)
𝑒𝑥𝑝(1.702
(𝛽0,𝑖+𝛽𝑦,𝑖+𝛃𝑧,𝑖
𝑇 𝐙)
𝜎𝑖
)−𝑒𝑥𝑝(1.702
(𝛽0,𝑖+𝛃𝑧,𝑖
𝑇 𝐙)
𝜎𝑖
)
).     (4.12) 
Likewise, proposition 3 sheds some light on how to find the higher cutoff of the 
biomarker, i.e., 𝑢𝑖
∗(𝐙). Following similar reasoning and using the approximation in (4.11), 
𝑢𝑖
∗(𝐙) can be solved analytically as 
         𝑢𝑖
∗(𝐙) =
𝜎𝑖
1.702
𝑙𝑛 (
1−
𝑟ℎ
1−𝑟ℎ
×
1−𝜋(𝐙)
𝜋(𝐙)
𝑟ℎ
1−𝑟ℎ
×
1−𝜋(𝐙)
𝜋(𝐙)
𝑒𝑥𝑝(1.702
(𝛽0,𝑖+𝛽𝑦,𝑖+𝛃𝑧,𝑖
𝑇 𝐙)
𝜎𝑖
)−𝑒𝑥𝑝(1.702
(𝛽0,𝑖+𝛃𝑧,𝑖
𝑇 𝐙)
𝜎𝑖
)
).        (4.13)      
Finally, we would like to point out that the 𝛽0,𝑖, 𝛽𝑦,𝑖, 𝛃𝑧,𝑖, and 𝜎𝑖 in (4.12) and (4.13) 
are unknown but can be estimated from a training dataset. For example, under the linear 
model in (4.7), 𝛽0,𝑖 , 𝛽𝑦,𝑖 , 𝛃𝑧,𝑖 , and 𝜎𝑖  can be estimated by an maximum likelihood 
estimation (MLE). If 𝐙 is high-dimensional, variable selection techniques may be adopted 
to select a small subset of 𝐙 that have non-zero coefficients, such as the well-known lasso 
model (Wee et al. 2013), followed by an MLE on the non-zero coefficients. However, 
regardless of the estimation method, there is sampling uncertainty in the estimated 𝛽0,𝑖, 
𝛽𝑦,𝑖, 𝛃𝑧,𝑖, and 𝜎𝑖 due to the finite sample size of the training dataset, which will further 
introduce uncertainty into 𝑢𝑖
∗(𝐙) and 𝑙𝑖
∗(𝐙). To better account for the sampling uncertainty, 
we use Monte Carlo simulation to generate an empirical sampling distribution for ?̂?𝑖
∗(𝐙) 
85 
 
and 𝑙𝑖
∗(𝐙), respectively, and then use the empirical means as the solutions to (4.13) and 
(4.12). This approach is found to be more robust to sampling uncertainty and have better 
accuracy in our case studies. Specifically, the empirical sampling distribution for ?̂?𝑖
∗(𝐙) is 
generated as follows (a similar procedure can be used for 𝑙𝑖
∗(𝐙)): Let 𝛽0,𝑖, 𝛽𝑦,𝑖, ?̃?𝑧,𝑖, and ?̃?𝑖 
be the estimated model parameters from the training dataset through MLE. We use Monte 
Carlo simulation to generate 𝑁 samples from the following empirical distributions: 
(
 
 
?̂?0,𝑖
(𝑡)
?̂?𝑦,𝑖
(𝑡)
?̂?𝑧,𝑖
(𝑡)
)
 
 
~𝑁
(
 
 
(
𝛽0,𝑖
𝛽𝑦,𝑖
?̃?𝑧,𝑖
) , ?̃?𝑖
2((𝟏 𝐲 𝐳)𝑇(𝟏 𝐲 𝐳))
−1
(𝟏 𝐲 𝐳)𝑇𝐱𝑖
)
 
 
,     (4.14)                     
?̂?𝑖
2(𝑡)
~
(𝐱𝑖−(?̃?0,𝑖+?̃?𝑦,𝑖𝐲+?̃?𝑧,𝑖
𝑇 𝐳))
𝑇
(𝐱𝑖−(?̃?0,𝑖+?̃?𝑦,𝑖𝐲+?̃?𝑧,𝑖
𝑇 𝐳))
𝜒𝑛−𝑝
2 ,                              (4.15) 
𝑡 = 1,… ,𝑁. 𝐱𝑖, 𝐲, and 𝐳 are training data for 𝑛 patients. 𝟏 is a 𝑛 × 1 vector of ones. 𝑝 is 
the column dimension of the predictor matrix (𝟏 𝐲 𝐳). Then, each sample generated 
from (4.14) and (4.15), i.e., ?̂?0,𝑖
(𝑡)
, ?̂?𝑦,𝑖
(𝑡)
, ?̂?𝑧,𝑖
(𝑡)
, and ?̂?𝑖
2(𝑡)
, is inserted into (4.13) to obtain 
?̂?𝑖
∗(𝐙)(𝑡). The average, ?̅̂?𝑖
∗(𝐙) =
∑ 𝑢𝑖
∗(𝐙)(𝑡)𝑁𝑡=1
𝑁
, is used as the final solution to (4.13).  
4.3.3 Algorithm for STC 
Section 3.1 and 3.2 assumed that the biomarker sequence is known and the 
discussion was focused on the 𝑖-th step (i.e., the 𝑖-th biomarker) of the modeling building 
process of the STC. In this section, we present the full algorithm. The input to the algorithm 
includes a specification on the biomarkers that are allowed to be used in a clinic. This may 
be clinic-specific depending on availability and resource constraints. The input also 
includes a training and a validation set on the biomarkers 𝐗 , patient characteristic 
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variables/risk factors 𝐙, and the diagnostic outcome 𝑌, the HR and LR thresholds, 𝑟ℎ and 
𝑟𝑙, and the prior, 𝜋(𝐙). Suppose 𝑝 biomarkers are available. Then, the objective or output 
of the algorithm is to find an optimal sequence of the biomarkers with cutoffs for each 
biomarker, 𝑢𝑖
∗(𝐙) and 𝑙𝑖
∗(𝐙), 𝑖 = 1, … , 𝑝. Since the number of biomarkers for a particular 
disease is usually small, we will perform an exhaustive search over all possible sequences. 
We will report three metrics computed on the validation set for comparing the sequences: 
positive prediction value (PPV), negative prediction value (NPV), and the percentage of 
patients classified as inconclusive. The first two metrics reflect the accuracy, where PPV 
measures the proportion of patients classified as HR that are true converters and NPV 
measures the proportion of patients classified as LR that are true non-converters. The last 
metric reflects the efficiency: the lower the inconclusive percentage, the more efficient the 
biomarker sequence.  
Specifically, given that 𝑝  biomarkers are available in a clinic, our algorithm 
performs three major steps for each of 𝑝! possible biomarker sequences. Without loss of 
generality, denote each sequence by 𝑋1 → 𝑋2 → ⋯ → 𝑋𝑝.  
Step 1 (initialization): Initialize the algorithm by having  𝑖 ← 1 and putting the entire 
training set into 𝐷𝑖−1.   
Step 2 (sequential estimation)  
Sub-step 2.1 (identification of the cutoffs for 𝑿𝒊): Fit a linear model as (4.7) for 
𝑋𝑖 using the training data in 𝐷𝑖−1, and obtain estimates for the model coefficients, 
𝛽0,𝑖, 𝛽𝑦,𝑖, ?̃?𝑧,𝑖, and ?̃?𝑖. Check the normality assumption of the model and apply box-
cox transformation to 𝑋𝑖 if needed. Use the estimated model coefficients to obtain 
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𝑁 Monte Carlo samples ?̂?0,𝑖
(𝑡)
, ?̂?𝑦,𝑖
(𝑡)
, ?̂?𝑧,𝑖
(𝑡)
, and ?̂?𝑖
2(𝑡)
, 𝑡 = 1,… ,𝑁. Insert each sample 
into (4.13) and (4.12) and obtain sample realizations for the cutoffs, i.e., ?̂?𝑖
∗(𝐙)(𝑡) 
and 𝑙𝑖
∗(𝐙)(𝑡) , 𝑡 = 1,… ,𝑁 . Use the sample averages, ?̅̂?𝑖
∗(𝐙)  and 𝑙 ̅𝑖
∗(𝐙) , as the 
estimated cutoffs for 𝑋𝑖.  
Sub-step 2.2 (subsetting of the training set): Apply the estimated cutoffs in sub-
step 2.1 to the patients in 𝐷𝑖−1 and only keep patients with 𝑙
̅
𝑖
∗(𝐙) < 𝑋𝑖 < ?̅̂?𝑖
∗(𝐙) in 
the training set. Denote the current training set by 𝐷𝑖. 
Sub-step 2.3 (continuation or stopping): Move onto the next biomarker by having  
𝑖 ← 𝑖 + 1 and going to sub-step 2.1, until 𝑖 + 1 = 𝑝. 
Step 3 (evaluation): Apply the estimated cutoffs for each biomarker, i.e.,  ?̅̂?𝑖
∗(𝐙) and 𝑙 ̅𝑖
∗(𝐙), 
𝑖 = 1, … , 𝑝, to the validation set and compute PPV, NPV, and the percentage of patients 
classified as inconclusive.  
This three-step algorithm will be applied to each of the 𝑝!  possible biomarker 
sequences.  These sequences will then be compared in terms of the diagnostic accuracy 
(PPV and NPV) and efficiency (percentage of inconclusive patients) evaluated on the 
validation set. Because multiple metrics are used in the comparison, an integrated metric 
may be used to help select the optimal sequence. Alternatively, a Pareto optimal frontier 
may be provided to practitioners to show the tradeoffs between multiple Pareto optimal 
solutions/sequences.    
4.3.4 Extension to non-Gaussian biomarkers 
When the biomarkers do not follow Gaussian distributions, one approach is to apply 
Box-Cox transformation to make them approximately Gaussian, which was mentioned in 
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Section 3.1. An alternative approach is to deal with the non-Gaussian distributions directly. 
Specifically, instead of linking the biomarker 𝑋𝑖 with 𝑌, 𝐙 by a linear model as in (4.7), we 
can use a Generalized Linear Model (GLM), i.e.,  
𝐸(𝑋𝑖) = 𝑔
−1(𝛽0,𝑖 + 𝛽𝑦,𝑖𝑌 + 𝛃𝑧,𝑖
𝑇 𝐙),                                               (4.16) 
where 𝑔(∙) is an appropriate link function depending on the distribution of the biomarker. 
Consequently, (4.8) and (4.9) change to 
𝑙𝑖
∗(𝐙) = {
max
𝑙𝑖(𝐙)
𝑙𝑖(𝐙)
𝑠. 𝑡.   
𝜑𝑋𝑖|𝑌=1,𝐙=𝐳(𝑙𝑖
(𝐙)) 
𝜑𝑋𝑖|𝑌=0,𝐙=𝐳(𝑙𝑖
(𝐙))
≤
𝑟𝑙
1−𝑟𝑙
×
1−𝜋(𝐙)
𝜋(𝐙)
 
,                                        (4.17) 
𝑢𝑖
∗(𝐙) = {
min
𝑢𝑖(𝐙)
𝑢𝑖(𝐙)
𝑠. 𝑡.   
1−𝜑𝑋𝑖|𝑌=1,𝐙=𝐳(𝑢𝑖
(𝐙))  
1−𝜑𝑋𝑖|𝑌=0,𝐙=𝐳(𝑢𝑖
(𝐙))  
≥
𝑟ℎ
1−𝑟ℎ
×
1−𝜋(𝐙)
𝜋(𝐙)
 
.                                  (4.18) 
𝜑𝑋𝑖|𝑌,𝐙(𝑥) is the CDF of 𝑋𝑖 given 𝑌 and 𝐙, which can be specificed according to the GLM 
in (4.16). 𝜑𝑋𝑖|𝑌,𝐙(𝑥)  is not Gaussian, so the approximation in (4.11) cannot be used. 
Consequently, (4.17) and (4.18) cannot be solved analytically but by a numerical search, 
which is computationally more intensive. The modified STC algorithm is the following: 
Step 1 (initialization): Initialize the algorithm by having  𝑖 ← 1 and putting the entire 
training set into 𝐷𝑖−1.   
Step 2 (sequential estimation)  
Sub-step 2.1 (identification of the cutoffs for 𝑔(𝐸(𝑿𝑖))): Fit a GLM as (4.16) 
using the training data in 𝐷𝑖−1, and obtain estimates for the model coefficients, 𝛽0,𝑖, 
𝛽𝑦,𝑖, and ?̃?𝑧,𝑖. In order to solve the optimization problems in (4.17), we can start 
from a small 𝑙𝑖(𝐙) for which the constraint holds, and increase 𝑙𝑖(𝐙) in small steps 
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until the constraint is violated. The last value of 𝑙𝑖(𝐙)  before the constrain is 
violated is the optimal solution 𝑙𝑖
∗(𝐙). Likewise, we can obtain the optimal solution 
𝑢𝑖
∗(𝐙) in (4.18).  
Sub-step 2.2 (subsetting of the training set): Apply the estimated cutoffs in sub-
step 2.1 to the patients in 𝐷𝑖−1 and only keep patients with 𝑙𝑖
∗(𝐙) < 𝑔(𝐸(𝑿𝑖)) <
𝑢𝑖
∗(𝐙) in the training set. Denote the current training set by 𝐷𝑖. 
Sub-step 2.3 (continuation or stopping): Move onto the next biomarker by having  
𝑖 ← 𝑖 + 1 and going to sub-step 2.1, until 𝑖 + 1 = 𝑝. 
Step 3 (evaluation): Apply the estimated cutoffs for each biomarker, i.e.,  𝑢𝑖
∗(𝐙) and 𝑙𝑖
∗(𝐙), 
𝑖 = 1, … , 𝑝, to the validation set and compute PPV, NPV, and the percentage of patients 
classified as inconclusive. 
4.4 Case studies in prediction of MCI conversion to AD 
In this section, we present two clinical applications using the proposed STC: Sub-
section 4.1 presents an application in clinical diagnosis, i.e., prediction/classification of 
MCI patients into HR, LR, or inconclusive categories so that appropriate medical decisions 
can be made for each patient. Sub-section 4.1 presents another application of using STC to 
help patient selection in clinical trials. As mentioned in Introduction, there has been a 
growing consensus in the medical society that treatment of AD should target on its early 
phases before irreversible brain damage occurs. MCI is such an early phase and therefore 
has been targeted by drug companies to develop treatment for slowing down or even 
stopping the progression to AD. However, it is well-known that MCI patients are 
heterogeneous and not all of them will eventually develop AD.  To be able to appropriately 
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assess the efficacy of an AD-defeating drug, it is important to identify a sub-cohort of MCI 
patients with a HR of converting to AD and enter these patients into the drug trial. This 
important task is known as patient selection in clinical trials and can be accomplished with 
the help of STC.  
The data used in this section was obtained from the ADNI database (http:// 
adni.loni.ucla.edu). The ADNI was launched in 2003 by the National Institute on Aging 
(NIA), the National Institute of Biomedical Imaging and Bioengineering (NIBIB), the Food 
and Drug Administration (FDA), private pharmaceutical companies, and non-profit 
organizations, as a $60 million, 5-year public-private partnership. The primary goal of 
ADNI has been to test whether MRI, PET, other biological markers, and clinical and 
neuropsychological assessment can be combined to measure the progression of MCI and 
early AD. Determination of sensitive and specific markers of very early AD progression is 
intended to aid researchers and clinicians to develop new treatments and monitor their 
effectiveness, as well as lessen the time and cost of clinical trials. The Principal Investigator 
of this initiative is Michael W.Weiner, MD, VA Medical Center and University of 
California-San Francisco. ADNI is the result of efforts of many co-investigators from a 
broad range of academic institutions and private corporations, and subjects have been 
recruited from over 50 sites across the US and Canada. The initial goal of ADNI was to 
recruit 800 adults, ages 55 to 90, to participate in the research, approximately 200 
cognitively normal older individuals to be followed for 3 years, 400 people with MCI to 
be followed for at least 3 years, and 200 people with early AD to be followed for 2 years. 
For up-to-date information, see http://www.adni-info.org/. 
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Specifically, our study includes 187 MCI patients included in the ADNI database 
who have complete data on three biomarkers, P-tau, FDG-PET, and Hippo, at their baseline 
visits, patient-specific variables/risk factors such as age, gender, education level, APOE e4 
status, and cognitive test scores, as well as conversion vs. non-conversion to AD at the end 
of their clinical follow-up time periods. A detailed description of the data is shown in Table 
11.  
Table 11: Description of the data 
Variable Non-Converters Converters 
Sample size 87 100 
Gender: female  % 59.8 58 
Age: ave. (std.) 73.1 (7.3) 73.6 (7.6) 
Education years: ave. (std.) 16.6 (2.6) 16.3 (2.7) 
APOE e4 status: carriers % 41.4 68 
Mini-mental State Examination score: ave. (std.) 27.9 (1.6) 26.7 (1.7) 
P-tau, 𝑝𝑔/𝑚𝐿: ave. (std.) 35.8 (22.8) 50.6 (25.1) 
FDG-PET, relative counts: ave. (std.) 1.25 (0.13) 1.16 (0.11) 
Hippo, 𝑚𝑚3: ave. (std.) 3449 (551) 3067 (497) 
 
Standardized biomarker acquisition and performance methods of ADNI are 
described at www.loni.ucla.edu/ADNI. Protocols of image and CSF analyses are reported 
in detail elsewhere (Jack et al. 2010, Jagust et al. 2009, Kim et al. 2011, Landau et al. 2010). 
In brief, the mean FDG count per subject (i.e., biomarker “FDG-PET”) was extracted from 
a composite region of interest on the basis of the AD-typical hypometabolic pattern (Jack 
et al. 2008, Kim et al. 2011). Hippocampal volumes (i.e., biomarker “Hippo”) were 
extracted from structural MRI scans (1.5 T) using the FreeSurfer software 
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http://surfer.nmr.mgh.harvard.edu (Kim et al. 2011). Peptide concentrations (i.e., 
biomarker “P-tau”) were measured in CSF using aliquots obtained from the same vial at 
the same thaw (Jagust et al. 2010).  
4.4.1 Clinical diagnosis of MCI conversion to AD 
4.4.1.1 Diagnosis of MCI conversion to AD with three biomarkers 
  
Figure 8: QQ plots for biomarkers after Box-Cox transformation in the sequence 
“P-tau->FDG-PET->Hippo” 
We first focus on a scenario that all three biomarkers, P-tau, FDG-PET, and Hippo, 
are available in the clinic. Then, the goal is to find an optimal sequence of the biomarkers 
with cutoffs for each biomarker, i.e., 𝑢𝑖
∗(𝐙) and 𝑙𝑖
∗(𝐙) , 𝑖 = 1,2,3 . Among known risk 
factors such as age, gender, education level, and APOE e4 status, only age is found to be 
significant in this dataset. Therefore, 𝐙 includes age. The HR and LR thresholds are set to 
be 𝑟ℎ = 0.8 and 𝑟𝑙 = 0.2, which are common choices in clinical diagnosis. Also, a uniform 
prior is adopted, i.e., 𝜋(𝐙) = 0.5. Three biomarkers compose 3! = 6 possible sequences. 
For each sequence, we apply the algorithm in Section 3.3 with a minor modification of 
using cross validation (CV) instead of arbitrarily splitting the entire dataset into a training 
and a validation set. The CV-based PPV, NPV, and percentage of inconclusive patients for 
93 
 
each sequence are summarized in Table 12. Box-Cox transformation on the biomarkers is 
used and the transformed biomarkers in each sequence follow Gaussian distributions. For 
example, Figure 8 shows the QQ plot of each transformed biomarker in the sequence “P-
tau->FDG-PET->Hippo”, which demonstrates clear normality.    
Table 12: CV-based PPV, NPV, and percentage of inconclusive patients for all 
possible sequences of three biomarkers using STC 
Sequence of biomarkers PPV NPV % inconclusive patients 
P-tau->FDG-PET->Hippo 74% 81% 59% 
FDG-PET->P-tau->Hippo 70% 74% 52% 
P-tau->Hippo->FDG-PET 71% 78% 56% 
Hippo->P-tau->FDG-PET 73% 78% 52% 
FDG-PET->Hippo->P-tau 72% 77% 58% 
Hippo->FDG-PET->P-tau 72% 77% 63% 
 
A clear trend of the results in Table 12 is that the NPVs are higher than PPVs 
regardless of the sequence of biomarkers. This suggests that the three biomarkers have a 
better capability for identifying non-converters than converters. Another observation is that 
the PPVs are lower than the HR threshold 𝑟ℎ = 0.8. This is reasonable because 𝑟ℎ = 0.8 is 
set for model training and the PPVs are computed based on CV which reflect the accuracy 
of the trained model applied to unseen data. The fact that the PPVs are only slightly lower 
than 0.8 implies that STC has good generalization capability. Likewise, the NPVs are only 
slightly lower than or almost equal to 1 − 𝑟𝑙 = 0.8 , which also indicates good 
generalization capability of STC. Last but not least, we observe that over half of the MCI 
patients in the dataset are found to be inconclusive no matter which sequence of the 
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biomarkers is used. This is expected because this study only uses baseline biomarker 
measurements to predict the conversion of MCI to AD. Use of baseline biomarkers for the 
prediction has clear clinical benefits as it enables early decision making for patients 
classified as HR and LR converters. On the other hand, it is highly likely that a conclusive 
classification is not possible for some MCI patients using baseline biomarker 
measurements alone. These patients need to be followed up and kept tracked of for the 
changes in their biomarker measurements over time before a conclusive prediction can be 
reached.  
To select an optimal biomarker sequence among the six possible ones in Table 12, 
we need to make a tradeoff between accuracy (measured by PPV and NPV) and efficiency 
(measured by the percentage of inconclusive patients) because no sequence optimizes the 
two criteria simultaneously. If accuracy is the primary consideration, the sequence “P-
tau->FDG-PET->Hippo” should be selected because it has the highest PPV (74%) and 
NPV (81%). This sequence, on the other hand, classifies 59% of MCI patients as 
inconclusive, which makes it the second least efficient sequence among the six. If 
efficiency is the primary consideration, the sequence  “Hippo->P-tau->FDG-PET” should 
be selected as it has the lowest percentage of inconclusive patients (52%), although its 
accuracy is sub-optimal.  
A commonly used approach in optimization when multiple criteria need to be 
optimized is to examine the Pareto optimal frontier. Figure 9 shows the Pareto optimal 
frontier for the six biomarker sequences. The vertical axis “efficiency” is defined as 1 −
percentage of inconclusive patients or the percentage of patients classified as HR or LR  
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Figure 9: Efficiency vs. accuracy of six possible sequences given all three 
biomarkers. Sequences in red are on the Pareto optimal frontier.  
by STC. The horizontal axis “accuracy” is defined as a weighted average of PPV and NPV, 
where the weights are proportions of samples classified as HR and LR, respectively. Each 
sequence is represented by a dot. Two dots in red are sequences on the Pareto optimal 
frontier. In particular, the sequence “P-tau->FDG-PET->Hippo” optimizes the accuracy 
criterion while “Hippo->P-tau->FDG-PET” optimizes the efficiency.  
 
(a) 
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Cutoffs as functions of age 
Cutoffs at 
median age 
𝑙1
∗(𝑎𝑔𝑒)
= 𝑒𝑥𝑝 (
𝑙𝑜𝑔 (−0.01 × 𝑙𝑛 (
1
3 × 𝑒
(16.83−0.04×𝑎𝑔𝑒) −
4
3 × 𝑒
(15.43−0.04×𝑎𝑔𝑒)) + 1)
−0.04
) 
19.4 
𝑢1
∗(𝑎𝑔𝑒)
= 𝑒𝑥𝑝 (
𝑙𝑜𝑔 (0.01 × 𝑙𝑛 (−
4
3 × 𝑒
(16.83−0.04×𝑎𝑔𝑒) +
1
3 × 𝑒
(15.43−0.04×𝑎𝑔𝑒)) + 1)
−0.04
) 
68.4 
𝑙2
∗(𝑎𝑔𝑒)
= 𝑒𝑥𝑝 (
𝑙𝑜𝑔 (0.01 × 𝑙𝑛 (−
4
3 × 𝑒
(−3.87+0.02×𝑎𝑔𝑒) +
1
3 × 𝑒
(−5.24+0.02×𝑎𝑔𝑒)) + 1)
0.15
) 
1.054 
2
∗(𝑎𝑔𝑒)
= 𝑒𝑥𝑝 (
𝑙𝑜𝑔 (−0.01 × 𝑙𝑛 (
1
3 × 𝑒
(−3.87+0.02×𝑎𝑔𝑒) −
4
3 × 𝑒
(−5.24+0.02×𝑎𝑔𝑒)) + 1)
0.15
) 
1.360 
𝑙3
∗(𝑎𝑔𝑒)
= 𝑒𝑥𝑝 (
𝑙𝑜𝑔 (80.17 × 𝑙𝑛 (−
4
3 × 𝑒
(−20.42+0.11×𝑎𝑔𝑒) +
1
3 × 𝑒
(−21.70+0.11×𝑎𝑔𝑒)) + 1)
0.86
) 
2471.8 
𝑢3
∗(𝑎𝑔𝑒)
= 𝑒𝑥𝑝 (
𝑙𝑜𝑔 (−80.17 × 𝑙𝑛 (
1
3 × 𝑒
(−20.42+0.11×𝑎𝑔𝑒) −
4
3 × 𝑒
(−21.70+0.11×𝑎𝑔𝑒)) + 1)
0.86
) 
3976.2 
(b) 
Figure 10: Cutoffs found by STC for biomarker sequence “P-tau->FDG-
PET->Hippo” represented by (a) a tree-like plot in which green/red/grey circles represent 
LR/HR/inconclusive categories and sizes of the circles are in proportion to the sample 
size of each branch. (b) Cutoffs of each biomarker as functions of “age” 
Next, we would like to show the cutoffs of each biomarker found by STC. We 
choose to show these for the sequence “P-tau->FDG-PET->Hippo” as an example using a 
tree-like plot in Figure 10. Specifically, In Figure 10(a), branches in green/red represent 
HR/LR converters classified by STC. The branch in grey represents the inconclusive 
category. Sizes of the branches/circles are in proportion to the sample sizes of the branches. 
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A clear observation is that less samples are classified as HR and LR as the tree goes deeper. 
This is a result from the sequential nature of STC, i.e., a later biomarker needs to classify 
samples that are failed to be classified (i.e., the inconclusive samples) by a previous 
biomarker so it has a “tougher” mission to accomplish. Figure 10(b) shows the cutoffs as 
functions of “age” using the approximations in (4.13) and (4.15). Values of the cutoffs at 
the median age of the dataset are also provided for illustration purposes.  
 
Figure 11: Efficiency vs. accuracy of six possible sequences given two out of 
three biomarkers. Sequences in red are on the Pareto optimal frontier. Each ellipse 
highlights two sequences with the same pair of biomarkers but in different orders. 
Moreover, we would like to point out that the findings from STC can help not only 
clinical diagnosis but also knowledge discovery such as discovering disease sub-types. 
Using the tree in Figure 10 as an example, there seem to exist three distinct sub-types of 
HR converters, i.e., the sub-types of P-tau-abnormality (P-tau ≥ 𝑢1
∗(𝑎𝑔𝑒)), FDG-PET-
abnormality (P-tau < 𝑢1
∗(𝑎𝑔𝑒) & FDG-PET ≤ 𝑙2
∗(𝑎𝑔𝑒)), and Hippo-abnormality (P-tau <
𝑢1
∗(𝑎𝑔𝑒) & FDG-PET > 𝑙2
∗(𝑎𝑔𝑒) & Hippo ≤ 𝑙3
∗(𝑎𝑔𝑒)). Indeed, there has been medical 
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evidence that the three biomarkers track distinct aspects of the AD pathophysiological 
process (Jack et al. 2010). That is, FDG-PET, as a measure for AD-related glucose 
hypometabolism, reflects reduction in synaptic density/activity and phenomena of 
diaschisis, Hippos, as a measure for hippocampal atrophy, reflects neural loss, while P-tau 
reflects intracellular hyperphosphorylation of tau. STC allows for a finer distinction of HR 
converters into different sub-types according to specific biomarker abnormality, which 
may lead to more targeted and effective treatment. Likewise, STC can help discover sub-
types of LR converters. This would facilitate the study of different pathophysiological 
mechanisms that lead to disease protection or resistance.  
4.4.1.2 Diagnosis of MCI conversion to AD with two biomarkers – a limited-resource 
scenario 
Next, we present the results of STC in a “limited-resource” scenario, e.g., when 
only two out of the three biomarkers are available. This situation is common in many clinics. 
We use the same setting as the previously-presented three-biomarker scenario, i.e., 𝑟ℎ =
0.8 , 𝑟𝑙 = 0.2 , 𝜋(𝐙) = 0.5 , and 𝐙 = {𝑎𝑔𝑒} . Two biomarkers compose six possible 
sequences. For each sequence, we apply the algorithm in Section 3.3 and compute the CV-
based PPV, NPV, and percentage of inconclusive patients. Figure 10 shows the Pareto 
optimal frontier for the six sequences, in which efficiency and accuracy are defined in the 
same way as Figure 9. The sequence “Hippo->P-tau” optimizes the accuracy criterion 
while “FDG-PET->P-tau” optimizes the efficiency. Furthermore, each ellipse includes two 
sequences with the same pair of biomarkers but in different orders. If a clinic only has the 
resource for testing two specific biomarkers, we can compare the two dots/sequences 
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within the same ellipse and select an order of the two biomarkers that is more appropriate 
in terms of efficiency or/and accuracy. For example, if a clinic only has FDG-PET and 
Hippos, we can compare the two dots within the middle ellipse. The dot at the upper-right 
corner corresponds to the sequence “Hippo->FDG-PET” and is clearly better because it 
has better efficiency and accuracy. 
4.4.1.3 Comparison between STC and decision tree 
Finally, we compare STC with the conventional decision tree. Specifically, we 
apply the C4.5 algorithm in the Weka software (Hall et al. 2009) to the same dataset as that 
used by STC. Because STC uses age in addition to three biomarkers, we include the same 
variables in C4.5 for a fair comparison. Parameters of C4.5 are tuned to optimize the CV 
accuracy. Figure 11 shows the decision tree generated by C4.5.  Compared with the tree 
generated by STC in Figure 10, we can obtain the following observations: Both methods 
find P-tau as the first biomarker to be used for the classification. This suggests that P-tau 
may be more informative than the other two biomarkers. The differences between the two 
methods are summarized as follows: 1) The CV-based PPV and NPV of the decision tree 
are 68% and 69%, respectively, which are significantly lower than the PPV (74%) and 
NPV (81%) of the optimal sequence found by STC. This is because the decision tree, by 
design, must assign a class membership to every sample, even when a sample does not 
have a significantly higher probability of belonging to one class than the other. This leads 
to potentially large classification errors. In contrast, STC only classifies samples with a HR 
or LR of conversion while putting samples with only a mild risk in either direction (i.e., a 
risk between LR and HR) in an inconclusive category. From a disease management point 
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of view, STC is more appropriate by allowing HR patients to receive immediate medical 
attention, LR patients to be put on long-term observation, and patients in between to be 
followed up to track the changes in their disease risks. 2)  According to the decision tree in 
Figure 11, no patients can be classified using a single biomarker. In contrast, according to 
the tree in Figure 10 produced by STC, 52.3% of the patients classified as HR and LR only 
need to be tested by P-tau. In this sense, STC means less diagnostic costs, less patient 
waiting time, and more timely medical decision making. 3) The decision tree in Figure 11 
is somewhat counter-intuitive. Biomarkers are expected to have a monotonic relationship 
with the risk of disease. For example, a higher P-tau, lower FDG-PET, or lower Hippo 
indicates a higher risk of AD pathology. However, there are several branches in Figure 11 
whose biomarker ranges are contrary to this expectation. For instance, the top-right green 
circle represents non-converters whose classification rule is P-tau> 28.5 and FDG-PET>
1.19 . This higher value range for P-tau is expected to indicate a higher risk of AD 
pathology. From a clinical utilization’s point of view, clinicians would be very reluctant to 
adopt such a model as the decision tree in Figure 11 regardless of the accuracy, because 
the model is against their medical knowledge and thus being difficult to understand and 
trust. In essence, decision tree is a pure data-driven model that does not integrate medical 
knowledge and biological principles into its model building process. In contrast, STC, by 
its unique design, honors the monotonic relationship between a biomarker and disease risk, 
and therefore is able to provide a model with good interpretability and clinical utility.    
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Figure 12: Decision tree generated by C4.5. Green/red circles represent non-
convert/converter categories and sizes of the circles are in proportion to the sample size 
of each branch. 
4.4.2 Selection of HR converters for clinical trials 
Here, our objective is to identify a sub-cohort of MCI patients with a HR of 
converting to AD and enter these patients into a drug trial. This objective is different from 
clinical diagnosis as presented in sub-section 4.1 in the sense that we only care about 
maximizing PPV, as opposed to accuracy that includes both PPV and NPV, and 
maximizing the number/proportion of patients classified as HR, as opposed to efficiency 
that includes patients classified as HR or LR.  To serve this objective, we modify the STC 
algorithm by treating 𝑟𝑙 as a tuning parameter ranging from 0.05 to 0.5 in increment of 0.05. 
We adopt the same setting as that in sub-section 4.1, i.e., 𝑟ℎ = 0.8, 𝜋(𝐙) = 0.5, and 𝐙 =
{𝑔𝑒}. Figure 12 shows the Pareto optimal frontier for the biomarker sequences, in which 
each dot represents a sequence at a specific 𝑟ℎ (a total of 6 sequences × 10 𝑟ℎ values = 60 
dots). On the frontier, the sequence “Hippo->P-tau->FDG-PET” at 𝑟𝑙 = 0.35 is probably 
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the one achieving the best tradeoff between the CV-based PPV (87%) and number of HR 
patients (30), and therefore recommended as the biomarker testing sequence used for HR 
converter patient selection in AD-related clinical trials. Finally, Figure 13 shows the cutoffs 
of each biomarker for the sequence “Hippo->P-tau->FDG-PET” at 𝑟𝑙 = 0.35 found by 
STC.  
 
Figure 13: Number of HR patients vs. PPV of six possible sequences given all 
three biomarkers at 𝑟𝑙 ranging from 0.05 to 0.5 in increment of 0.05. Sequences in red are 
on the Pareto optimal frontier.  
 
(a) 
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Cutoffs as functions of age 
Cutoffs at 
median age 
𝑙1
∗(𝑎𝑔𝑒)
= 𝑒𝑥𝑝 (
𝑙𝑜𝑔 (209.97 × 𝑙𝑛 (−
4
3 × 𝑒
(−19.80+0.11×𝑎𝑔𝑒) +
1
3 × 𝑒
(−21.12+0.11×𝑎𝑔𝑒)) + 1)
0.97
) 
2613.8 
𝑢1
∗(𝑎𝑔𝑒)
= 𝑒𝑥𝑝 (
𝑙𝑜𝑔 (−209.97 × 𝑙𝑛 (
7
5 × 𝑒
(−19.80+0.11×𝑎𝑔𝑒) −
13
5 × 𝑒
(−21.12+0.11×𝑎𝑔𝑒)) + 1)
0.97
) 
3470.1 
𝑙2
∗(𝑎𝑔𝑒)
= 𝑒𝑥𝑝 (
𝑙𝑜𝑔 (−0.01 × 𝑙𝑛 (
7
5 × 𝑒
(16.28−0.03×𝑎𝑔𝑒) −
13
5 × 𝑒
(15.13−0.03×𝑎𝑔𝑒)) + 1)
−0.04
) 
29.7 
𝑢2
∗(𝑎𝑔𝑒)
= 𝑒𝑥𝑝 (
𝑙𝑜𝑔 (0.01 × 𝑙𝑛 (−
4
3 × 𝑒
(16.28−0.03×𝑎𝑔𝑒) +
1
3 × 𝑒
(15.13−0.03×𝑎𝑔𝑒)) + 1)
−0.04
) 
91.5 
𝑙3
∗(𝑎𝑔𝑒)
= 𝑒𝑥𝑝 (
𝑙𝑜𝑔 (0.01 × 𝑙𝑛 (−
4
3 × 𝑒
(−0.85−0.03×𝑎𝑔𝑒) +
1
3 × 𝑒
(−1.86−0.03×𝑎𝑔𝑒)) + 1)
0.19
) 
0.992 
3
∗(𝑎𝑔𝑒)
= 𝑒𝑥𝑝 (
𝑙𝑜𝑔 (−0.01 × 𝑙𝑛 (
7
5 × 𝑒
(−0.85−0.03×𝑎𝑔𝑒) −
13
5 × 𝑒
(−1.86−0.03×𝑎𝑔𝑒)) + 1)
0.19
) 
1.261 
(b) 
Figure 14: Cutoffs found by STC for biomarker sequence “Hippo->P-tau->FDG-
PET” represented by (a) a tree-like plot in which green/red/grey circles represent 
LR/HR/inconclusive categories and sizes of the circles are in proportion to the sample 
size of each branch. (b) Cutoffs of each biomarker as functions of “age” 
4.5 Conclusion 
In this paper, we developed a STC for predicting the conversion of MCI to AD. 
The uniqueness of the STC is to find an optimal testing sequence of the biomarkers and 
two-sided cutoffs of each biomarker that satisfy pre-specified accuracy requirements while 
minimizing the proportion of inconclusive diagnosis. The cutoffs can be customized for 
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each individual patient by taking into account patient demographic and genetic variables 
that are potential risk factors for AD. We formulated STC into an optimization problem 
and performed theoretical analysis to prove the existence and uniqueness of the solution to 
STC. Then, we proposed two approaches for estimating the cutoffs of the biomarkers, 
including a numerical approach and an approximate-analytical approach, with 
consideration of sampling uncertainty. Next, we presented the full algorithm integrating 
the estimation approaches for the cutoffs with a search of the optimal sequence. Finally, 
we presented two applications of STC using the ADNI data. In the first application, we 
used STC to identify an optimal sequence of three and two biomarkers (as an example of 
a resource-limited situation) and the associated cutoffs for classifying MCI patients into 
HR converters, LR converters, or the inconclusive category. The CV-based PPV and NPV 
of the optimal sequence are close to the pre-specified HR and LR thresholds that reflected 
the expected accuracy. STC also allowed multiple criteria, e.g., accuracy and efficiency, to 
be optimized using a Pareto optimal frontier. The results also helped identify subtypes 
within HR converters. Compared with the conventional decision tree classifier, STC 
achieved higher PPV and NPV, saved biomarker testing costs and patient waiting time, 
facilitated timely medical decision making, and produced a model that is consistent with 
medical knowledge and biological principles and thus being clinically more trust-worthy. 
In the other application, we used STC to identify a sub-cohort of MCI patients with a HR 
of converting to AD. With a slight modification of the STC algorithm, we were able to 
identify such a sub-cohort with a high CV-based PPV (87%) and a reasonable size 
appropriate for clinical trials.   
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Finally, we would like to point out that STC is applicable to other disease diagnosis 
for which multiple biomarkers need to be tested, such as the Parkinson’s disease and cancer. 
The key benefit of STC is to allow physicians to test the biomarkers sequentially with a 
known sequence optimized for each patient’s demographic profile, and on an as-needed 
basis. This would save the diagnostic time – a benefit to the patient, and the resources – a 
benefit to the health care provider. We plan to explore the application of STC to other 
diseases in future work.  
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CHAPTER 5 
CONCLUSIONS AND FUTURE WORK 
There are rich data available in today’s healthcare systems due to technology advancements, 
such as diagnostic imaging, smart sensing, and health information systems, which offers a 
great opportunity of Precision Medicine. My research focus on developing data fusion and 
system informatics approaches for quality and performance improvement of healthcare 
systems from diagnosis to care to system-level decision-making. In my dissertation, I focus 
on three emerging problems in healthcare and develop novel statistical models and machine 
learning algorithms. In collaboration with healthcare domain experts, my research has 
explored a few healthcare domains, including imaging-based disease diagnosis, 
coordinated patient care, and system-level medical decision-making.  
For disease diagnosis/subtyping, I proposed a new method, MFMM, for clustering 
multi-mode image data to discover migraine subtypes. MFMM employed a double-𝐿21-
penalized likelihood formulation to enable hierarchical selection of imaging modes and 
features. We applied MFMM to migraine subtype discovery based on brain cortical area, 
cortical thickness, and volume measurements from MRI. Two clusters/subtypes were 
found and well separated using a total of seven factors. Subjects in the two clusters had 
significantly different clinical characteristics. Findings from this study showed promise for 
imaging-based subtyping of migraine and patient stratification toward Precision Medicine. 
In my future research, MFMM could be extended to include mixed-type features, and even 
applied to subtype discovery of other diseases.   
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For coordinated patient care, I developed a Multi-response Multi-level Model to 
fuse NCCI data and reveal how care coordination activities conducted by nurses are related to 
their demographics, workload, and characteristics of their practice environment. The long-
term goal of this research is to inform interventions to improve staff nurse care coordination 
within hospital units that would in turn lead to improved patient outcomes, e.g., shorter 
length of stay, few medication errors, less likelihood for re-admission, and greater 
satisfaction.  
There are many opportunities in healthcare systems for data science research, and 
as industrial engineer, I would like to consider medical problems from a system level and 
involve multi-perspectives, such as accuracy, efficiency, safety and quality, to develop novel 
systems engineering approaches and support system-level decision-making in healthcare.   
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Appendix A-I: Deriving the expectations in (2.7) 
(A-I.1) Deriving 𝐸𝒇𝑚,𝑖,𝒔𝑖|𝒙1,𝑖,…,𝒙𝑀,𝑖 ;?̃?(− log 𝑓(𝒇𝑚,𝑖|𝒔𝑖; 𝚯)).  
According to (2.3), the distribution of 𝒇𝑚,𝑖| 𝑠𝑘,𝑖 = 1;𝚯 is 𝑁(𝐚𝑚,𝑘, 𝚺𝑚). Inserting 
the probability density function of this distribution into the above expectation and ignoring 
constants, we can get 
∑
{
 
 
 
 
1
2
𝑙𝑜𝑔|𝚺𝑚| +
1
2
(𝐸(𝒇𝑚,𝑖|𝒙𝑚,𝑖, 𝑠𝑘,𝑖 = 1; ?̃?) − 𝐚𝑚,𝑘)
𝑇
𝚺𝑚
−1(𝐸(𝒇𝑚,𝑖|𝒙𝑚,𝑖, 𝑠𝑘,𝑖 = 1; ?̃?) − 𝐚𝑚,𝑘) +
1
2
𝑡𝑟 (𝚺𝑚
−1𝐸(𝒇𝑚,𝑖𝒇𝑚.𝑖
𝑇 |𝒙𝑚,𝑖, 𝑠𝑘,𝑖 = 1; ?̃?)) }
 
 
 
 
𝐾
𝑘=1
  
𝑓(𝑠𝑘,𝑖 = 1|𝒙1,𝑖, … , 𝒙𝑀,𝑖,; ?̃?).                                                                                         (A-1)             
The distribution of 𝒇𝑚,𝑖|𝒙𝑚,𝑖, 𝑠𝑘,𝑖 = 1; ?̃?  is 𝑁(?̃?𝑚𝑘(𝒙𝑚,𝑖), ?̃?𝑚𝑘) , where ?̃?𝑚𝑘(𝒙𝑚,𝑖) =
?̃?𝑚𝑘(?̃?𝑚
𝑇 ?̃?𝑚
−1𝒙𝑚,𝑖 + ?̃?𝑚
−1?̃?𝑚,𝑘)  and ?̃?𝑚𝑘 = (?̃?𝑚
𝑇 ?̃?𝑚
−1?̃?𝑚 + ?̃?𝑚
−1)
−1
.  Therefore, 
𝐸(𝒇𝑚,𝑖|𝒙𝑚,𝑖, 𝑠𝑘,𝑖 = 1; ?̃?) = ?̃?𝑚𝑘(𝒙𝑚,𝑖)  and 𝐸(𝒇𝑚,𝑖𝒇𝑚.𝑖
𝑇 |𝒙𝑚,𝑖, 𝑠𝑘,𝑖 = 1; ?̃?) = ?̃?𝑚𝑘 −
?̃?𝑚𝑘(𝒙𝑚,𝑖)
𝑇
?̃?𝑚𝑘(𝒙𝑚,𝑖) in (A-1). Finally, to derive the 𝑓(𝑠𝑘,𝑖 = 1|𝒙1,𝑖, … , 𝒙𝑀,𝑖,; ?̃?) in (A-
1), we can use the Bayes’ theorem and get    
𝑓(𝑠𝑘,𝑖 = 1|𝒙1,𝑖, … , 𝒙𝑀,𝑖,; ?̃?) =
?̃?𝑘 ∏ 𝑓(𝒙𝑚,𝑖|𝑠𝑘,𝑖=1;?̃?)
𝑀
𝑚=1
∑ ?̃?𝑘 ∏ 𝑓(𝒙𝑚,𝑖|𝑠𝑘,𝑖=1;?̃?)
𝑀
𝑚=1
𝐾
𝑘=1
, 
where 𝒙𝑚,𝑖|𝑠𝑘,𝑖 = 1; ?̃?~𝑁(?̃?𝑚?̃?𝑚,𝑘 + ?̃?𝑚𝒛𝑖 , ?̃?𝑚?̃?𝑚?̃?𝑚
𝑇 + ?̃?𝑚 ).                 
(A-I.2) Deriving 𝐸𝒇𝑚,𝑖|𝒙𝑚,𝑖;?̃?(− log 𝑓(𝒙𝑚,𝑖|𝒇𝑚,𝑖, 𝒛𝑖; 𝚯)).  
According to (2.1), the distribution of 𝒙𝑚,𝑖|𝒇𝑚,𝑖, 𝒛𝑖; 𝚯 is 𝑁(𝐇𝑚𝒇𝑚,𝑖 + 𝐁𝑚𝒛𝑖 , 𝚿𝑚). 
Inserting the probability density function of this distribution into the above expectation and 
ignoring constants, we can get 
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1
2
𝑙𝑜𝑔|𝚿𝑚| +
1
2
(𝒙𝑚,𝑖 − 𝐇𝑚𝐸(𝒇𝑚,𝑖|𝒙𝑚,𝑖; ?̃?) − 𝐁𝑚𝒛𝑖 )
𝑇
𝚿𝑚
−1(𝒙𝑚,𝑖 − 𝐇𝑚𝐸(𝒇𝑚,𝑖|𝒙𝑚,𝑖; ?̃?) − 𝐁𝑚𝒛𝑖 ) +
1
2
𝑡𝑟 (𝐇𝑚
𝑇𝚿𝑚
−1𝐇𝑚 (𝐸(𝒇𝑚,𝑖𝒇𝑚.𝑖
𝑇 |𝒙𝑚,𝑖; ?̃?) − 𝐸(𝒇𝑚,𝑖|𝒙𝑚,𝑖; ?̃?)𝐸(𝒇𝑚,𝑖|𝒙𝑚,𝑖; ?̃?)
𝑇
))
     
(A-2) 
Using the result in (A-I.1), we can get 𝐸(𝒇𝑚,𝑖|𝒙𝑚,𝑖; ?̃?) = ∑ ?̃?𝑚𝑘(𝒙𝑚,𝑖)
𝐾
𝑘=1 𝑓(𝑠𝑘,𝑖 =
1|𝒙𝑚,𝑖; ?̃?) , and 𝐸(𝒇𝑚,𝑖𝒇𝑚.𝑖
𝑇 |𝒙𝑚,𝑖; ?̃?) = ∑ (?̃?𝑚𝑘 − ?̃?𝑚𝑘(𝒙𝑚,𝑖)
𝑇
?̃?𝑚𝑘(𝒙𝑚,𝑖))
𝐾
𝑘=1 𝑓(𝑠𝑘,𝑖 =
1|𝒙𝑚,𝑖; 𝚯
(𝜔)) in (A-2).  
(A-I.3) Deriving 𝐸𝒔𝒊|𝒙1,𝑖,…,𝒙𝑀,𝑖 ;?̃?(− log 𝑓(𝒔𝑖; 𝚯)).  
According to (2.2), log 𝑓(𝒔𝑖; 𝚯) = ∑ 𝑠𝑘,𝑖𝑙𝑜𝑔(𝑤𝑘)
𝐾
𝑘=1 . Inserting it into the above 
expectation, we can get 𝐸𝒔𝒊|𝒙1,𝑖,…,𝒙𝑀,𝑖 ;?̃?(− log 𝑓(𝒔𝑖; 𝚯)) = −∑ 𝑙𝑜𝑔(𝑤𝑘)
𝐾
𝑘=1 𝑓(𝑠𝑘,𝑖 =
1|𝒙1,𝑖, … , 𝒙𝑀,𝑖; ?̃?) .      Δ 
Appendix A-II: Proof of Proposition 1 
We first need to write the minimization problem in (2.9) into the form of (2.11). 
This can be achieved by making 𝐽 = 𝑃𝑚, 𝜷
(𝑗) = 𝐡𝑚
𝑗
, and  
𝐿(𝜷|𝐃) = ∑ 𝐸𝒇𝑚,𝑖|𝒙𝑚,𝑖;?̃?(− log 𝑓(𝒙𝑚,𝑖|𝒇𝑚,𝑖, 𝒛𝑖; 𝚯))
𝑁
𝑖=1 .               (A-3) 
Since the QM condition requires 𝐿(𝜷|𝐃) satisfying two assumption, we will need to write 
𝐿(𝜷|𝐃) into a format that facilitates checking of the assumptions. Through some derivation 
and dropping the terms not involving 𝜷, we can write 𝐿(𝜷|𝐃) as  
𝐿(𝜷|𝐃) = 𝜷𝑇(∑ 𝐂𝑚𝑖
𝑁
𝑖=1 )𝜷 − 2(∑ 𝒃𝑚,𝑖
𝑇𝑁
𝑖=1 )𝜷                           (A-4) 
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where 𝐂𝑚𝑖 =
1
2
𝑡𝑟(𝜳𝑚
−1) [(𝟏𝑃𝑀×𝑃𝑀⊗ (𝐸𝒇𝑚,𝑖|𝒙𝑚,𝑖;𝜣(𝜔)(𝒇𝑚,𝑖))
𝑇
)
𝑇
(𝟏𝑃𝑀×𝑃𝑀⊗
(𝐸𝒇𝑚,𝑖|𝒙𝑚,𝑖;𝜣(𝜔)(𝒇𝑚,𝑖))
𝑇
) + (𝟏𝑃𝑚
𝑇 ⨂𝟏𝑟𝑚
𝑇 )(𝟏𝑃𝑚
𝑇 ⨂𝟏𝑟𝑚
𝑇 )
𝑇
𝑡𝑟 (𝐸 (𝒇𝑚,𝑖(𝒇𝑚,𝑖)
𝑇
|𝒙𝑚,𝑖; 𝜣
(𝜔)) −
𝐸(𝒇𝑚,𝑖|𝒙𝑚,𝑖; 𝜣
(𝜔))𝐸(𝒇𝑚,𝑖|𝒙𝑚,𝑖; 𝜣
(𝜔))
𝑇
)]  and 𝒃𝑚,𝑖
𝑇 =
1
2
𝑡𝑟(𝜳𝑚
−1)𝒙𝑚,𝑖
𝑇 (𝟏𝑃𝑀×𝑃𝑀 ⊗
(𝐸𝒇𝑚,𝑖|𝒙𝑚,𝑖;𝜣(𝜔)(𝒇𝑚,𝑖))
𝑇
).  
Next, we will prove (A-4) satisfy the two assumptions required by the QM condition: 
(i) It is straightforward to get ∇𝐿(𝜷|𝐃) = 2(∑ 𝐂𝑚𝑖
𝑁
𝑖=1 𝜷 − ∑ 𝒃𝑚,𝑖
𝑇𝑁
𝑖=1 ), which exist 
everywhere. 
(ii) To prove this assumption, we define a function 𝑙(𝑡) = 𝐿(𝜷∗ + 𝑡(𝜷 − 𝜷∗)|𝐃). By 
the mean value theorem, there exists 𝑎 ∈ (0, 1) such that 
𝑙(1) = 𝑙(0) + 𝑙′(𝑎)= 𝑙(0) + 𝑙′(0) + (𝑙′(𝑎) − 𝑙′(0)).           (A-5) 
Using the 𝐿(𝜷|𝐃) in (A-4), we can get 
𝑙′(0) = 2(𝜷 − 𝜷∗)𝑇(∑ 𝐂𝑚𝑖
𝑁
𝑖=1 𝜷
∗ −∑ 𝒃𝑚,𝑖
𝑇𝑁
𝑖=1 ) = (𝜷 − 𝜷
∗)𝑇∇𝐿(𝜷∗|𝐃),    (A-6) 
and 
𝑙′(𝑎) − 𝑙′(0) = 2𝑎(𝜷 − 𝜷∗)𝑇 ∑ 𝐂𝑚𝑖
𝑁
𝑖=1 (𝜷 − 𝜷
∗) =
1
2
(𝜷 − 𝜷∗)𝑇(4𝑎 ∙ ∑ 𝐂𝑚𝑖
𝑁
𝑖=1 )(𝜷 −
𝜷∗)  ≤ (𝜷 − 𝜷∗)𝑇(4 ∙ ∑ 𝐂𝑚𝑖
𝑁
𝑖=1 )(𝜷 − 𝜷
∗).                                                                    (A-7) 
Substituting (A-6) and (A-7) into (A-5), we have 
𝑙(1) ≤ 𝑙(0) + (𝜷 − 𝜷∗)𝑇∇𝐿(𝜷∗|𝐃) +
1
2
(𝜷 − 𝜷∗)𝑇(4 ∙ ∑ 𝐂𝑚𝑖
𝑁
𝑖=1 )(𝜷 − 𝜷
∗). 
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Noting that 𝑙(1) = 𝐿(𝜷|𝐃) , 𝑙(0) = 𝐿(𝜷∗|𝐃), and let 𝚲 = 4 ∙ ∑ 𝐂𝑚𝑖
𝑁
𝑖=1 , we proved the 
second assumption of the QM condition, i.e., (3.12), holds for our problem.                     Δ 
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Appendix B-I: Pseudo code for the EM and BCD algorithms for parameter estimation. 
 
Figure B1: An EM framework for estimating the proposed model in (3.6) 
 
Input: data of predictors, 𝐖, 𝐙; data of 𝕊 response variables, {𝒚𝑠}𝑠=1
𝕊 ; regularization 
parameters, 𝜆1, 𝜆2; adaptive weights 𝛽𝑝𝑠, ?̃?𝑞𝑠, 𝑝 = 1, … , ℙ, 𝑞 = 1, … , ℚ, 𝑠 =
1, … , 𝕊. 
Initialize:  
𝜷𝑠
(0) 
, 𝒅𝑠
(0) 
, 𝚪s
(0) 
by fitting a multilevel model for each response separately,  
𝑠 = 1,… , 𝕊. 
𝜔 ← 0. 
Iterate until convergence: 
E-step: compute ?̂?𝑠
(𝜔) 
, 𝐔s
(ω)
, 𝜎𝑠
2(𝜔) using (10), (11), and (12), respectively. 
M-step: alternate between following two sub-steps to get 𝜷𝑠
(𝜔+1) 
, 𝒅𝑠
(𝜔+1) 
, 
𝚪s
(ω+1) 
. 
(i) Solve 𝚪s
(ω+1) 
analytically, given 𝜷𝑠
(𝜔) 
, 𝒅𝑠
(𝜔) 
 
(ii) Solve 𝜷𝑠
(𝜔+1) 
, 𝒅𝑠
(𝜔+1) 
 using the BCD algorithm in Figure 3, given 
𝚪s
(ω+1) 
 
ω ← ω + 1. 
Output: estimates for 𝜷𝑠
 , 𝒅𝑠
 , 𝚪s
 , 𝜎𝑠
2, 𝑠 = 1, … , 𝕊. 
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Figure B2: A BCD algorithm for solving the optimization in (3.12) 
 
Appendix B-II: Proof of Theorem 1 
We will show the existence of a local maximizer of 𝑄({𝝓𝑠}𝑠=1
𝕊 )  in the 
neighborhood of the true value ?̃?1. To achieve this purpose, we show that for an arbitrary 
positive 𝜀, there exits a sufficiently large non-zero constant C such that for a sufficiently 
large N,  
                𝑃 {
𝑠𝑢𝑝
‖𝑢‖ = 𝐶  𝑄 (
?̃?1 +
𝑢
√𝑁
𝟎
) < 𝑄 (?̃?
1
𝟎
)} ≥ 1 −  𝜀.      
 (B-1) 
Note that  
Input: regularization parameters, 𝜆1, 𝜆2; current estimates for 𝜎𝑠
2, 𝐀𝑠, 𝒃𝑠
𝑇, 𝑠 = 1, … , 𝕊; 
adaptive weights 𝛽𝑝𝑠, ?̃?𝑞𝑠, 𝑝 = 1, … , ℙ, 𝑞 = 1, … , ℚ, 𝑠 = 1,… , 𝕊. 
Iterate until convergence: 
At each iteration, update ℙ + ℚ coordinates one-by-one (let ?̂?𝑠
 , ?̂?𝑠
  denote the 
estimates obtained in the previous iteration):   
Update the p-th fixed effect: 
𝑙𝑝𝑠 ←
1
σs
2 (𝐀s
p
[?̂?1𝑠 ⋯ ?̂?𝑝−1,𝑠 0 ?̂?𝑝+1,𝑠 ⋯ ?̂?ℙ𝑠 ?̂?𝑠
𝑇]𝑇 − 𝑏𝑝𝑠), 𝑠 =
1, … , 𝕊 
If ‖(𝑙𝑝1 × 𝛽𝑝1, … , 𝑙𝑝𝕊 × 𝛽𝑝𝕊)‖2
≤ λ1 
𝜷𝒑 ← 𝟎 
Else 
Do a one-dimensional search over 𝜷𝑝 = (𝛽𝑝1, … , 𝛽𝑝𝕊) as follows: 
If ?̂?𝑝1, … , ?̂?𝑝,𝑠−1, ?̂?𝑝,𝑠+1, … , ?̂?𝑝,𝕊 are all zeros and |𝑙𝑝𝑠 × 𝛽𝑝𝑠| ≤ 𝜆1 
𝛽𝑝𝑠 ← 0  
Else if ?̂?𝑝1, … , ?̂?𝑝,𝑠−1, ?̂?𝑝,𝑠+1, … , ?̂?𝑝,𝕊 are not all zeros and 𝑙𝑝𝑠 = 0 
𝛽𝑝𝑠 ← 0  
Else 
Use standard software to solve the minimization problem with respect to 
𝛽𝑝𝑠 
End if 
End if 
Update the q-th random effect in a similar way.  
Output: estimates for 𝜷𝑠
 , 𝒅𝑠
 , 𝑠 = 1,… , 𝕊. 
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𝐷𝑚(𝑢) =  𝑄 (
?̃?1 +
𝑢
√𝑁
𝟎
) − 𝑄 (?̃?
1
𝟎
) = ∑ {𝑙 (?̃?𝑠1
𝑇 +
𝑢𝑠
√𝑁
) −𝑆𝑠=1
𝑙(?̃?𝑠1
𝑇 )} −𝜆𝑁1(∑ √∑ (
𝛽𝑝𝑠(1)+
𝑢 𝑝𝑠
√𝑁
?̃?𝑝𝑠(1)
)
2
𝕊
𝑠=1  
ℙ
𝑝=1 − ∑ √∑ (
𝛽𝑝𝑠(1)
?̃?𝑝𝑠(1)
)
2
𝕊
𝑠=1  
ℙ
𝑝=1 ) −
𝜆𝑁2(∑ √∑ (
𝑑𝑞𝑠(1)+
𝑢 𝑞𝑠
√𝑁
?̃?𝑞𝑠(1)
)
2
𝕊
𝑠=1  
ℚ
𝑞=1 − ∑ √∑ (
𝑑𝑞𝑠(1)
?̃?𝑞𝑠(1)
)
2
𝕊
𝑠=1  
ℚ
𝑞=1 ). 
Using a Taylor series expansion, we have 
𝐷𝑚(𝑢) =∑ {
1
√𝑁
(∇𝑙(?̃?𝑠1))
𝑇
𝑢𝑠 +
1
2𝑁
𝑢𝑠
𝑇[∇2𝑙(?̃?𝑠1)]𝑢𝑠}
𝑆
𝑠=1
 
−𝜆𝑁1(∑ √∑ (
𝛽𝑝𝑠(1)+
𝑢 𝑝𝑠
√𝑁
?̃?𝑝𝑠(1)
)
2
𝕊
𝑠=1  
ℙ
𝑝=1 −∑ √∑ (
𝛽𝑝𝑠(1)
?̃?𝑝𝑠(1)
)
2
𝕊
𝑠=1  
ℙ
𝑝=1 ) −
𝜆𝑁2(∑ √∑ (
𝑑𝑞𝑠(1)+
𝑢 𝑞𝑠
√𝑁
?̃?𝑞𝑠(1)
)
2
𝕊
𝑠=1  
ℚ
𝑞=1 − ∑ √∑ (
𝑑𝑞𝑠(1)
?̃?𝑞𝑠(1)
)
2
𝕊
𝑠=1  
ℚ
𝑞=1 ).      (B-2)  
Under common regularity conditions, the remainder term vanishes. For the first partial 
derivatives of 𝑙(𝝓𝑠1), ∇𝑙(𝝓𝑠1), the e-th partial derivative for each corresponding 𝜷𝑠(1) , 
𝒅𝑠(1), and 𝜸𝑠(1) satisfies 
𝐸 {
𝜕
𝜕𝛽𝑒𝑠(1)
𝑙(𝝓𝑠1)} = 𝐸[𝐖(1)𝑒
𝑇 ?̃?𝑠(1)
−1  (𝒚𝑠 −𝐖(1)𝜷𝑠(1))]|𝝓𝑠1=?̃?𝑠1 = 0,  
𝐸 {
𝜕
𝜕𝑑𝑒𝑠(1)
𝑙(𝝓𝑠1)}
= 𝐸 [
1
2
[−𝑇𝑟(?̃?𝑠(1)
−1 𝐒𝑠(1)
𝑒 )
+  (𝒚𝑠 −𝐖(1)𝜷𝑠(1))
𝑇
(?̃?𝑠(1)
−1 𝐒𝑠(1)
𝑒 ?̃?𝑠(1)
−1 )(𝒚𝑠 −𝐖(1)𝜷𝑠(1))]] |𝝓𝑠1=?̃?𝑠1 = 0, 
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𝐸 {
𝜕
𝜕𝛾𝑒𝑠(1)
𝑙(𝝓𝑠1)} = 𝐸 [
1
2
[−𝑇𝑟(?̃?𝑠(1)
−1 𝐓𝑠(1)
𝑒 ) +  (𝒚𝑠 −𝐖(1)𝜷𝑠(1))
𝑇
(?̃?𝑠(1)
−1 𝐓𝑠(1)
𝑒 ?̃?𝑠(1)
−1 )(𝒚𝑠 −
𝐖(1)𝜷𝑠(1))]] |𝝓𝑠1=?̃?𝑠1 = 0, 
where 𝐖(1)𝑒 corresponds to the e-th column of stacked matrix 𝐖(1) , and 𝐒𝑠(1)
𝑒  and 𝐓𝑠(1)
𝑒  
are block diagonal matrices of the partial derivatives of ?̃?𝑠(1) and are given by 
𝐒𝑠(1)
𝑒 = 𝐙𝑠(1) {
𝜕
𝜕𝑑𝑒𝑠(1)
((𝐈 ⊗ 𝐃𝑠(1))(𝐈 ⊗ 𝚪𝑠(1))(𝐈 ⊗ 𝚪𝑠(1))
𝑇
(𝐈 ⊗ 𝐃𝑠(1))
𝑇
)} 𝐙𝑠(1)
𝑇  and  
𝐓𝑠(1)
𝑒 = 𝐙𝑠(1)(𝐈 ⊗ 𝐃𝑠(1)) {
𝜕
𝜕𝛾𝑒𝑠(1)
((𝐈 ⊗ 𝚪𝑠(1))(𝐈 ⊗ 𝚪𝑠(1))
𝑇
)} (𝐈 ⊗ 𝐃𝑠(1))
𝑇
𝐙𝑠(1)
𝑇 . 
For total number of response 0 ≤ 𝑆 < ∞, we have 
1
√𝑁
∑ [𝐖(1)𝑒
𝑇 ?̃?𝑠(1)
−1  (𝒚𝑠 −𝐖(1)𝜷𝑠(1))]
𝑆
𝑠=1
|𝝓𝑠1=?̃?𝑠1 = 𝑶𝑝(1) 
1
√𝑁
∑ [
1
2
[−𝑇𝑟(?̃?𝑠(1)
−1 𝐒𝑠(1)
𝑒 ) +  (𝒚𝑠 −𝐖(1)𝜷𝑠(1))
𝑇
(?̃?𝑠(1)
−1 𝐒𝑠(1)
𝑒 ?̃?𝑠(1)
−1 )(𝒚𝑠 −𝐖(1)𝜷𝑠(1))]]
𝑆
𝑠=1 |𝝓𝑠1=?̃?𝑠1 = 𝑶𝑝(1)  
1
√𝑁
∑ [
1
2
[−𝑇𝑟(?̃?𝑠(1)
−1 𝐓𝑠(1)
𝑒 ) +  (𝒚𝑠 −𝐖(1)𝜷𝑠(1))
𝑇
(?̃?𝑠(1)
−1 𝐓𝑠(1)
𝑒 ?̃?𝑠(1)
−1 )(𝒚𝑠 −𝐖(1)𝜷𝑠(1))]]
𝑆
𝑠=1 |𝝓𝑠1=?̃?𝑠1 = 𝑶𝑝(1).       
(B-3) 
Also,  
1
𝑁
∑ ∇2𝑙(?̃?𝑠1)
𝑆
𝑠=1 ⟶𝑝−∑ 𝐼(?̃?𝑠1)
𝑆
𝑠=1 ,                            (B-4) 
where 𝐼(?̃?𝑠1) is the Fisher information evaluated at ?̃?𝑠1.  
Substituting (S-3) and (S-4) into (S-2), we have  
𝐷𝑚(𝑢) =∑ {𝑶𝑝(1)𝑢𝑠 −
1
2
𝑢𝑠
𝑇[𝐼(?̃?𝑠1) + 𝑜𝑝(1)]𝑢𝑠}
𝑆
𝑠=1
 
127 
 
−𝜆𝑁1(∑ √∑ (
𝛽𝑝𝑠(1)+
𝑢 𝑝𝑠
√𝑁
?̃?𝑝𝑠(1)
)
2
𝕊
𝑠=1  
ℙ
𝑝=1 −∑ √∑ (
𝛽𝑝𝑠(1)
?̃?𝑝𝑠(1)
)
2
𝕊
𝑠=1  
ℙ
𝑝=1 ) −
𝜆𝑁2(∑ √∑ (
𝑑𝑞𝑠(1)+
𝑢 𝑞𝑠
√𝑁
?̃?𝑞𝑠(1)
)
2
𝕊
𝑠=1  
ℚ
𝑞=1 − ∑ √∑ (
𝑑𝑞𝑠(1)
?̃?𝑞𝑠(1)
)
2
𝕊
𝑠=1  
ℚ
𝑞=1 ). 
For the penalty term, if 
𝜆𝑁1
√𝑁
⟶ 0 and 
𝜆𝑁2
√𝑁
⟶ 0 as 𝑁 ⟶ ∞,  
𝜆𝑁1(∑ √∑ (
𝛽𝑝𝑠(1)+
𝑢 𝑝𝑠
√𝑁
?̃?𝑝𝑠(1)
)
2
𝕊
𝑠=1  
ℙ
𝑝=1 − ∑ √∑ (
𝛽𝑝𝑠(1)
?̃?𝑝𝑠(1)
)
2
𝕊
𝑠=1  
ℙ
𝑝=1 )⟶𝑝 0, and 
𝜆𝑁2(∑ √∑ (
𝑑𝑞𝑠(1)+
𝑢 𝑞𝑠
√𝑁
?̃?𝑞𝑠(1)
)
2
𝕊
𝑠=1  
ℚ
𝑞=1 − ∑ √∑ (
𝑑𝑞𝑠(1)
?̃?𝑞𝑠(1)
)
2
𝕊
𝑠=1  
ℚ
𝑞=1 )⟶𝑝 0. 
For 𝐷𝑚(𝑢), under regularity conditions, 𝐼(?̃?𝑠1) is finite and positive definite, hence the 
second term dominates the first term and the penalty term uniformly in ‖𝑢‖ = 𝐶 for a 
sufficiently large number C. Hence, there exists a local maximum in the ball 
{(
?̃?1 +
𝑢
√𝑁
𝟎
) | ‖𝑢‖ ≤ 𝐶} with probability 1 −  𝜀, and hence there exists a local maximizer 
?̂? = (?̂?
1
𝟎
) of ?̃? = (?̃?
1
𝟎
) such that ‖?̂?1 − ?̃?1‖ = 𝑶𝑝(
1
√𝑁
).               Δ 
Appendix B-III: Proof of Theorem 2 
To be clear, let’s fix the notation first. For the parameter of response s, 𝝓𝑠 =
(𝝓𝑠1
𝑇 , 𝝓𝑠2
𝑇 )𝑇, the sum of lengths corresponding to each parameter is 𝑘𝑠 = 𝑘𝑠1 + 𝑘𝑠2 =
𝑘𝛽 + 𝑘𝑑 + 𝑘𝛾 = 𝑘𝛽1 + 𝑘𝑑1 + 𝑘𝛾1 + 𝑘𝛽2 + 𝑘𝑑2 + 𝑘𝛾2  .  
128 
 
To prove theorem 2, it’s sufficient to show that with probability tending to 1 as 
𝑁 ⟶ ∞, for any 𝝓1 satisfying ‖𝝓1 − ?̃?1‖ ≤
𝐶
√𝑁
 and for some small 𝜀𝑁 =
𝐶
√𝑁
  and for 
each 𝑒𝑠 = (𝑘𝑠1 + 1),⋯ , (𝑘𝑠1 + 𝑘𝑠2), we have 
                        
𝜕
𝜕𝜙𝑒𝑠
𝑄 (
𝝓1
𝝓2
) < 0, for 0 < 𝜙𝑒𝑠 < 𝜀𝑁 , 
                         
𝜕
𝜕𝜙𝑒𝑠
𝑄 (
𝝓1
𝝓2
) > 0, for −𝜀𝑁 < 𝜙𝑒𝑠 < 0.                              (B-5)   
Note that  
𝜕
𝜕𝜙𝑒𝑠
𝑄 (
𝝓1
𝝓2
) =
𝜕
𝜕𝜙𝑒𝑠
 𝑙(𝝓𝑠) −
𝜕
𝜕𝜙𝑒𝑠
(
 𝜆𝑁1∑√∑(
𝛽𝑝𝑠
𝛽𝑝𝑠
)
2𝕊
𝑠=1
 
ℙ
𝑝=1
+ 𝜆𝑁2∑√∑(
𝑑𝑞𝑠
?̃?𝑞𝑠
)
2𝕊
𝑠=1
 
ℚ
𝑞=1
)
. 
Using Taylor expansion about 
𝜕
𝜕𝜙𝑒𝑠
 𝑙(𝝓𝑠), we have  
𝜕
𝜕𝜙𝑒𝑠
𝑄 (
𝝓1
𝝓2
) =
𝜕
𝜕𝜙𝑒𝑠
 𝑙(?̃?𝑠1) − ∑
𝜕2
𝜕𝜙𝑒𝑠𝜕𝜙𝑓𝑠
𝑘𝑠
𝑓𝑠=1
𝑙(?̃?𝑠1)(𝜙𝑓𝑠 − ?̃?𝑓𝑠 ) +
1
2
∑ ∑ ∑
𝜕3
𝜕𝜙𝑒𝑠𝜕𝜙𝑓𝑠𝜕𝜙𝑔𝑠
𝑘𝑠
𝑔𝑠=1
𝑘𝑠
𝑓𝑠=1
𝑁
𝑖=1 𝑙𝑖(𝝓𝑠1
∗ )(𝜙𝑓𝑠 − ?̃?𝑓𝑠 )(𝜙𝑔𝑠 − ?̃?𝑔𝑠) −
𝜕
𝜕𝜙𝑒𝑠
(𝜆𝑁1∑ √∑ (
𝛽𝑝𝑠
?̃?𝑝𝑠
)
2
𝕊
𝑠=1  
ℙ
𝑝=1 + 𝜆𝑁2∑ √∑ (
𝑑𝑞𝑠
?̃?𝑞𝑠
)
2
𝕊
𝑠=1  
ℚ
𝑞=1 ),                                       (B-6)    
  
where 𝝓𝑠1
∗  lies between ?̃?𝑠1 and 𝝓𝑠1.  
In the proof of Theorem 1, the first order partial derivative for the  𝑒𝑠
𝑡ℎterm of 
𝛽𝑠(1) and 𝑑𝑠(1) is  
𝜕
𝜕𝛽𝑒𝑠(1)
𝑙 (?̃?𝑠1) = 𝐖(1)𝑒𝑠
𝑇 ?̃̃?𝑠(1)
−1  (𝒚𝑠 −𝐖(1)?̃?𝑠(1)). 
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𝜕
𝜕𝑑𝑒𝑠(1)
𝑙 (?̃?𝑠1) = 0, 
respectively. The second order derivatives are 
1
𝑁
∇2𝑙(𝝓𝑠)|𝝓𝑠=?̃?𝑠 ⟶𝑝− 𝐼(𝝓𝑠)|𝝓𝑠=?̃?𝑠 =
1
𝑁
𝐸(∇2𝑙(𝝓𝑠))|𝝓𝑠=?̃?𝑠, 
where 𝐸(∇2𝑙(𝝓𝑠)) is given as  
𝐸(∇2𝑙(𝝓𝑠)) = 𝐸
[
 
 
 
𝐿
𝜷𝑠(1)𝜷𝑠(1)
𝐿
𝜷𝑠(1)𝒅𝑠(1)
𝐿
𝜷𝑠(1)𝜸𝑠(1)
𝐿
𝜷𝑠(1)𝒅𝑠(1)
𝐿
𝒅𝑠(1)𝒅𝑠(1)
𝐿
𝒅𝑠(1)𝜸𝑠(1)
𝐿
𝜷𝑠(1)𝜸𝑠(1)
𝐿
𝒅𝑠(1)𝜸𝑠(1)
𝐿
𝜸𝑠(1)𝜸𝑠(1)]
 
 
 
 , 
where {𝐿
𝜷𝑠(1)𝜷𝑠(1)
} = −𝐖(1)
𝑇 ?̃?𝑠(1)
−1
 𝐖(1), and  𝐸 {𝐿𝜷𝑠(1)𝒅𝑠(1)
} and 𝐸 {𝐿
𝜷𝑠(1)𝜸𝑠(1)
} have the 𝑒𝑠
𝑡ℎ 
column being 
𝐸 {𝐿
𝜷𝑠(1)𝒅𝑠(1)
}
𝑒𝑠
= −𝐸 [𝐖(1)𝑒𝑠
𝑇 (?̃?𝑠(1)
−1
𝐒𝑠(1)
𝑒𝑠 ?̃?𝑠(1)
−1
)(𝒚
𝑠
− 𝐖(1)𝜷𝑠(1))] |𝝓𝑠=?̃?𝑠 = 0,  
𝐸 {𝐿
𝜷𝑠(1)𝜸𝑠(1)
}
𝑒𝑠
= −𝐸 [𝐖(1)𝑒𝑠
𝑇 (?̃?𝑠(1)
−1
𝐓𝑠(1)
𝑒𝑠 ?̃?𝑠(1)
−1
)(𝒚
𝑠
− 𝐖(1)𝜷𝑠(1))] |𝝓𝑠=?̃?𝑠 = 0 , 
respectively.   
Considering 𝜙𝑒𝑠 = 𝛽𝑒𝑠(1), the expansion given in (B-6) yields 
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1
√𝑁
𝜕
𝜕𝛽𝑒𝑠(1)
𝑄 {(
𝝓1
𝝓2
)}
=
1
√𝑁
(𝑶𝑝(√𝑁) −∑ {−𝐖(1)𝑒𝑠
𝑇
?̃?𝑠(1)
−1
𝐖(1)𝑓𝑠 + 𝑜𝑝(1)}
𝑘𝛽
𝑓𝑠=1
(𝛽𝑓𝑠 − 𝛽𝑓𝑠)
−∑ 𝑜𝑝(1)(𝑑𝑓𝑠 − ?̃?𝑓𝑠)
𝑘𝛽+𝑘𝑑
𝑓𝑠=𝑘𝛽+1
−∑ 𝑜𝑝(1)(𝛾𝑓𝑠 − ?̃?𝑓𝑠)
𝑘𝛽+𝑘𝑑+𝑘𝛾
𝑓𝑠=𝑘𝛽+𝑘𝑑+1
+∑ ∑ ∑ 𝐖(1)𝑖,𝑓𝑠
𝑇 (?̃?𝑠(1)𝑖∗
−1 𝐒𝑠(1)𝑖
𝑔𝑠  ?̃?𝑠(1)𝑖∗
−1 )𝐖(1)𝑖,𝑔𝑠(𝛽𝑓𝑠
𝑘𝛽+𝑘𝑑
𝑔𝑠=𝑘𝛽+1
𝑘𝛽
𝑓𝑠=1
𝑁
𝑖=1
− 𝛽𝑓𝑠)(𝑑𝑔𝑠 − ?̃?𝑔𝑠)
+∑ ∑ ∑ 𝐖(1)𝑖,𝑓𝑠
𝑇 (?̃?𝑠(1)𝑖∗
−1 𝐓𝑠(1)𝑖
𝑔𝑠  ?̃?𝑠(1)𝑖∗
−1 )𝐖(1)𝑖,𝑔𝑠(𝛽𝑓𝑠
𝑘𝛽+𝑘𝑑+𝑘𝛾
𝑔𝑠=𝑘𝛽+𝑘𝑑+1
𝑘𝛽
𝑓𝑠=1
𝑁
𝑖=1
− 𝛽𝑓𝑠)(𝛾𝑔𝑠 − ?̃?𝑔𝑠)
+
1
2
∑ ∑ ∑ 𝐖(1)𝑖,𝑒𝑠
𝑇
𝜕2?̃?𝑠(1)𝑖∗
−1
𝜕𝑑𝑓𝑠 𝜕𝑑𝑔𝑠
(𝒚
𝑖𝑠
− 𝐖(1)𝜷𝑠(1)∗)(𝑑𝑓𝑠
𝑘𝛽+𝑘𝑑+𝑘𝛾
𝑔𝑠=𝑘𝛽+𝑘𝑑+1
𝑘𝛽+𝑘𝑑
𝑓𝑠=𝑘𝛽+1
𝑁
𝑖=1
− ?̃?𝑓𝑠)(𝛾𝑔𝑠 − ?̃?𝑔𝑠)
+
1
2
∑ ∑ ∑ 𝐖(1)𝑖,𝑒𝑠
𝑇
𝜕2?̃?𝑠(1)𝑖∗
−1
𝜕𝛾𝑓𝑠 𝜕𝛾𝑔𝑠
(𝒚
𝑖𝑠
𝑘𝛽+𝑘𝑑+𝑘𝛾
𝑔𝑠=𝑘𝛽+𝑘𝑑+1
𝑘𝛽+𝑘𝑑+𝑘𝛾
𝑓𝑠=𝑘𝛽+𝑘𝑑+1
𝑁
𝑖=1
− 𝐖𝑖(1)𝜷𝑠(1)∗)(𝛾𝑓𝑠 − ?̃?𝑓𝑠)(𝛾𝑔𝑠 − ?̃?𝑔𝑠)
+∑ ∑ ∑ 𝐖(1)𝑖,𝑒𝑠
𝑇
𝜕2?̃?𝑠(1)𝑖∗
−1
𝜕𝑑𝑓𝑠 𝜕𝛾𝑔𝑠
(𝒚
𝑖𝑠
− 𝐖𝑖(1)𝜷𝑠(1)∗)(𝑑𝑓𝑠
𝑘𝛽+𝑘𝑑+𝑘𝛾
𝑔𝑠=𝑘𝛽+𝑘𝑑+1
𝑘𝛽+𝑘𝑑
𝑓𝑠=𝑘𝛽+1
𝑁
𝑖=1
− ?̃?𝑓𝑠)(𝛾𝑔𝑠 − ?̃?𝑔𝑠)) −
𝜕
𝜕𝛽𝑒𝑠(1)
(
 𝜆𝑁1∑√∑(
𝛽𝑝𝑠
𝛽𝑝𝑠
)
2𝕊
𝑠=1
 
ℙ
𝑝=1
)
, 
where ‖𝝓∗ − ?̃?‖ ≤ ‖𝝓 − ?̃?‖. Since ‖𝝓 − ?̃?‖ ≤
𝐶
√𝑁
,   
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1
√𝑁
𝜕
𝜕𝛽𝑒𝑠(1)
𝑄 {(
𝝓1
𝝓2
)} = 𝑶𝑝(1) −
1
√𝑁
𝜕
𝜕𝛽𝑒𝑠(1)
(𝜆𝑁1∑ √∑ (
𝛽𝑝𝑠
?̃?𝑝𝑠
)
2
𝕊
𝑠=1  
ℙ
𝑝=1 ). 
Considering the last term,  
1
√𝑁
𝜕
𝜕𝛽𝑒𝑠(1)
(𝜆𝑁1∑ √∑ (
𝛽𝑝𝑠
?̃?𝑝𝑠
)
2
𝕊
𝑠=1  
ℙ
𝑝=1 ) =
{
  
 
  
 𝜆𝑁1
𝑠𝑖𝑔𝑛(𝛽𝑝𝑒𝑠)
√𝑁|?̃?𝑝𝑒𝑠|
𝑖𝑓 ∑ (
𝛽
𝑝𝑠′
?̃?
𝑝𝑠′
)
2
= 0𝑠′≠𝑒𝑠  
𝜆𝑁1
𝛽𝑝𝑒𝑠
?̃?𝑝𝑒𝑠
2
√𝑁√∑ (
𝛽𝑝𝑠
?̃?𝑝𝑠
)
2
𝕊
𝑠=1
𝑖𝑓 ∑ (
𝛽
𝑝𝑠′
?̃?
𝑝𝑠′
)
2
≠ 0𝑠′≠𝑒𝑠
. 
In either case, the sign of  
1
√𝑁
𝜕
𝜕𝛽𝑒𝑠(1)
𝑄 {(
𝝓1
𝝓2
)} is determined by that of 𝛽𝑒𝑠(1). Similarly, 
the sign of  
1
√𝑁
𝜕
𝜕𝑑𝑒𝑠(1)
𝑄 {(
𝝓1
𝝓2
)} is also determined by that of 𝑑𝑒𝑠(1). (B-5) is proved.                
Δ 
Appendix B-IV: Proof of Theorem 3 
From Theorem 1, we proved that there exists a local maximizer ?̂? = (?̂?
1
𝟎
) of 
?̃? = (?̃?
1
𝟎
) such that ‖?̂?1 − ?̃?1‖
𝐹
= 𝑶𝑝(
1
√𝑁
) and the local maximizer satisfies the set of 
penalized likelihood equation 
𝜕𝝓1
𝑄(𝝓)|
𝝓=(?̂?
1
𝟎
)
 = 
𝜕
𝜕𝝓1
{∑ 𝑙(𝝓𝑠)
𝕊
𝑠=1 }|𝝓=(?̂?
1
𝟎
)
−
𝜕
𝜕𝝓1
{𝜆𝑁1∑ √∑ (
𝛽𝑝𝑠(1)
?̃?𝑝𝑠(1)
)
2
𝕊
𝑠=1  
ℙ
𝑝=1 +
𝜆𝑁2∑ √∑ (
𝑑𝑞𝑠(1)
?̃?𝑞𝑠(1)
)
2
𝕊
𝑠=1  
ℚ
𝑞=1 } |𝝓=(?̂?
1
𝟎
)
= 0 . 
Using the Taylor series expansion and multiplying through by 
1
𝑁
, we have 
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1
𝑁
(∇𝑙(?̃?11)
𝑇
,⋯ , ∇𝑙(?̃?𝑆1)
𝑇
)
𝑇
− ((𝐼(?̃?11)(?̂?11 − ?̃?11))
𝑇
,⋯ , (𝐼(?̃?𝑆1)(?̂?𝑆1 −
?̃?𝑆1))
𝑇
)
𝑇
− (𝒗1
𝑇 ,⋯ , 𝒗𝕊
𝑇)𝑇 = 0   
√𝑁((𝐼(?̃?11)(?̂?11 − ?̃?11))
𝑇
,⋯ , (𝐼(?̃?𝑆1)(?̂?𝑆1 − ?̃?𝑆1))
𝑇
+ (𝒗1
𝑇 ,⋯ , 𝒗𝕊
𝑇))
𝑇
=
√𝑁{𝐼(?̃?1)(?̂?1 − ?̃?1) + (𝒗1
𝑇 , ⋯ , 𝒗𝕊
𝑇)𝑇} =
1
√𝑁
(∇𝑙(?̃?11)
𝑇
,⋯ , ∇𝑙(?̃?𝑆1)
𝑇
)
𝑇
  
Because of the proof of Theorem 1, it follows from the multivariate central limit theorem 
that 
1
√𝑁
(∇𝑙(?̃?11)
𝑇
, ⋯ , ∇𝑙(?̃?𝑆1)
𝑇
)
𝑇
⟶𝑑 𝑁(0, 𝐼(?̃?
1)) , where 𝐼(?̃?1) =
𝑑𝑖𝑎𝑔(𝐼(?̃?11),⋯ , 𝐼(?̃?𝑆1)).  
Therefore,  
√𝑁{𝐼(?̃?1)(?̂?1 − ?̃?1) + (𝒗1
𝑇 , ⋯ , 𝒗𝕊
𝑇)𝑇} ⟶𝑑 𝑁(0, 𝐼(?̃?
1)) 
which can be written as 
                     √𝑁 𝐼(?̃?1) ((?̂?1 − ?̃?1) + 𝐼(?̃?1)−1(𝒗1
𝑇 ,⋯ , 𝒗𝕊
𝑇)𝑇) ⟶𝑑 𝑁(0, 𝐼(?̃?
1)) .         Δ 
Appendix B-V: Definitions of “organizing”, “checking”, “mobilizing”, “exchanging”, 
“assisting”, and “backfilling” in the NCCI 
“Organizing” is creating a structure that allows care coordination to be carried out 
in a safe and timely way. “Checking” is evaluating accuracy, timeliness, and completion 
of steps required in the sequence to carry out care coordination processes. “Mobilizing” is 
directly and indirectly getting others take actions for which they are accountable and are 
required to carry out care coordination processes. “Exchanging” is giving and receiving 
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information needed to carry out care coordination processes. “Assisting” is getting or 
giving help to carry out one or more steps in care coordination process that a nurse would 
ordinarily do themselves. “Backfilling” is doing the work of other members of the care 
team for which they were responsible but did not do to carry out care coordination 
processes.  
Appendix B-VI: The derivation for obtaining (3.7), (3.8), and (3.9) 
p(?̃?𝑠|𝒚𝑠, 𝝓𝑠
(𝜔)) =
p(𝒚𝑠, ?̃?𝑠|𝝓𝑠
(𝜔)
)
p(𝒚𝑠|𝝓𝑠
(𝜔)
)
. Taking logarithm for both sides,  
        𝑙𝑜𝑔 p(?̃?𝑠|𝒚𝑠; 𝝓𝑠
(𝜔)) = 𝑙𝑜𝑔 p(𝒚𝑠, ?̃?𝑠|𝝓𝑠
(𝜔)) − 𝑙𝑜𝑔 p(𝒚𝑠|𝝓𝑠
(𝜔)).                (B-7) 
According to (3.5), 
𝑙𝑜𝑔 p(𝒚𝑠, ?̃?𝑠|𝝓𝑠
(𝜔)) = −
∑ n𝑖
𝑁
𝑖=1 +𝑁𝑄
2
𝑙𝑜𝑔(2𝜋) −
∑ n𝑖
𝑁
𝑖=1 +𝑁𝑄
2
log (𝜎𝑠
2(𝜔)) −
1
2𝜎𝑠
2(𝜔)
(‖𝒚𝑠 −
𝐙?̃?𝑠
(𝜔)?̃?𝑠
(𝜔)?̃?𝑠 −𝐖𝜷𝒔
(ω)‖
2
+ ?̃?𝑠
𝑇?̃?𝑠).                                                                               (B-8)                                                                                   
Furthermore, we can get:  
𝑜𝑔 p(𝒚𝑠|𝝓𝑠
(𝜔)) = −
∑ n𝑖
𝑁
𝑖=1
2
log(2𝜋) −
1
2
log(|?̃?𝑠|) −
1
2
(𝒚𝑠 −𝐖𝜷𝑠
(ω))
𝑇
?̃?𝑠
−1(𝒚𝑠 −𝐖𝜷𝑠
(ω)),      
                        (B-9) 
where ?̃?𝑠 = 𝐷𝑖𝑎𝑔(𝐕s1, … , 𝐕sN)  and 𝐕𝑖 = 𝜎𝑠
2(𝜔)(𝐙𝑖 𝐃𝑠
(𝜔)𝚪𝑠
(𝜔)𝚪𝑠
𝑇(𝜔)𝐃𝑠
(𝜔)𝐙𝑖
𝑇 + 𝐈) , 𝑖 =
1, … , 𝑁.  
Inserting (B-8) and (B-9) into (B-7), we can get 
𝑙𝑜𝑔 p(?̃?𝑠|𝒚𝑠; 𝝓𝑠
(𝜔))  
134 
 
= −
∑ n𝑖
𝑁
𝑖=1 +𝑁𝑄
2
log(2𝜋) −
∑ n𝑖
𝑁
𝑖=1 +𝑁𝑄
2
log (𝜎𝑠
2(𝜔)) −
1
2𝜎𝑠
2(𝜔)
(‖𝒚𝑠 − 𝐙?̃?𝑠
(𝜔)?̃?𝑠
(𝜔)?̃?𝑠 −
𝐖𝜷𝒔
(ω)‖
2
+ ?̃?𝑠
𝑇?̃?𝑠) +
∑ n𝑖
𝑁
𝑖=1
2
log(2𝜋) +
1
2
log(|?̃?𝑠|) +
1
2
(𝒚𝑠 −𝐖𝜷𝑠
(ω))
𝑇
?̃?𝑠
−1(𝒚𝑠 −
𝐖𝜷𝑠
(ω))  
= −
𝑁𝑄
2
log(2𝜋) −
1
2
log (|𝐔𝑠
(ω)|) −
1
2
(?̃?𝑠 − ?̂?𝑠
(𝜔) )𝑇𝐔𝑠
(ω)−1
(?̃?𝑠 − ?̂?𝑠
(𝜔) ) ,                    (B-10)                          
where ?̂?𝑠
(𝜔) 
and 𝐔𝑠
(ω)
 follow the definition in (7) and (8).  The form of (S-10) means that 
?̃?𝑠|𝒚𝑠, 𝝓
(𝜔)~𝑁(?̂?𝑠
(𝜔)  , 𝐔𝑠
(ω)
).  
Furthermore, by (3.4),  
𝑙(𝝓(𝜔)|{𝒚𝑠}𝑠=1
𝕊 ) = −
1
2
∑ {𝑙𝑜𝑔 ⌊?̃?𝑠
(𝜔)
⌋ + (𝒚𝑠 −𝐖𝜷𝒔
(𝜔))
𝑇
?̃?𝑠
(𝜔)−1
(𝒚𝑠 −𝐖𝜷𝒔
(𝜔))}𝕊𝑠=1  ,      
(B-11) 
where ?̃?𝑠
(𝜔)
= 𝐷𝑖𝑎𝑔(𝐕𝑠1
(𝜔), … , 𝐕𝑠𝑁
(𝜔))  and 𝐕𝑠𝑖
(𝜔) =
𝜎𝑠
2(𝜔)(𝐙𝑖 𝐃𝑠
(𝜔)𝚪𝑠
(𝜔)𝚪𝑠
𝑇(𝜔)𝐃𝑠
(𝜔)𝐙𝑖
𝑇 + 𝐈) , 𝑖 = 1, … ,𝑁 . Taking derivative of (B-11) with 
respect to 𝜎𝑠
2(𝜔), 
       
𝜕𝑙(𝝓(𝜔)|{𝒚𝑠}𝑠=1
𝕊 )
𝜕𝜎𝑠
2(𝜔)
=−
1
2
{
∑ n𝑖
𝑁
𝑖=1
𝜎𝑠
2(𝜔)
−
(𝒚𝑠−𝐖𝜷𝑠
(𝜔)
)
𝑇
(𝐙?̃?𝑠
(𝜔)
?̃?𝑠
(𝜔)
?̃?𝑠
(𝜔)𝑇
?̃?𝑠
(𝜔)𝑇
𝐙𝑇)
−1
(𝒚𝑠−𝐖𝜷𝑠
(𝜔)
)
𝜎𝑠
4(𝜔)
}. (B-12)                
Making (B-12) equal to zero and solving for 𝜎𝑠
2(𝜔), we can get (3.9).                                    Δ                                  
 
 
 
135 
 
APPENDIX C 
SUPPLEMETNAL MATERIALS FOR CHAPTER 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
136 
 
Appendix C-I: Proof of Proposition 2 
Proof: Let =
𝑙𝑖(𝐙)−(𝛽0,𝑖+𝛃𝑧,𝑖
𝑇 𝐙)
𝜎𝑖
 , 𝛿 =
𝛽𝑦,𝑖
𝜎𝑖
, 𝑟(𝑥) =
Φ(𝑥−𝛿)
Φ(𝑥)
, and 𝑟0 =
𝑟𝑙
1−𝑟𝑙
×
1−𝜋(𝐙)
𝜋(𝐙)
. Then, the 
constraint in (4.8) becomes 𝑟(𝑥) ≤ 𝑟0. Here, 𝛿 > 0 because 𝛽𝑦,𝑖 represents the increase in 
the biomarker value as 𝑌 changes from 0 (non-diseased) to 1 (diseased). Recall that we 
made an assumption earlier on that there is a positive correlation between each biomarker 
and the disease risk, which suggests that 𝛽𝑦,𝑖 > 0. Also, 𝑟0 > 0 by definition. 
Next, we will show that 𝑟(𝑥) is strictly monotonically increasing from 0 to 1 as 𝑥 
increases from −∞ to +∞. When 𝑥 → +∞, we have  
lim
𝑥→+∞
𝑟(𝑥) =  
lim
𝑥→+∞
Φ(𝑥−𝛿)
lim
𝑥→+∞
Φ(𝑥)
=
1
1
= 1. 
When  𝑥 → −∞, using L’Hospital’s Rule, we have  
lim
𝑥→−∞
𝑟(𝑥) = lim
𝑥→−∞
Φ(𝑥−𝛿)
Φ(𝑥)
 = lim
𝑥→−∞
∫
1
√2𝜋
𝑒
−
𝑡2
2 𝑑𝑡
𝑥−𝛿
−∞
∫
1
√2𝜋
𝑒
−
𝑡2
2 𝑑𝑡
𝑥
−∞
= lim
𝑥→−∞
1
√2𝜋
𝑒
−
(𝑥−𝛿)2
2
1
√2𝜋
𝑒
−
𝑥2
2
=
lim
𝑥→−∞
𝑒𝛿𝑥−
𝛿2
2 = 0.  
For finite 𝑥, 𝑟(𝑥) is strictly monotonically increasing because 
𝑑 𝑟(𝑥)
𝑑𝑥
= 𝑑(
∫
1
√2𝜋
𝑒
−
𝑡2
2 𝑑𝑡
𝑥−𝛿
−∞
∫
1
√2𝜋
𝑒
−
𝑡2
2 𝑑𝑡
𝑥
−∞
) 𝑑𝑥⁄ =
𝑒
−
(𝑥−𝛿)2
2 ×∫ 𝑒
−
𝑡2
2 𝑑𝑡
𝑥
−∞ −𝑒
−
𝑥2
2 ×∫ 𝑒
−
𝑡2
2 𝑑𝑡
𝑥−𝛿
−∞
(∫ 𝑒
−
𝑡2
2 𝑑𝑡
𝑥
−∞ )
2   
=
𝑒
−
𝑥2
2 ×∫ 𝑒
−
𝑡2
2 𝑑𝑡
𝑥
𝑥−𝛿
(∫ 𝑒
−
𝑡2
2 𝑑𝑡
𝑥
−∞ )
2 +
𝑒
(−
𝛿2
2
+𝑥𝛿)
×∫ 𝑒
−
𝑡2
2 𝑑𝑡
𝑥
−∞
(∫ 𝑒
−
𝑡2
2 𝑑𝑡
𝑥
−∞ )
2 > 0.  
Hence, when 0 < 𝑟0 < 1, the feasible region of 𝑥 is (−∞, 𝑥0], where 𝑥0 satisfies 
𝑟(𝑥0) = 𝑟0. Because 𝑟(𝑥) strictly monotonically increases with respect to 𝑥, the maximum 
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𝑟(𝑥) is achieved at 𝑥0 and this solution is unique. When 𝑟0 ≥ 1, the feasible region of 𝑥 is 
[−∞,+∞]. The maximum 𝑟(𝑥) is achieved at +∞ and this solution is unique.                    Δ 
 
 
 
 
